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I Abstract 
Proteins are the functional units executing the genetic program of living cells. Protein 
activity has to be modulated and adapted to environmental and intracellular 
conditions throughout the life cycle of every cell. In higher eukaryotes, complex 
multidomain proteins and multisubunit complexes have evolved to integrate large 
numbers of input signals to control key steps in metabolism, growth and proliferation. 
Structural studies of authentic eukaryotic multidomain proteins are required to 
understand their emergent properties resulting from interdomain and intersubunit 
crosstalk and conformational dynamics. However, due to problems in sample 
preparation and characterization, resolving the structures of large eukaryotic protein 
assemblies remains a considerable challenge. This thesis provides novel structural 
and mechanistic insights to three highly relevant eukaryotic protein systems, based 
on integrative multimethod approaches to tackle the inherent complexity of each 
case.  
Mammalian target of rapamycin (mTOR) is the master regulator of growth and 
proliferation; it senses nutrient and growth signals and in response mediates the 
switch between anabolism and catabolism. Dysregulation of mTOR signaling is 
implicated in metabolic diseases and cancer, and mTOR is an established drug 
target. mTOR is comprised in two structurally and functionally distinct signaling 
complexes, mTORC1 and mTORC2. In Chapter 2, we determine the structure of the 
human mTORC1, containing the protein subunits mTOR, Raptor and mLST8, bound 
to FKBP12, by combining cryo-electron microscopy of the assembled complex at 
5.9 Å resolution and crystallographic studies of the 149 kDa Raptor from Chaetomium 
thermophilum at 4.3 Å resolution. The core scaffold of the complex is formed by 
mTOR; the Raptor N-terminal conserved (RNC) domain is bound in vicinity to the 
mTOR catalytic site, suggesting a key role of the RNC in substrate recognition and 
delivery. 
Polo-like kinase 4 (PLK4) is a central controller of centriole duplication. Chapter 3 
identifies a mechanism for PLK4 regulation by the partner protein STIL by using 
biochemical mapping, kinase assays, super resolution microscopy, isothermal 
calorimetry in combination with structural studies of the interaction of the PLK4-
polobox 3 (PB3) domain with a coiled-coil region of STIL (STIL-CC). NMR 
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spectroscopy provides a solution structure of the isolated PLK4-PB3 and 
crystallographic structure determination reveals the mode of complex formation of 
PLK4-PB3 and STIL-CC. Mutations in STIL-CC abrogate the interaction to PB3 and 
diminish centriole duplication in cells, demonstrating the relevance of the PLK4-STIL 
interaction for centriole duplication. 
Acetyl-CoA carboxylase (ACC) catalyzes the conversion of acetyl-CoA to malonyl-
CoA, providing the building blocks for fatty acid synthesis. Eukaryotic ACCs are large 
multidomain proteins, that comprise a unique 120 kDa regulatory central domain (CD) 
besides the N- and C-terminal catalytic domains biotin carboxylase (BC) and carboxyl 
transferase (CT). In chapter 4 we determine the structure of the human and yeast CD 
and provide intermediate resolution crystal structures of up to nearly full-length ACC 
from Chaetomium thermophilum. In combination with functional assays, these data 
reveal the structural basis for phosphorylation-dependent control of yeast ACC 
activity. 
In summary, the results presented in this thesis provide new structural and 
mechanistic insights into crucial eukaryote-specific regulatory properties of large 
multidomain proteins and protein complexes. These studies open important routes 
for further dissecting functional mechanisms by targeted biochemical and biophysical 
approaches. In particular for mTORC1, the current results provide a basis for 
analyzing the interactions with signaling partner proteins. Interdomain crosstalk and 
regulated protein conformational dynamics in these systems are closely linked to 
disease. Targeting interdomain interactions may serve as a relevant strategy for 
therapeutic intervention, e. g. in cancer therapy. The detailed depiction of intact 
assemblies of ACC and mTORC1 provides the structural groundworks for such 
approaches.   
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1 Introduction 
1.1 Phosphorylation is a key mechanism for controlling 
protein function in metabolism and proliferation 
Proteins are the functional units of all living cells. They carry out a tremendous diversity 
of tasks: Catalyzing chemical reactions, organizing trafficking within cells, sensing 
extracellular signals, transporting cargo or measuring electric potential across lipid 
membranes, maintaining the cellular integrity, activating, inhibiting, translocating or 
degrading other proteins and initiating the synthesis of new proteins. The activity of 
individual proteins is regulated on multiple levels in order to efficiently and tightly adjust 
their activity in response to environmental conditions. Long term control is achieved 
via biosynthesis of new proteins and degradation of redundant proteins. Whilst this 
system is well suited for the adaptation to new cellular roles and major environmental 
changes, it is also slow and energy demanding. Immediate regulation can be mediated 
by small molecules that directly bind a target protein and in turn cause its activation, 
inhibition or allosteric modulation. Another mode of short-term regulation is through 
external or internal stimulation of signaling cascades that affect protein activity by 
complex formation, altered localization, and most prominently post-translational 
modifications.  
A versatile and central example of post-translational modification is the adenosine 
triphosphate (ATP)-dependent transfer of a phosphoryl group onto a target protein, 
termed phosphorylation, catalyzed by protein kinase enzymes (Figure 1.1). Kinases 
are classified into Ser/Thr-kinases, Tyr-kinases and His-kinases based on the type of 
residue of its substrate, on which the phosphoryl group is covalently attached to. A 
kinase target can either be activated or inhibited upon phosphorylation. This can be 
achieved for instance through induction of a conformational change or the 
modification of a binding site for another protein. Importantly, the phosphoryl group 
can be removed by a phosphatase as soon as a specific function is no longer needed. 
This oftentimes results in an equilibrium situation between a phosphorylated and non-
phosphorylated form. Regulation of the activity of the kinase or the counteracting 
phosphatase allows fine graded control over a large dynamic range of the target 
protein. The human genome encodes 518 different kinases, which is 1.7 % of all 
1  Introduction 
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human genes1. Protein kinases mediate the majority of signal transduction in human 
cells. They also control a vast number of processes in metabolism, transcription, cell 
cycle regulation, differentiation. 
 
Figure 1.1 Regulation control by protein kinases. 
Protein kinases transfer a phosphoryl group from ATP onto a target protein. The protein is 
either activated (A) or inhibited (B) upon phosphorylation. The phosphoryl group can be 
removed by a phosphatase. 
This thesis aims to elucidate the structural basis of phosphorylation-mediated control 
of key regulatory processes in eukaryotic cells: Chapter 2 covers the structure 
determination of the mammalian target of rapamycin complex 1 (mTORC1) kinase 
accompanied by structural studies of the isolated subunit Raptor. mTORC1 is the 
master regulator of cell growth and is oftentimes deregulated in metabolic diseases 
and cancer. Chapter 3 explores the role of the human Polo-like kinase 4 (PLK4) in 
centriole duplication, a vital process during the cell cycle. Chapter 4 addresses the 
phosphorylation-mediated regulation of human and yeast acetyl-CoA carboxylase 
(ACC), a giant multi-enzyme that catalyzes the committed step in fatty acid and sterol 
biosynthesis. 
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1.2 mTOR – the master regulator of cell growth and 
proliferation 
1.2.1 Discovery of mTOR as the cellular target of rapamycin 
In 1975 a macrolide with potent antifungal activity was isolated from the soil bacterium 
Streptomyces hygroscopicus (Figure 1.2)2. The bacterium was cultivated from a soil 
sample collected on the Easter Island (called Rapa Nui in the local polynesian 
language). The macrolide was termed rapamycin, a combination of its origin and its 
antifungal properties2. Later, rapamycin was shown to also have important 
antiproliferative as well as immunosuppressive effects in mammals3,4. Rapamycin’s 
mode of action remained unknown for over a decade after the discovery of its effects. 
In 1991, Heitman et al. identified two genes in a genetic screen in budding yeast, 
TOR1 and TOR2 (for target of rapamycin 1 and 2), whose gene products convey the 
toxic effect of rapamycin5. In Addition, yeast strains lacking the FK506-binding protein 
of 12 kDa (FKBP12), a peptidylprolyl isomerase (PPIase), are completely resistant to 
rapamycin. This observation suggested a mechanism where rapamycin and FKBP12 
form a gain of function complex, that acts on TOR1 and TOR2. Shortly after, the 
human ortholog mammalian TOR (mTOR) was identified6-8. mTOR possesses 43% 
and 39% sequence identity to TOR2 and TOR1, respectively, and is conserved in all 
eukaryotes. Whereas budding yeast and fission yeast possess two TORs, other yeast 
genera and eukaryotes including mammals only have a single TOR gene9.  
 
Figure 1.2 The macrolide rapamycin is produced by Streptomyces hygroscopicus. 
A Scanning electron microscopy micrographs of Streptomyces hygroscopicus taken by Dietz 
and Mathews10. Individual spores are arranged in a spiral fashion. The scale bar indicates 2 
µm. B Chemical structure of the bioactive macrolide rapamycin produced by Streptomyces 
hygroscopicus. 
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1.2.2 mTOR is a member of the PIKK family of kinases 
 
Figure 1.3 Domain organization in members of the PIKK family. 
Left: Overview of the individual process each PIKK is involved. Right: PIKKs share a conserved 
domain architecture with a large number of α-helical repeats. The number of residues of each 
protein is indicated below the respective scheme. TRRAP has a non-catalytic kinase domain 
depicted with an asterisk.  
mTOR is the founding member of the phosphatidylinositol-3 kinase related kinase 
(PIKK) family, that possess sequence relation to phosphatidylinositol kinases (PIK), but 
clearly cluster outside that family and form a distinct group11. There are five additional 
members besides mTOR: Ataxia telangiectasia mutated (ATM), Ataxia telangiectasia 
and Rad3-related protein (ATR), DNA-dependent protein kinase catalytic subunit 
(DNA-PKcs), serine/threonine-protein kinase (SMG1) and 
Transformation/transcription domain-associated protein (TRRAP). PIKKs are very 
large proteins (2549 – 4128 amino acids) with a conserved domain composition and 
besides mTOR typically regulate DNA damage responses (Figure 1.3)12. They all 
possess a carboxy-terminal Ser/Thr-kinase domain, whereas TRRAP lacks key 
catalytic residues and no kinase activity has been reported13. The kinase domain is 
related to phosphatidylinositol-3 kinases (PI3K)14, but does not have lipid kinase 
activity. Adjacent to the kinase lies the FAT domain, named after the three 
representative proteins FRAP (FKBP12-rapamycin associated protein, obsolete name 
for mTOR), ATM and TRRAP15. The FAT domain spans approximately 500 residues 
and is predicted to comprise α-helical repeats16. The amino-terminal rest of the PIKKs, 
which makes up half of the entire protein in the case of mTOR, consists of a variable 
number of Huntingtin, elongation factor 3, protein phosphatase 2A and yeast kinase 
Tor1 (HEAT) repeats17. mTOR possesses an additional FKBP12-rapamycin binding 
domain (FRB), that is absent in other PIKKs and is responsible for conveying the 
inhibitory effect by binding rapamycin together with FKBP1218. However, FRB-like 
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insertions have been identified in SMG1, DNA-PKcs and TRRAP19. PIKKs are often 
regulated by translocation to distinct sites, where a specific activator can induce the 
kinase activity12,17. Besides, their activity can be modulated by post-translational 
modifications or by binding to accessory proteins.  
 
1.2.3 mTOR functions in two distinct multi-protein complexes 
Members of the PIKK family form very large multi-protein assemblies to accomplish 
their task. DNA-PKcs in complex with Ku70 and Ku80 is directed to DNA lesion sites 
and provides a scaffold for their repair12. ATR with its binding partner ATR-interacting 
protein (ATRIP) is recruited to exposed single-stranded DNA and coordinates the 
maintenance of DNA integrity12. The 289 kDa mTOR kinase exists in two distinct 
signaling complexes: mTOR complex 1 and 2 (mTORC1 and mTORC2, Figure 1.4). 
mTORC1 comprises the core components mTOR, the 149 kDa regulatory-associated 
protein of mammalian target of rapamycin (Raptor)20,21 and mammalian lethal with sec-
13 protein 8 (mLST8)22. Raptor is implicated in subcellular localization of mTORC1, 
recruitment of substrates and scaffolding functions23. mLST8 directly binds the mTOR 
kinase domain and modulates the kinase activity22. Proline-rich Akt substrate of 40 
kDa (PRAS40) is a negative regulator of mTORC1 and is only bound under non-
stimulating conditions24-26. 
mTORC2 comprises a core formed by mTOR, the 192 kDa rapamycin-insensitive 
companion of mTOR (Rictor)27,28 together with mLST8 and mammalian stress-
activated map kinase-interacting protein 1 (mSIN1)29,30. DEP domain-containing 
mTOR interacting protein (DEPTOR)31 can both bind and inhibit mTORC1 and 
mTORC2. The two complexes form oligomers, most likely dimers, where each protein 
is present in two copies per complex32-34. 
Rapamycin inhibits mTORC1 towards some, but not all substrates, which turned out 
to be an extremely useful tool for many of the studies elucidating the mTOR signaling 
pathways described in the following two sections. mTORC2 is insensitive to acute 
rapamycin treatment27,28. However, prolonged rapamycin exposure can reduce 
mTORC2 signaling in certain cell lines35. 
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Figure 1.4 Composition and signaling of mTOR complex 1 and 2. 
mTOR acts in the two structurally and functionally distinct signaling complexes mTORC1 and 
mTORC2. mTORC1 core components are mTOR, Raptor and mLST8. The negative regulator 
PRAS40 is bound to Raptor under non-stimulating conditions. mTORC2 core proteins are 
mTOR, Rictor, mLST8 and mSIN1. DEPTOR can bind and inhibit both complexes. The two 
complexes sense nutrients and growth factors and regulate a multitude of metabolic 
processes. 
1.2.4 Upstream regulators of mTORC1 and mTORC2 
The two mTOR complexes sense the extracellular and intracellular environment. 
mTORC1 integrates at least four major input signals: growth factors, amino acids, 
cellular energy status and oxygen levels. Positive mTORC1 signaling requires two 
prerequisites: First, mTORC1 needs to translocate to the lysosomal membrane, which 
is achieved by the amino acid sensing branch. And second, the lysosomal anchored 
Ras homolog enriched in brain (Rheb) must be in an activated, GTP-bound state 
induced by the growth factor sensing branch (Figure 1.5). 
Growth factors 
Growth factors enable mTOR signaling beyond the immediate environment of a single 
cell. This pathway can effectively reach entire organs and even coordinate mTOR 
signaling on the whole body level. 
Insulin or insulin-like growth factor 1 (IGF1) stimulates mTORC1 activity via the PI3K 
pathway. RAC-alpha serine/threonine-protein kinase (Akt), ribosomal protein S6 
kinase alpha-1(RSK1) as well as extracellular-signal-regulated kinase 1/2 (ERK1/2) are 
activated and in turn inactivate the tuberous sclerosis complex (TSC, comprising 
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TSC1, TSC2 and TBC1 domain family member 7, TBC1D7) via inhibitory 
phosphorylation23,36. TSC is the GTPase-activating protein (GAP) of Rheb, a lysosome-
anchored GTP-binding protein. Rheb-GTP activates mTORC1 in an unknown 
manner23. Thus, positive growth factor sensing inactivates TSC, enabling Rheb to 
activate mTORC1 signaling. In Addition, Akt can stimulate mTORC1 activity in a TSC 
independent manner via phosphorylation of the negative regulator PRAS40, resulting 
in its dissociation from Raptor24-26. 
Amino acids 
The availability of nutrients in the form of amino acids is a prerequisite for the synthesis 
of new proteins and cell growth. Thus, their sensing is crucial for proper mTORC1 
signaling. Some amino acids have proven to be more potent mTORC1 activators than 
others37 and different mechanisms for their sensing have been unveiled. 
Amino acid sensing is integrated via a GTPase dimer composed of Ras-related 
GTPase (Rag) proteins. RagA or the functionally redundant RagB forms a 
heterodimeric complex with either RagC or its equivalent RagD, respectively. The 
RagA/B-RagC/D complex is tethered to the lysosomal membrane via the pentameric 
Ragulator complex38,39. The RagA/B-GTP and RagC/D-GDP state binds Raptor and 
brings mTORC1 to the lysosome, whereas the RagA/B-GDP and RagC/D-GTP state 
fails to localize mTORC1 to the lysosome40. The regulation of the nucleotide binding 
state of the Rags is complex and is only starting to be understood. A number of 
mechanisms have been discovered: 
An important factor is the trimeric “GAP activity toward Rags” (GATOR1) complex. 
Active GATOR1 results in RagA/B being loaded with GDP, incompetent of mTORC1 
binding41. GATOR1 is under negative control of the pentameric GATOR2, an integrator 
of leucine and arginine sensing. In the absence of leucine, Sestrin-2 is bound to 
GATOR2, preventing the inhibition of GATOR142. During leucine stimulation, Sestrin-2 
binds free leucine, dissociates from GATOR and ultimately leads to RagA/B being 
GTP-loaded and able to bind mTORC1. An analogous mechanism has been 
suggested for arginine sensing, with “cellular arginine sensor for mTORC1 1” 
(CASTOR1) dissociating upon arginine binding and relieving its inhibitory effect on 
GATOR243. 
Glutamine is sensed indirectly via the product of glutaminolysis, α-ketoglutarate 
(αKG)44. Leucine binds and activates glutamate dehydrogenase (GDH), which 
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catalyzes the deamination of glutamate to αKG in glutaminolysis. αKG stimulation is 
sufficient to target mTORC1 to the Rags by a yet unknown mechanism. 
The exact roles of the GAP of RagA/B (Folliculin) and the GEF of RagC/D (Ragulator) 
need to be explored. Furthermore, unraveling the integration of the different input 
mechanisms with previously suggested inside-out amino acid sensing mechanisms 
from the lysosomal lumen involving the vacuolar H+-ATPase (v-ATPase)45 and the 
protein SLC38A946 provide challenging tasks for future studies. 
Energy status 
Adenosine triphosphate (ATP) provides energy for a vast amount of cellular processes. 
Hence, cells need to sense the availability of ATP prior to the activation of anabolic, 
energy consuming pathways. The AMP-activated protein kinase (AMPK) is active 
under low energy levels and phosphorylates TSC247, feeding into the insulin sensing 
pathway described above. Furthermore, AMPK can directly reduce mTORC1 activity 
via an inhibitory phosphorylation of Raptor48. 
Hypoxia 
Cells downregulate energy consuming processes under low oxygen tension. 
“Regulated in development and DNA damage” (REDD1) inactivates mTORC1 singling 
by relieving an inhibitory interaction between TSC2 and the protein 14-3-349. 
 
mTORC2 
Knowledge on mTORC2 signaling is sparse. mTORC2 activity is insensitive to 
nutrients but does respond to insulin stimulation. The mechanism involves association 
of the ribosome with mTORC2 in a PI3K dependent manner50. In Addition, the 
localization of mTORC2 to an endoplasmic reticulum (ER) subcompartment named 
mitochondria-associated ER membrane (MAM) appears to be crucial for proper 
mTORC2 signaling51. 
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Figure 1.5 The mTOR signaling pathways. 
mTOR responds to environmental signals: Amino acids sensing pathways localize mTORC1 to 
the lysosomal surface through the Rag proteins, where mTORC1 is activated by Rheb under 
growth factor stimulation via the PI3K signaling. mTORC1 additionally senses the cellular 
energy status and the oxygen level, while mTORC2 solely responds to growth factor 
stimulation. Positive mTOR signaling affects a multitude of metabolic processes as indicated. 
mTORC1 substrates S6K and 4EBP1 promote protein translation. Positive mTOR signaling 
additionally activates pyrimidine biosynthesis, mRNA biogenesis, lipid biosynthesis and inhibits 
autophagy, cell cycle arrest and apoptosis.  
1.2.5 Downstream effectors of mTORC1 and mTORC2 
The two mTOR complexes act on a vast number of metabolic processes. In favorable 
growth conditions activated mTORC1 promotes key anabolic processes in order to 
deliver the building blocks for the generation of new biomass (Figure 1.5). 
Protein translation 
By far the best characterized mTORC1 effector pathway is the activation of protein 
translation in response to mTORC1 stimulation. S6 kinase (S6K) is a well characterized 
and established mTORC1 substrate. Phosphorylation at Thr389 induces a 
subsequent phosphorylation at Thr229 by phosphoinositide-dependent kinase 1 
(PDK1), which fully activates S6K. S6K in turn activates a multitude of effectors that 
promote mRNA biogenesis and protein translation52. Moreover, S6K downregulates 
growth factor sensing via inhibition of IRS1, enabling negative feedback regulation of 
mTORC1 signaling53. 
A second well characterized mTORC1 substrate is eukaryotic translation initiation 
factor 4E-binding protein (4EBP1). Phosphorylated 4EBP1 is unable to bind and inhibit 
eukaryotic translation initiation factor 4E (eIF4E), a key factor for cap-dependent 
translation54. 
Pyrimidine biosynthesis 
Nucleotides are the building blocks for DNA and RNA. Thus their availability is a 
prerequisite for the synthesis of new genetic material. mTORC1 stimulation promotes 
de-novo pyrimidine synthesis by S6K-mediated phosphorylation of the enzyme 
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase 
(CAD) at Ser185955. CAD is 243 kDa multienzyme that comprises catalytic domains 
for the first three steps of pyrimidine biosynthesis. It generates a pyrimidine ring from 
glutamine, bicarbonate and aspartic acid. 
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Lipid biosynthesis 
Lipids are the structural components of all biological membranes. Cell growth comes 
along with the increase of the membrane surface and thus demands the synthesis of 
new lipids. mTORC1 regulates the transcription of lipogenic genes such as fatty acid 
synthase (FAS) or acetyl-CoA carboxylase (ACC) via sterol regulatory element-binding 
protein (SREBP) transcription factors. SREBPs are either activated by S6K in an 
unknown manner56 or through Lipin-1. Lipin-1 inhibits SREBP activity. Stimulated 
mTORC1 directly phosphorylates Lipin-1 and prevents translocation to the nucleus 
and hence relieves the inhibition on SREBP. 
Autophagy 
Autophagy regulates the degradation of cellular structures and the recycling of their 
components. This is especially important when the availability of nutrients is restricted. 
Stimulated mTORC1 signaling also promotes growth by inhibiting autophagy via UNC-
51-like kinase 1 (ULK1). AMPK activates ULK1 under starvation, which in turn induces 
autophagosome formation. mTORC1 mediated phosphorylation of ULK1 disrupts the 
interaction between ULK1 and AMPK and thus directly inhibits autophagy57. 
 
mTORC2 
mTORC2 regulates several members of the AGC (protein kinase A, protein kinase G 
and protein kinase C) kinase family, namely Akt, serum- and glucocorticoide-induced 
protein kinase 1 (SGK1) and protein kinase C-α (PKC-α). mTORC2 phosphorylation 
of Akt at Ser473 in combination with phosphorylation of Ser308 via the insulin sensing 
pathway described earlier fully activates Akt58. Akt and SGK1 inactivate forkhead box 
protein O1 (FoxO1) and FoxO3a, transcription factors for proteins involved in 
metabolism, stress resistance, cell cycle arrest and apoptosis59. Activation of PKC-α 
is implicated in cytoskeleton organization27,28. 
 
1.2.6 mTOR is a therapeutic target in immunology and oncology 
Not long after the discovery of its immunosuppressive properties, rapamycin was 
approved by the FDA in 1999 for prevention of allograft rejection after organ 
transplantation and has been widely used ever since60. In 2002 its clinical application 
was extended to the prevention of restenosis after coronary stent surgery by inhibiting 
growth of vascular smooth muscles61. The fact that mTOR deregulation is also 
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implicated in cancer as well as the tolerability of rapamycin in patients guided efforts 
to expand its use to oncology. Two rapamycin derivatives (commonly referred to as 
rapalogues), temsirolimus and everolimus, are approved and used since 2007 and 
2009, respectively, to treat advanced kidney cancer, mantle cell lymphoma and 
pancreatic neuroendocrine tumors62. However, their clinical success was well below 
the high expectations. Possible explanations might be the fact that rapamycin 
treatment only affects some but not all mTORC1 substrates and is largely ineffective 
towards mTORC2. Moreover, negative feedback regulation of PI3K-signaling by S6K 
is lost upon mTORC1 inhibition, which stimulates PI3K-Akt signaling and ultimately 
inhibits apoptosis via FoxO62. Recent attempts aim to target mTOR signaling more 
broadly. Specific mTOR ATP-competitors that act on both mTOR complexes as well 
as dual mTOR/PI3K inhibitors additionally tackling loss of negative feedback regulation 
are currently in clinical trials63. 
 
1.2.7 mTORC1 substrate recognition 
The diversity of the mTOR kinase substrates requires means for their recognition in 
order to deliver them to the catalytic site and ensure specificity. A highly conserved 
TOR signaling (TOS) motif has been identified both in S6K (FDIDL, amino acids 5-9) 
and 4EBP1 (FEMDI, amino acids 114-118)64,65. An intact TOS-motif is required for 
binding by the mTORC1 subunit Raptor, suggesting a dedicated role of Raptor in 
substrate recognition and delivery to the mTOR kinase. Mutations in the TOS-motif 
abrogate the interaction between Raptor and the S6K / 4EBP1 and strongly reduce 
the phosphorylation of mTORC1-targeted sites66,67. The negative mTORC1 regulator 
PRAS40 comprises a TOS-like sequence (FVMDE, amino acids 129-133). PRAS40 
binds Raptor in a TOS-dependent manner. The competition of PRAS40 with mTORC1 
substrates for Raptor binding has been suggested to be the inhibitory mechanism24. 
Furthermore, 4EBP1 comprises an amino-terminal RAIP-motif (amino acids 13-16), 
which is required for mTOR mediated phosphorylation68,69. 
mTORC1 substrate recognition is complex and not only mediated by TOS-motif 
binding. First, No TOS-motifs have been identified in other mTORC1 substrates like 
ULK1 or Lipin-157,70. And secondly, the mTORC1 specific inhibitor rapamycin 
completely inhibits the phosphorylation of S6K, but does only partially inhibit 
phosphorylation of 4EBP171,72. Kinase assays on synthetic mTORC1 substrate 
peptides suggest that the primary sequence around the phosphorylation site 
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determines the sensitivity towards Rapamycin inhibition73. However, it is very likely that 
more factors, such as the accessibility of the phosphorylation site and additional 
recognition motifs outside the target region further modulate the substrate recognition. 
 
1.2.8 Structural biology of the mTOR complexes 
Structural knowledge on mTOR and PIKKs in general is sparse. High resolution 
structure determination of intact mTOR complexes was mainly hindered by the huge 
size of approximately 1 MDa for mTORC1 and 1.2 MDa for mTORC2 and the 
difficulties to produce them in sufficient amounts. However, crystal structures of some 
mTOR fragments in complex with specific binding partners are available. Moreover, 
the solution structure of the carboxy-terminal α-helix of mTOR has been determined 
by NMR and suggests a role for redox-dependent structural and cellular stability74. 
The crystal structure of the isolated mTOR FRB domain in complex with rapamycin 
and FKBP12 has been solved already in 1996 (Figure 1.6A)18. FKBP12 adopts a five-
stranded antiparallel β-sheet preceded by a short α-helix. The FRB forms a four-helix 
bundle. Rapamycin is bound to both domains and forms the dimer interface. The 
macrolide is almost entirely buried between the two domains. The structure explains 
the specificity of the FKBP12-Rapamycin interaction with mTOR, but does not reveal 
the mechanism of mTORC1 inhibition.  
Recently, a crystal structure of a carboxy-terminal mTOR fragment (amino acids 1376-
2549, mTOR∆N) comprising the FAT, FRB and kinase domain bound to mLST8 was 
determined (Figure 1.6B)19. The kinase domain adopts a bilobal fold similar to PI3K 
and canonical protein kinases. The mLST8 β-propeller is bound to the kinase C-lobe, 
restricting the access to the catalytic cleft. The FRB is an amino-terminal extension of 
the kinase N-lobe and further hinders the access to the active site. Modeling of 
FKBP12 onto the FRB domain restricts the catalytic cleft even more. The kinase is 
wrapped by the entirely α-helical FAT domain, giving the fragment a compact shape. 
The kinase in the mTOR∆N-mLST8 fragment is in an intrinsically active conformation. 
Thus, the catalytic activity is likely regulated by the surroundings of the active site in 
the mTOR complexes. The activity is modulated by the mTOR negative regulatory 
domain (NRD, residues 2430-2450), whose deletion has a positive effect on kinase 
activity75,76. The NRD is not resolved in the crystal structure due to high flexibility, but 
it is located in close vicinity to the catalytic site and might restrict its access even more. 
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the core, leaving the remaining density to account for mTOR. The reconstruction 
confirms the presumed dimeric architecture32,34, but the insights into the assembly and 
interaction of individual domains are negligible due to the very low resolution. The 
second study subjected Saccharomyces cerevisiae TOR1 and a TOR-KOG1 
(kontroller of growth protein 1, Raptor ortholog) complex to negative stain electron 
microscopy78. Despite the high sequence identity between TOR and mTOR (42%) as 
well as KOG1 and Raptor (42%) the two reconstructions largely differ from the model 
of human mTORC1 (Figure 1.6D) . Overall the quality of the hollowed reconstruction 
is poor and prohibits a meaningful interpretation. 
The domain composition of Raptor and Rictor are solely based on bioinformatic 
studies. Homology searches of Raptor have identified a caspase-like domain in the N-
terminal conserved (RNC) region, followed by three HEAT repeats and a seven bladed 
WD40 propeller at the carboxy-terminal end20,21,79. Rictor comprises several conserved 
regions of unknown structure or fold27,28. No high-resolution structure for any parts of 
Raptor or Rictor are available that would permit dissection of their specific functions 
in mTOR complex assembly and signaling. 
  

1  Introduction 
 
 33 
(Figure 1.7A). PLK1 is the ancestral member of the family and is most closely related 
to Polo, Cdc5 and Plo184. At least three gene duplication gave rise to PLK2, PLK3, 
PLK4 and PLK584,85. They all share a conserved amino-terminal Ser/Thr-kinase86. 
However, PLK5 has a truncated kinase that does not possess any catalytic activity87,88. 
All members additionally comprise at least two Polo-boxes (PB), the characteristic 
feature of the PLKs89. PBs possess a six-stranded antiparallel β-sheet followed by an 
α-helix which spans across the entire sheet (Figure 1.7B). 
 
1.3.2 Polo-like kinase 1 
PLK1, the best characterized member of the human PLKs, drives a variety of 
processes during cell cycle progression, including centrosome maturation, mitotic 
entry, chromosome maturation and cytokinesis83,84. Its activity is controlled through 
four levels of regulation: 1) PLK1 can be activated by phosphorylation of a highly 
conserved Threonine (Thr210) located in the activation loop90. 2) Binding of targets by 
the Polo-boxes increases the kinase activity which might together with Thr210 
phosphorylation relieve an autoinhibitory interaction between the kinase domain and 
the Polo-boxes80. 3) PLK1 expression levels are tightly controlled, peaking at the G1-
M phase transition91. 4) And lastly, PLK1 is ubiquitinated by anaphase promoting 
complex (APC) and targeted for proteasomal degradation. APC is most active during 
late M-Phase and early G1 phase, which coincides with PLK1 having its major roles 
during mitosis92,93.  
PLK1 has two carboxy-terminal PBs, PB1 and PB2, which together form the Polo-
box domain (PBD) and typically bind phosphorylated (also referred to as “primed”) 
targets80,94,95. The target can either be primed by PLK1 itself (self-priming and binding) 
or by another kinase like Cyclin-dependent kinase 1 (Cdk1, non-self-priming and 
binding)89. More recent studies have revealed that the PBD can also bind non-
phosphorylated targets in the case of Polo and the 205 kDa microtubule-associated 
protein (Map205) in Drosophila melanogaster96,97. Much less is known about the 
regulation of PLK2 and PLK3, but their similarity to PLK1 suggests related 
mechanisms of regulation84. 
 
1.3.3 Polo-like kinase 4 
PLK4 has a specialized role in centriole duplication98. Overexpression of PLK4 in 
human cells increases centriole number, whereas PLK4 depletion reduces the number 
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of centrioles99,100. Centrioles are cylindrical microtubular structures that make up the 
core of the centrosome (Figure 1.7C)101,102. A single centrosome comprising two 
centrioles is present during G1-phase. The centrosome is duplicated before mitosis 
to later anchor the bipolar spindle during cell division. The two centrioles within the 
centrosome are separated and both provide the basis for the generation of a new 
daughter centriole. Strict control of centriole duplication is a prerequisite for proper 
chromosome segregation103. Similar to PLK1, PLK4 activity is regulated on multiple 
levels: 1) The abundance of PLK4 is precisely controlled through transcriptional 
regulators and degradation as described below. PLK4 reaches the highest levels 
during mitosis and is almost undetectable in the interphase104,105. 2) PLK4 is kept in an 
inactive state and is activated in S-phase. 3) Activated PLK4 trans-
autophosphorylates, as monitored by phosphorylation of Ser305106, leading to 
proteasomal degradation via ubiquitination. This negative feedback loop ensures that 
PLK4 is only active during a short time period and thus prevents the cell from over 
duplication of centrioles107. 
PLK4 is structurally distinct from its paralogs. In contrast to the PBD present in PLK1-
3, PLK4 possesses a cryptic polo box (CPB) domain108. The CPB domain is composed 
of two Polo-boxes with minor variations to the classical Polo-box fold, which have a 
different relative orientation compared to PB1 and PB2 in PLK1109,110. Two CPB 
domains can interact and allow PLK4 to dimerize. The CPB binds both centrosomal 
protein 152 (Cep152) and centrosomal protein 192 (Cep192) in a mutually exclusive 
manner, which is crucial for PLK4 localization and repositioning during centriole 
duplication111. The kinase domain and the CPB are bridged by a 314 residue linker, 
L1. Another peculiarity of PLK4 compared to its paralogs is the presence of a third 
Polo-box (PB3) at the carboxy-terminal end. The crystal structure of the isolated 
murine PB3 reveals a domain-swapped dimer suggesting a role in PLK4 
oligomerization112. However, the physiological relevance of this structure, crystallized 
under extreme conditions is doubtful. 
The mode of action of PLK4 involves centriolar targeting to distinct Cep152 and 
Cep192 scaffolds113. Activated PLK4 very likely recruits spindle assembly abnormal 
protein 6 homolog (SAS-6), as it has been demonstrated in Caenorhabditis. 
elegans114. SAS-6 self-assembles into a nine-fold symmetric cartwheel and appears 
to provide the structural framework for the synthesis of a new centriole115,116. The 
mechanisms of PLK4 activation are largely unknown. Very likely yet unidentified protein 
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factors are involved. The identification of such modulators and their respective roles 
would allow a more complete comprehension of centriole duplication regulation.  
 
1.4 The acetyl-CoA carboxylase 
Acetyl-CoA carboxylase (ACC) is a prominent example of a proliferative metabolic 
enzyme that is under the control of the mTOR pathway. Mammals possess two ACCs: 
ACC1 and ACC2. The cytosolic ACC1 catalyzes the biotin-dependent carboxylation 
of acetyl-CoA to malonyl-CoA. This reaction provides the building block for fatty acid 
synthesis and is the rate limiting step of long-chain fatty acid biosynthesis117. ACC2 
shares 73% sequence identity to ACC1, and possesses an amino-terminal extension 
that anchors it to the outer mitochondrial membrane118. Malonyl-CoA produced by 
ACC2 inhibits carnitine O-palmitoyltransferase I (CPT-I), an enzyme that induces the 
transport of long-chain fatty acids into the mitochondria for β-oxidation119,120. The 
central role of ACC in lipid metabolism makes it an attractive target for drug discovery 
against type 2 diabetes, obesity and other manifestations of the metabolic 
syndrome121,122. Moreover, elevated levels of de novo fatty acid synthesis are a 
hallmark of proliferating cancer cells due to an increased demand of membrane 
lipids23. Hence, ACC is a promising anti-cancer drug target. 
 
1.4.1 Regulation of eukaryotic ACCs 
Human ACCs are regulated on multiple levels. First, the expression levels are regulated 
by SREBP transcription factors under involvement of mTORC1 in response to nutrient 
and growth factor stimulation as described in the previous section (1.2.5.) Short-term 
regulation is mediated via citrate, which acts as an allosteric activator and stimulates 
the formation of ACC polymers of up to 8 MDa, the most active ACC form123. 
Reversible phosphorylation by AMPK and “cAMP-dependent protein kinase” (PKA) 
decreases the sensitivity towards citrate, and thus inactivates ACC. ACC activity is 
further modulated by the polymer-promoting “mid1-interacting G12-like protein” 
(MIG12)124. Breast cancer susceptibility gene 1 (BRCA1) inhibits ACC activity via 
binding of phosphorylated Ser1263125-127. Furthermore, phosphorylation at Ser80 and 
Ser1201 are implicated with regulation128,129. 
The highly conserved ACC from Saccharomyces cerevisiae (46% sequence identity 
to human ACC1) has not been reported to form polymers. Its activity is mainly 
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(BCCP), that shuttles the reaction intermediate from the first active site to the second. 
In the case of Escherichia coli (E. coli), ACC consists of individual proteins (Figure 
1.8B), that form an unstable multi-subunit complex with the stoichiometry 
(BC)2(BCCP)4(CTα,CTβ)2118,133. Most eukaryotic ACCs on the other hand are large 
(~250 kDa) multienzymes, which comprise all functional units as domains on a single 
poly-peptide chain118. In eukaryotic ACC, the carboxy-terminal CT and the amino-
terminal BC are bridged by a structurally and functionally poorly characterized central 
domain (CD) (Figure 1.8B)118. Structural information on eukaryotic ACCs is limited to 
crystal structures of isolated BC134, BCCP135 and CT136 domains. No structural 
information is available for the CD, that makes up one third of the entire ACC. Very 
likely the CD has a key role in ACC regulation reflected by the presence of several 
phosphorylation sites and the interaction with the inhibitory protein BRCA1. Structural 
studies on full-length eukaryotic ACCs are impeded by their size and by the dynamic 
nature of the system. It is of great relevance to structurally characterize the assembly 
and domain arrangement in eukaryotic ACCs, which needs to permit substrate 
shuttling by the BCCP . Moreover, it would allow to dissect the role of the central 
domain, that might mediate eukaryotic specific regulation by binding auxiliary proteins 
or providing a platform for regulatory phosphorylation.  
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1.5 Aims of the thesis 
Despite their fundamental role in key metabolic processes, detailed structural 
information on mTOR complexes is limited to smaller fragment structures. Insights on 
the assembly of the individual components into large complexes are almost 
completely absent, mainly due to the challenges of studying such large, multi-protein 
complexes. This hinders the understanding of central questions in the mTOR signaling 
network. What is the basic mTORC1 architecture and which are the interacting 
domains between individual subunits? Which structures are involved in substrate 
recognition? Which regions may provide a platform for regulatory proteins? Therefore, 
the main aim of this thesis was to obtain a high-quality medium resolution model, 
which allows interpretation on a pseudo residue level. Of special interest was the 
structural analysis of the mTORC1-defining subunit Raptor, which determines the 
functional specificity of mTOR in mTORC1. I aimed to understand, which structural 
features of Raptor contribute to its three central roles, namely substrate recognition, 
scaffolding and Rag-targeting. 
 
Chapter 2 presents the structure determination of mTORC1 by a hybrid-method 
approach using cryo-electron microscopy of recombinant human mTORC1 combined 
with crystallographic studies of Chaetomium thermophilum Raptor. The structure 
provides major insights into the architecture of human mTOR complex 1 and 
implications for the substrate recognition by Raptor. Furthermore, the work sets a 
structural framework to address subsequent questions of mTORC1 and mTORC2 
regulation. This chapter is reproduced from the publication “Architecture of human 
mTOR complex 1” (Aylett C.H.S.*, Sauer E.*, Imseng S.*, Boehringer D., Hall M.N., 
Ban N. Maier T., Science, 2016). 
 
Chapter 3 covers the identification of STIL as a PLK4 regulator and the implications 
for centriole duplication. The activating mechanisms of the Polo-like kinase 4 is poorly 
understood. Especially interesting was the identification of unknown protein factors 
and the characterization of their function in PLK4 regulation. Structure determination 
of the PLK4-PB3/STIL-CC complex in combination with co-immunoprecipitation 
experiments, cellular assays, ITC experiments and NMR studies reveal an activating 
role of STIL towards PLK4. The structure additionally determines a new mode for 
substrate binding by a Polo-box. This chapter is reproduced from the publication “STIL 
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binding to Polo-box 3 of PLK4 regulates Centriole Duplication” (Arquint C.*, 
Gabryjonzyk A*., Imseng S.*, Boehm R.*, Sauer E., Hiller S., Nigg E.A., Maier T., eLife, 
2015). 
 
Chapter 4 addresses the structural basis for the regulation of eukaryotic ACCs. 
Eukaryotic acetyl-carboxylases are very large and highly dynamic multi-enzymes. 
Structures were only available for isolated catalytic domains, but not for the non-
catalytic central domain (CD) or the overall multienzyme. The CD is implicated in 
regulation by phosphorylation, but its structure and function were unknown. Here, we 
report the crystallographic structure determination of the human and budding yeast 
central domain and integrate the results with intermediate and low resolution structural 
data on near full-length ACC from Chaetomium thermophilum. Altogether, our results 
reveal the mechanism of phosphorylation control of yeast ACC activity. This chapter 
is reproduced from the publication “The Dynamic Organization of Fungal Acetyl-CoA 
Carboxylase” (Hunkeler M.*, Stuttfeld E.*, Hagmann A., Imseng S., Maier T., Nature 
Communications, 2016). 
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2.1 Abstract 
Target of rapamycin (TOR), a conserved protein kinase and central controller of cell 
growth, functions in two structurally and functionally distinct complexes: TORC1 and 
TORC2. Dysregulation of mammalian TOR (mTOR) signaling is implicated in 
pathologies that include diabetes, cancer, and neurodegeneration. We resolved the 
architecture of human mTORC1 (mTOR with subunits Raptor and mLST8) bound to 
FK506 binding protein (FKBP)–rapamycin, by combining cryo–electron microscopy at 
5.9 angstrom resolution with crystallographic studies of Chaetomium thermophilum 
Raptor at 4.3 angstrom resolution. The structure explains how FKBP-rapamycin and 
architectural elements of mTORC1 limit access to the recessed active site. Consistent 
with a role in substrate recognition and delivery, the conserved amino-terminal domain 
of Raptor is juxtaposed to the kinase active site.  
 
2.2 Introduction 
Since its discovery in 1991 as the target of the immunosuppressant rapamycin, TOR 
has emerged as a central regulator of cell growth and metabolism. TOR was identified 
in yeast5,14; the mammalian ortholog is mTOR. The serine and threonine kinase activity 
of TOR is tightly regulated in response to physiological conditions, and aberrant mTOR 
signaling occurs in multiple pathologies, including diabetes, cancer, and 
neurodegeneration137,138. 
TOR is the core component of two, functionally distinct signaling complexes, TOR 
complex 1 (TORC1) and TORC220,21,23,27,28,139,140. TORC1 is sensitive to rapamycin and 
regulates cell growth by activating protein, lipid, and nucleotide synthesis and by 
inhibiting autophagy. TORC2 is less well characterized but is rapamycin insensitive 
and controls diverse cellular processes through phosphorylation of several targets. 
Mammalian TORC1 (mTORC1) contains, in addition to mTOR, Raptor (regulatory-
associated protein of mTOR)20,21, mammalian homolog of protein Lethal with Sec 
Thirteen (mLST8)22,139, and possibly several noncore subunits. Whereas mTOR and 
mLST8 are also found in mTORC2, Raptor is absent. Instead, Rictor (rapamycin-
insensitive companion of mTOR)27,28,139 and additional subunits29,30,141 are required for 
mTORC2 activity. 
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The regulation of mTORC1 signaling involves interactions with several binding partners 
and translocation of mTORC1 within the cell23,140. mTORC1 is activated in response 
to nutrients (amino acids) through the Rag guanosine triphosphatase (GTPase) 
signaling pathway40,142, by growth factors through inhibition of the tuberous sclerosis 
complex 1 and 2 (TSC1 and TSC2) heterodimer and thereby activation of the small 
GTPase Rheb143,144, and by cellular energy status through adenosine 
monophosphate–activated protein kinase (AMPK) phosphorylation of TSC2 and 
Raptor47,48.  
TOR is the founding member of the phosphatidylinositol-kinase–related kinase (PIKK) 
family11, members of which share an elaborate domain organization. The kinase 
domain is situated at the C terminus, following long arrays of first HEAT (Huntingtin, 
EF3A, ATM, TOR), and then tetratricopeptide (TPR), repeats16,145. The crystal structure 
of a compact C-terminal fragment of human mTOR containing the FAT (Frap, ATM, 
TRRAP) domain and the kinase domain has been resolved in complex with its obligate 
accessory protein, mLST819.  
Inhibition of mTOR by rapamycin is dependent on the formation of a complex with an 
intracellular receptor, FK506-binding protein (FKBP)146,147, which then binds mTOR in 
mTORC1. FKBP interacts with mTOR through the hydrophobic rapamycin molecule, 
which binds pockets in each protein5,18,148. The N terminus of the kinase domain forms 
the FKBP-rapamycin complex binding (FRB) domain, which juts outward from the N-
lobe19. Binding of the FKBP-rapamycin complex to the FRB domain has been 
predicted to narrow the active-site cleft19, suggesting that rapamycin inhibition is due 
to steric hindrance71. The FRB domain also binds cognate mTOR targets, and the 
mutation of key residues in the FRB domain impairs phosphorylation of model 
substrates19.  
The catalytic activity and substrate specificity of mTORC1 are regulated by Raptor. 
Raptor is a multidomain protein, predicted by sequence similarity to consist of an RNC 
(Raptor N-terminal Conserved) domain, a central set of armadillo repeats, and a C-
terminal β-propeller20,21. Raptor functions in substrate binding, being required for 
phosphorylation of many mTORC1 substrates, the best characterized of which are the 
translational regulators ribosomal protein S6 kinase (S6K1) and eukaryotic translation 
initiation factor 4E-binding protein (4EBP). Phosphorylation of these substrates is 
dependent on their TOR signaling (TOS) motif, which binds Raptor directly66,67. 
Biochemical investigation of the oligomeric state and composition of TORCs 
demonstrated that TOR and mTOR complexes are dimeric, and allowed assignment 
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of core components. Owing to difficulties in working with intact mTORC1, however, 
information on the three-dimensional arrangement of proteins and domains within the 
complex was limited to crystal structures of fragments18,19, and a low-resolution (26 Å) 
reconstruction through cryo–electron microscopy (cryo-EM)77 revealing twofold-
symmetric, dimeric particles roughly 300 Å by 200 Å by 100 Å in size. In that study, 
however, the handedness of the reconstruction and the position of individual subunits 
could not be reliably assigned.  
We resolved the structures of human mTORC1 and Chaetomium thermophilum 
Raptor (CtRaptor) at 5.9 and 4.3 Å resolution by cryo-EM and X-ray crystallography, 
respectively. We provide a description of the architecture of mTORC1 at a secondary 
structural level, placing the folded domains of all three mTORC1 subunits and 
revealing their relative arrangement within the complex.  
 
2.3 Results and Discussion 
2.3.1 Determination of the cryo-EM structure of mTORC1  
We coexpressed and copurified human mTOR, Raptor, and mLST8 from insect cells, 
obtaining a homogeneous mTORC1 complex with a molecular size of ~1.0 MD 
(Supplemental Figure 2.1A,B). Purified material phosphorylated the mTORC1 
substrate 4EBP1 and was inhibited by torin1 or FKBP-rapamycin, as expected for 
native mTORC1 (Supplemental Figure 2.1C). For structural studies, a stable mTORC1 
sample was generated by expression in the presence of rapamycin followed by mild 
glutaraldehyde gradient fixation149. Single-particle analysis of cryo–electron 
micrographs from this mTORC1 sample yielded a reconstruction with an overall 
resolution of 5.9 Å (gold-standard Fourier shell correlation = 0.143 cut-off), within 
which only a few peripheral regions were ordered to lower resolution (Supplemental 
Figure 2.2, Supplemental Figure 2.3). Secondary structural elements were clearly 
resolved throughout most remaining regions of the complex, allowing all folded 
domains predicted within mTORC1 to be assigned. The reconstruction presented 
here is complemented by the crystal structure of C. thermophilum Raptor that fits the 
EM density of human mTORC1 and confirms the segregation of the Raptor and mTOR 
repeat regions. Both the crystal structure of the C-terminal fragment of mTOR19 and 
the Raptor structure fit our density, allowing us to determine the handedness of the 
reconstruction (Figure 2.1 and Supplemental Figure 2.4). The overall shape of our 
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reconstruction agrees with that of the published reconstruction; however, it appears 
that the handedness of the previous reconstruction was assigned incorrectly77. 
 
Figure 2.1 mTORC1 adopts a dimeric, lozenge-shaped architecture.  
The reconstructed density obtained without masking peripheral regions, filtered to its global 
resolution (6.1 Å) and contoured at 3σ, is shown as a translucent surface, and the 
corresponding model in cartoon representation. Each successive panel (A to D) is rotated as 
indicated. Raptor is in shades of green, mTOR in purples (N-terminal HEAT repeats) and blues 
(C-terminal FAT and kinase domains), mLST8 in orange, and FKBP in red. The active site, at 
the base of a restrictive cleft, is indicated by a magenta asterisk. A tinted surface representation 
showing the surface corresponding to one of each of the subunits within the proposed model 
of mTORC1 is inset. 
2.3.2 mTORC1 forms a hollow dimer with minimal subunit contacts  
mTORC1 adopts a cage-like, dimeric architecture in which the C2 symmetry axis 
passes through a large cavity (>60 Å across in places), leading to its characteristic 
hollow lozenge shape (Figure 2.1A,B). The kinase domains of mTOR are located near 
the center of the assembly and come close to each other but do not make contact. 
Raptor and mLST8 contribute peripheral parts of the complex, making up the 
pinnacles of the longer and shorter axes of the lozenge, respectively. When viewed 
from an angle perpendicular to the symmetry axis, one face of mTORC1 is 
characterized by the mTOR kinase domains and mLST8 subunits, with both active-
A B
DC
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site clefts opening outward from this side of the complex (Figure 2.1A,C). The opposite 
face comprises the N-terminal HEAT repeat domains of mTOR, which form 
superhelical α-solenoids (Figure 2.1B,D). Raptor binds within the well-ordered juncture 
of two HEAT repeat domains. The RNC domain abuts the FRB region of the mTOR 
kinase domain, and the more C-terminal armadillo repeat and β-propeller domains 
extend outward, becoming less well resolved (Figure 2.1B,C). 
 
2.3.3 The mTOR HEAT repeats contain two α-helical solenoids  
  
Figure 2.2 Model showing the suggested domain organization of the mTOR dimer.  
A, B The C- terminal kinase and FAT domains of mTOR form a compact unit, and the N-
terminal HEAT domains adopt an elongated structure with two separate a-solenoids: the 
“horn” and “bridge.” The proposed model is shown in cartoon representation, rotated as 
indicated. Symmetry-related mTOR domains are shown in gray. C Linear representation of the 
domain organization of mTOR. The residue numbers indicate the domain boundaries; domain 
lengths are consistent in residues. 
The N-terminal portion of mTOR has a bipartite structure consisting largely of α-
solenoid helical repeats. The extended, N-terminal region merges directly into the 
more compact, C-terminal fragment, which wraps around the kinase domain. The 
repetitive N terminus of mTOR, a prototypical HEAT repeat16,145, forms two α-solenoids 
(Figure 2.2). The larger section is a highly curved superhelix, which we have dubbed 
the “horn,” seven repeats of which can be placed at the individual-helix level. The 
remaining repeats are less clearly resolved, indicating local flexibility. The smaller 
region adopts a relatively linear arrangement consisting of seven HEAT repeats and a 
helical linkage to the compact fragment, which we refer to as the “bridge” (Figure 2.2) 
The horn and bridge HEAT domains pack against one another. Nevertheless both 
sections are predominantly exposed to the environment, supporting a purported role 
A B
C
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in binding mTOR regulators. The bridge region merges directly into the TPR repeats 
of the FAT domain (Figure 2.2) and the prior crystal structure of this region fits our 
density with only minor adjustments19 (Figure 2.1 and Supplemental Figure 2.4).While 
no linkage between the two HEAT domains is visualized, their termini are in close 
proximity to one another. Although we cannot definitively assign sequence to regions 
of density at this resolution, the available evidence from studies of homologs150 
supports an interpretation in which the domains are continuous and contiguous, with 
the horn representing the N-terminal section and the bridge the more C-terminal part 
(see 2.4). This suggested topology is shown in Figure 2.2 
 
2.3.4 mTOR HEAT repeats bridge the kinase domains  
 
Figure 2.3 The horn and bridge of mTOR complete a full dimeric interaction, linking 
the two FAT-PIKK units.  
A The complete interaction is shown intact, and the reconstruction, filtered to its global 
resolution (5.9 Å) and contoured at 6σ, is indicated as a translucent surface; the corresponding 
model is shown as a secondary structural cartoon. B The interaction surface is shown with the 
point of view rotated as indicated. The symmetry-related horn domain is denoted horn′. 
Although Raptor is proposed to mediate mTOR dimerization by binding between the 
mTOR subunits77, our structure reveals that mTOR itself forms a complete dimer 
(Figure 2.2). The horn and bridge HEAT domains pack against one another, and the 
first HEAT repeat of the mTOR horn region is buried against the base of the adjacent 
mTOR FAT domain, completing an interlocking interaction between the two subunits 
(Figure 2.3A). Dimerization changes the conformation of the FAT domain of mTOR 
relative to that in the monomeric crystal structure (Supplemental Figure 2.4)19. TPR 
helices 4 to 12 rotate to accommodate the interaction, presenting the interface and 
stacking neatly across the first repeat of the horn (Figure 2.3B). Notably, the 
A B
90º
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extension absent in human Raptor (Supplemental Figure 2.6). Several smaller 
proteolytic fragments remained associated with the Raptor core (Supplemental Figure 
2.6). Experimental phases for CtRaptor crystals were determined with a mercury 
derivative, and a backbone model was traced at a resolution of 4.3 Å (Supplemental 
Figure 2.7). CtRaptor adopts an extended Z shape with the RNC and β-propeller 
domains arranged at opposite ends of the armadillo domain (Figure 2.4).  
The N-terminal RNC domain exhibits an α-β-α sandwich fold that is structurally related 
to that found in CASPases (Supplemental Figure 2.8A), consistent with conserved 
motifs in both families 79. The RNC domain is connected to the armadillo domain 
through four helices, three of which originate from a large insertion (relative to the 
CASPase fold) between strand one and a shortened helix four, and the fourth from 
the C terminus of the RNC domain. Two of the active-site residues of CASPases are 
conserved in the RNC domain 79. Our model of CtRaptor reveals that there is also 
structural conservation of the corresponding regions. However, the N terminus of helix 
1, which contributes a key arginine residue to the CASPase active site, is displaced 
by more than 13 Å in CtRaptor.  
The Raptor armadillo domain comprises seven helical hairpins, five of which are 
canonical armadillo repeats (Supplemental Figure 2.8B). The β-propeller domain of 
Raptor associates with the armadillo repeats through the interaction of blades two and 
three with repeats five, six, and seven. The interaction takes place at the rim of the b 
propeller, leaving the face accessible for putative interacting proteins (Figure 2.4 and 
Supplemental Figure 2.8B). Three additional stretches of extended CtRaptor peptide 
are visible in the electron density (Figure 2.4 and Supplemental Figure 2.7). Stretch 1, 
belonging to the N terminus, originates at the b propeller, spans the entire armadillo 
domain, and joins the N terminus of the RNC domain. Stretch 2 forms a V-shaped 
helical segment at the C terminus of the repeat domain beneath the b propeller. 
Stretch 3 runs along the concave face of the armadillo domain. Stretches 2 and 3 
likely represent the linker region between the armadillo and β-propeller domains, 
corresponding to the fragments observed by mass spectrometry (Supplemental 
Figure 2.6). The corresponding linker region of human Raptor (residues 700 to 900) is 
frequently phosphorylated151; based on our structural data, such posttranslational 
modification could affect interactions with the Raptor core in vivo.  
The conformation of CtRaptor in crystals is close to that of human Raptor in the 
mTORC1 EM reconstruction, allowing us to fit the crystal structure as a rigid body into 
the EM density. The projection of the β-propeller domain of Raptor away from the core 
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of mTORC1 is consistent with a role for this domain in the recruitment of regulatory 
proteins (Figure 2.1, Figure 2.4)40,142. The Raptor RNC domain is positioned directly at 
the mTOR active-site cleft, implying its involvement in Raptor-mediated substrate 
recognition (Figure 2.1, Figure 2.4)66,67.  
 
2.3.6 Raptor stabilizes the mTOR HEAT domains  
Raptor is necessary for formation of the mTORC1 complex. The principal interaction 
between Raptor and mTOR consists of an α-solenoid stack formed between the horn 
and bridge domains of mTOR and the Raptor armadillo domain (Figure 2.5A). The 
horn and bridge domains run antiparallel to each other, forming a contact offset by 
half their depth (Figure 2.5B). The N-terminal helices of the Raptor armadillo repeat 
and the base of the RNC domain occupy this “step,” making up the remaining 
interaction surface with the loops of the HEAT repeats within the bridge and helices of 
those in the horn (Figure 2.5A). Given that Raptor provides roughly two-thirds of the 
interaction surface stabilizing the HEAT domains, the stability of the N-terminal regions 
of mTOR would be weakened in its absence. The formation of the mTORC1 dimer is 
also dependent on the interaction between the (flexible) horn N-terminal HEAT domain 
of mTOR and the C-terminal FAT domain. Without stabilization of the mTOR N-
terminal HEAT repeats in a single conformation, dimers could not be readily formed. 
Raptor binding thus may favor the dimerization of mTOR molecules without directly 
engaging in dimer formation 77,139. 
 
Figure 2.5 Raptor binds to and organizes the N terminus of mTOR through a horn-
bridge-armadillo a-solenoid stack  
A The complete interaction is shown with the reconstructed density, filtered to its global 
resolution (5.9 Å) and contoured at 6σ, indicated as a translucent surface; the corresponding 
model is shown as a secondary structural cartoon. B The antiparallel a-solenoid stack is shown 
as a secondary structural cartoon; the image generated with the point of view rotated as 
indicated and the threefold interaction surface are shown with dotted magenta lines.  
A B
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2.3.7 Implications of mTORC1 for substrate selectivity and delivery  
The structure of the C-terminal mTOR fragment revealed that the kinase domain is 
held in a catalytically active conformation by the surrounding FAT domain and 
segments inserted within the kinase domain itself19. The FRB domain and mLST8 limit 
access to the adenosine 5′-triphosphate (ATP)–binding cleft, preventing activity 
toward noncognate substrates, which would otherwise be problematic for a 
constitutively active enzyme. In our assembled complex, access to the active site is 
further restricted by Raptor. Whereas the FRB domain and mLST8 narrow the active-
site cleft from the N- and C-lobe sites, respectively, the RNC domain additionally 
restricts access from the solvent-exposed surface below the FRB domain. This results 
in the enclosure of the active-site cleft from all directions, reducing its width to ~20 Å 
(Figure 2.6).  
 
Figure 2.6 The RNC domain of Raptor is positioned adjacent to the FRB domain of 
mTOR, complementing the active-site cleft of the kinase domain  
A,B View into the active-site cleft of one half of an mTORC1 dimer. The reconstructed density, 
filtered to its global resolution (5.9 Å) and contoured at 3σ, is indicated as a translucent surface, 
and the corresponding model is shown in cartoon representation. The active site is indicated 
with a magenta asterisk. Panel (B) is shown with the perspective rotated, as indicated. C,D 
Schematic illustrating the proposed mode of substrate (gray) binding and delivery to the mTOR 
active site.  
A B
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Raptor directly interacts with substrate proteins through their TOS motifs, FDIDL in 
S6K66 and FEMDI in 4EBP164, which include a conserved aspartate at position four. 
Given the structural similarity between the RNC domain and CASPases, which 
recognize four-residue sequences with an aspartate at position four, equivalent 
residues in CASPase and Raptor may function in substrate recognition (Figure 
2.6C,D). The corresponding site is located directly within the mTORC1 active-site cleft, 
~50 Å from the kinase center and optimally positioned for recruitment and delivery of 
subtrate to the active site (Figure 2.6). Considering that the peripheral Raptor b 
propeller has been proposed to bind proteins involved in regulating mTORC1, it is 
possible that this regulation occurs via the peptide stretch connecting the b propeller 
to the RNC domain of Raptor.  
Our cryo-EM maps of mTORC1 reveal additional density next to the FRB domain 
(Figure 2.6). This density represents a copurified complex of Spodoptera frugiperda 
FKBP (SfFKBP) and rapamycin, which was used to enhance mTORC1 expression. 
SfFKBP shares 78% identity to human FKBP12, and its presence in purified mTORC1 
was confirmed by mass spectrometry. The FKBP-rapamycin density further reduces 
the active-site cleft to ~10 Å. It also lies between the RNC domain and the active site, 
supporting steric hindrance as the mechanism by which rapamycin may inhibit mTOR 
toward certain substrates, but not others71 (Figure 2.6B). Although it has been 
proposed that FKBP-rapamycin binding compromises mTORC1 stability, possibly by 
displacing Raptor77, we do not observe this effect. Furthermore, the FRB domain that 
binds FKBP-rapamycin18,148 is not near the dimerization interface; nor does it contact 
the RNC domain, making it unlikely that the binding of FKBP-rapamycin would 
destabilize mTORC1 by steric hindrance (Figure 2.6B).  
 
2.3.8 Implications for mTORC2 and other kinases  
The architecture of mTORC1 provides a structural basis for studying mTORC1 
function. Given the similar overall appearance of our structure and that of TORC2150,152, 
we anticipate that the architecture of mTORC1 might be conserved in parts of 
mTORC2. In particular, we anticipate that the mode of dimerization, in which a 
complete dimer is formed through mTOR-mTOR contacts alone, will be conserved. 
An interaction of Rictor in mTORC2 with the bridge and horn HEAT domains, similar 
to that of Raptor in mTORC1, could stabilize the N terminus of mTOR and facilitate 
mTORC2 dimerization. Raptor forms this interaction through its armadillo repeat 
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domain; a large domain of Rictor is also predicted to form an α-helical solenoid. Other 
members of the PIKK kinase family, including ATM, require accessory proteins that 
interact with HEAT repeats and are thought to dimerize in vivo. Although the N-
terminal HEAT-repeat domains of the family are their least conserved parts, it appears 
possible, given the residual sequence similarity, that PIKK family members may have 
common modes of interaction11.  
 
2.4 Experimental Procedures 
2.4.1 Laboratory materials 
Unless otherwise stipulated, chromatography equipment was provided by GE 
Healthcare (Schenectady, USA), chemicals were provided by Sigma Aldrich (St. Louis, 
USA), electron microscopy consumables were provided by Agar Scientific (Stansted, 
UK), and molecular graphics were generated using Chimera 153 and PyMol 
(Schrödinger LLC, New York, USA). 
 
2.4.2 Expression and purification of mTORC1 
Human mTORC1 was produced using the “MultiBac” baculovirus expression system 
(Geneva Biotech, Geneva, Switzerland) according to the protocol of Fitzgerald and 
colleagues154, using strains and media procured from “Expression Systems” (Davis, 
USA) and “Lonza” (Basel, Switzerland), respectively. Briefly, a fusion vector containing 
mTORC1 (pAB2G-mTOR, pIDK-His10-myc-flag-Raptor, pIDC-mLST8) was 
generated in vitro using Cre recombinase and then recombined, within EmBacY cells, 
with a bacmid containing the baculovirus genome. The presence of each mTORC1 
subunit within the purified bacmid was verified by PCR, and baculovirus virions 
expressing mTORC1 were generated for large-scale infection of Sf21 cells in serum-
free medium supplemented with glutamine and 2.5 µM rapamycin. mTORC1 was 
expressed for 120 hours prior to sonication of the cells in lysis buffer (250 mM NaCl, 
50 mM NaBicine pH 8.0, 5 mM MgCl2). The lysate was cleared by centrifugation at 
142 500 g and then incubated overnight with anti-flag agarose beads (GenScript, 
Piscataway, USA). After washing with lysis buffer, mTORC1 was eluted with flag-
peptide (0.1 mg/mL), concentrated to 0.5 mL and applied to a tandem Superose 6 
“Increase” gel filtration column equilibrated into 150 mM NaCl, 10 mM NaBicine, 1 
mM TCEP (Supplemental Figure 2.1). 
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2.4.3 Multi-angle laser light scattering (MALLS) 
Determination of the absolute molecular weight of mTORC1 was performed using 
MALLS. Purified mTORC1 was fractionated in the indicated buffer (Supplemental 
Figure 2.1B) using an analytical Superose 6 10/300 GL size exclusion column (0.2 
mL/min) coupled directly to a miniDAWN Treos instrument (Wyatt Technologies, 
Goleta, USA). Protein concentration in the eluting peaks was determined in-line 
through measurements of the refractive index (ΔRI optiLab REX - Wyatt Technologies, 
Goleta, USA). 
 
2.4.4 Kinase activity assay 
In vitro kinase activity assays were performed in 50 mM KCl, 25 mM K-HEPES pH 
7.4, 5 mM MgCl2 and 5 mM MnCl2 using 4EPB1 (Stratagene, La Jolla, USA) as a 
substrate (Supplemental Figure 2.1C). Purified mTORC1 (0.4 µg/µL, final 
concentrations are indicated throughout) was mixed with 4EBP1 (0.08 µg/µL) in a 50 
µL reaction. Reactions were initiated by the addition of ATP (50 µM), incubated for 30 
min at 37 °C, terminated through the addition of 12.5 µL 5x SDS-PAGE sample buffer 
and analysed by Western blot using antibodies to 4EBP (1:1000 dilution #9 452, Cell 
Signaling Technologies, Beverly, USA) and phospho-4EBP (1:1000 dilution #2 855, 
Cell Signaling Technologies, Beverly, USA). When assays were performed in the 
presence of Torin1 (20 µM) or rapamycin/FKBP12 (20 µM), mTORC1 was pre-
incubated with the respective inhibitor for 5 min on ice prior to the addition of 4EBP1 
and ATP. 
 
2.4.5 Generation of an initial reference EM density 
A sample of mTORC1 was crosslinked in 0.1% (v/v) glutaraldehyde at 0.07 mg/ml in 
150 mM NaCl, 10 mM NaBicine, 1 mM TCEP for 15 min on ice. The crosslinked 
sample was applied to a carbon coated holey carbon grid and stained with 2% (w/v) 
uranyl acetate. The grid was imaged in an FEI F20 electron microscope (FEI Company, 
Hillsboro, USA) with 82 000 magnification at 200 kV acceleration voltage. Micrographs 
were acquired with a total dose of 20 e/A2 and at an applied defocus of between -0.9 
and -1.7 μm. From 16 micrographs 2 544 single particle images were selected semi-
automatically using BOXER 155 after manually marking representative particles in each 
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micrograph. The CTF was determined with CTFFIND3156, images were binned four-
fold, and extracted using RELION157. The images were classified into 50 classes in two 
dimensions using RELION and eight well-defined classes (53%) selected for initial 
three-dimensional reconstruction. Initial models were created using the 
e2initialmodel.py function in EMAN 2.1 applying C2 symmetry155. A 3D model, which 
showed a good agreement with the 2D class images, was filtered to 60 Å and used 
as an initial reference in a RELION reconstruction. The resulting initial model (resolution 
31 Å, semi-independent half set FSC) was used for further cryo-EM refinement. 
 
2.4.6 Cryo-EM sample preparation and cross-linking 
Purified mTORC1 was applied to a 5 – 30 % (w/w) sucrose gradient in 100 mM NaCl, 
50 mM NaBicine pH 8.0, 1 mM TCEP, the higher sucrose concentration buffer of 
which had been supplemented with 0.125 % glutaraldehyde (Grade I). Samples were 
subjected to ultracentrifugation for 14 hours at 100 000 · g in an SW32 rotor, and 
recovered by gradient fractionation. The recovered peak was quenched through the 
addition of NH4Cl to a final concentration of 50 mM, and then concentrated to 100 
nM in 100 kDa cutoff Vivaspin concentrators. The buffer was further exchanged three 
times with 100 mM NaCl, 10 mM NaBicine pH 8.0, 1 mM TCEP in order to minimise 
the amount of residual sucrose in the final sample. 
 
2.4.7 Cryo-EM data collection 
Samples of mTORC1 (4 μL) were applied to holey carbon copper grids (R 2/2 – 
Quantifoil) bearing an additional fine film of carbon. Grids were blotted for three 
seconds and then plunged directly into a mixture of liquid ethane (33%) and propane 
(67%) mixture using a vitrobot mark 1 (FEI Company, Hillsboro, USA) at 6 ºC and 
100% humidity. Data were then recorded semi-automatically using EPU on a Titan 
Krios transmission electron microscope equipped with a Falcon II direct electron 
detector (FEI Company, Hillsboro, USA) at 300 kV, 100 719-fold magnification and at 
an applied defocus of between -2.0 and -4.0 μm, resulting in 6 299 images of 4 096 
by 4 096 pixels with a pixel size of 1.39 Å on the object scale. Each image was 
recorded as seven separate frames, comprising a total exposure of 25 electrons/Å2, 
which were subsequently aligned and summed using DOSEFGPUDRIFTCORR 158 to 
obtain a final image. 
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2.4.8 Cryo-EM data processing and refinement 
Poor quality micrographs were rejected by eye, based on the extent and regularity of 
the Thon rings observed in the contrast transfer function (Supplemental Figure 
2.3A,B). Estimation of the contrast transfer function was carried out for each image 
using CTFFIND3156, particles were selected using boxer155, and refinement thereafter 
performed using RELION157. Two-dimensional reference-free alignment of 569 086 
boxed particles into 100 classes was performed initially using images binned four-fold; 
particles that did not yield high-resolution class averages were excluded from further 
refinement. Three-dimensional classification into 8 classes was then performed with 
RELION using the 50 Å low-pass filtered initial reference, yielding 309 792 high-quality 
mTORC1 particles after a single class with reduced Raptor occupancy had been 
excluded. These particles were then refined using full-sized images in a “gold-
standard” refinement resulting in a density map with an estimated resolution of 6.1 Å 
without masking away more weakly resolved regions. Further refinement within a tight 
mask of the core regions with a Gaussian falloff, generated by thresholding the density 
at 6 σ, yielded a reconstruction with an estimated resolution of 5.9 Å at a Fourier shell 
correlation of 0.143157. 
 
2.4.9 Cloning, expression and purification of CtRaptor 
CtRaptor (accession number: G0S1S2) was cloned from genomic DNA into 
pAceBac2 with a N-terminal His10-tag and TEV protease cleavage site. Baculovirus 
was generated in Sf9 cells (VWR, Radnor, USA) using the MultiBac expression system 
(Geneva Biotech, Geneva, Switzerland) according to manufacturer’s protocols. 
Expression cultures were infected with a virus dilution of 1:100 (v/v) and typically 
harvested after 68 hours. The protein was purified using High Affinity Nickel Charged 
Resin (Genscript, Piscataway, USA). The N-terminal tag was removed by incubation 
with tobacco etch virus protease and rebinding to High Affinity Nickel Charged Resin. 
The protein was then applied to a size-exclusion chromatography column (HiLoad 
16/600 Superdex 200 pg). Peak fractions were concentrated to 10 mg mL-1 for 
crystallisation. 
 
2.4.10 Crystallization and structure determination of CtRaptor 
Full-length CtRaptor was set for crystallisation using the sitting-drop vapour diffusion 
method. Extensive screening did not yield any crystal hits. The protein was therefore 
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proteolytically digested by incubating 1 μg Thermolysin (Proti-Ace 2, Hampton 
Research) per mg of CtRaptor in 50 mM HEPES pH 8.0, 150 mM NaCl, 1 mM CaCl2 
and 2 mM TCEP prior the size-exclusion chromatography. Initial crystals grew in drops 
containing precipitant solution (0.1 M Bis-Tris pH 5.5, 3 M NaCl) in 1:1 (v/v) ratio at 19 
°C. After several rounds of optimization, 3-dimensional crystals were grown in drops 
containing precipitant solution (0.1 M Bis-Tris pH 5.2-5.3, 2.6 M NaCl) in 1:1 (v/v) ratio 
at 30 °C. In order to obtain phase information, crystals were derivatised with 5 mM of 
ethylmercury-donating Thimerosal for 3 minutes, back- soaked, cryoprotected by 
addition of ethylene glycol to 25% (v/v) and directly flash- frozen in liquid nitrogen. X-
Ray diffraction data were collected at beamlines X06SA (PXI) and X06DA (PXIII) with a 
PILATUS 6M and PILATUS 2M detector, respectively, and raw data were processed 
using XDS159. Initial crystals belonged to space group P41212 with unit cell parameters 
of a=b=195 Å, c=291 Å, and diffracted to approximately 6 Å resolution. Eleven to 
thirteen mercury positions were located in a mercury derivative dataset to 5.8 Å 
resolution using SHELXC/D160 via the HKL2MAP interface161. Density modification led 
to an electron density map that allowed building an initial model by rigid-body docking 
of helical repeats and a template β-propeller. MR-SAD phasing using PHASER162 
employing the initial model resulted in a figure of merit of 0.586 for 19 Hg sites. Post-
crystallization treatment using high concentrations of malonate resulted in crystal 
dehydration and led to crystals that still belonged to space group P41212, but with 
unit cell parameters of a=b=184 Å, c=273 Å, diffracting to better than 4.5 Å resolution. 
Multi-crystal and NCS-averaging between the original 5.8 Å resolution Hg-derivative 
set and a 4.3 Å resolution native dataset in the dehydrated crystal form, each 
containing two molecules per asymmetric unit, lead to excellent electron density maps 
with clearly recognizable secondary structure elements and mostly connected peptide 
backbone. This experimentally phased electron density map was interpreted by 
tracing with poly-alanine guided by predicted secondary and domain structure in O 
and Coot163. Assignment of the blades of the β-propeller was obtained by comparing 
the location of anomalous mercury sites with the location of cysteine residues, the 
preferentially derivatised sites, in a homology model. The limited resolution precludes 
modeling of side chains and side chain-based register assignment. Using an MLHL 
target to incorporate phase information and hydrogen bond restraints in addition to 
Ramachandran restraints to stabilise main-chain conformation, our final poly-alanine 
model refines against experimental data at 4.3 Å to Rwork/Rfree of 0.37/0.39. This 
value is in the expected range for a correct model lacking side chain atoms beyond 
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the β-carbon position. The number of Ramachandran outliers increases from 0.2% to 
2.8% when no Ramachandran restraints are applied, which is still in a reasonable 
range 
 
2.4.11 Docking and modeling into the cryo-EM map 
Given the availability of a high-quality crystal structure of mTOR/mLST8 (PDB ID 4JSN: 
chains B and D), which fitted very cleanly into the correct hand of the density 
(Supplemental Figure 2.3), we docked this component first; mLST8 and residues 
1 442 to 1 609 of mTOR exhibited slightly different conformations from those resolved 
in the crystal structure and their fit was therefore optimised separately. The crystal 
structure of CtRaptor was docked similarly with minimal adjustment. Consensus 
homology models were then prepared with PHYRE164 for mTOR residues 1 to 1 375, 
which have been pruned of loops and deposited as UNK residues. Initial rigid-body 
fitting of all models was carried out using UCSF Chimera153, and the models then 
readjusted to the observed secondary structure using COOT163. To correct the 
geometry of the final models and to remove steric clashes, the model was subjected 
to 300 iterations of geometry and B-factor minimisation using PHENIX.refine165, during 
which secondary structural and Ramachandran restraints were applied. After 
minimisation, the cross-resolution between the reconstruction and the model was 7.1 
Å (Fourier shell correlation cut-off = 0.5). 
 
2.4.12 Assignment of proposed mTOR HEAT repeat topology 
Two sources of prior primary information on PIKK HEAT repeat topology are available. 
The density making up the bridge region directly joins the FAT domain, while the 
known structure of DNA-PKcs166 exhibits a very similar topology within the 
corresponding bridge (denoted forehead in the study166) adjacent the FAT domain, 
implying that the FAT-HEAT linkage is conserved. A cross-linking mass spectrometry 
study of TORC233 identified “intra-links” between N-terminal residues of the HEAT 
repeat domain and the parts of the FAT and PIKK domains adjacent the horn. If one 
assumes that the N-terminus of the horn represents the N-terminus of mTOR, further 
“intra-links” to the FAT domain from the HEAT repeat domain could also be satisfied. 
There are sufficient residues (~30) within many HEAT-repeat loops to bridge a large 
distance (>100 Å if completely extended), however loops do not typically cover such 
large distances, and therefore smaller distances are considered more parsimonious. 
2  Architecture of human mTOR complex 1 
 
 59 
The terminus of the bridge region is within ~40 Å of that of the disordered end of the 
horn density through clear space, but ~70 Å from the end abutting the adjacent mTOR 
FAT domain through two regions of density, and over 100 Å from any other plausible 
terminus. In the absence of large insertions within the two HEAT-repeat domains, we 
conclude that other topologies are highly unlikely, but cannot be formally excluded 
without higher resolution data. 
 
2.4.13 Accession numbers 
The cryo-EM density maps representing mTORC1 have been deposited in the EM 
Databank as EMD-3212 and EMD-3213 and the corresponding model in the Protein 
Data Bank as PDB ID 5FLC. The crystal structure of CtRaptor has been deposited in 
the Protein Data Bank as PDB ID 5EF5. 
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2.5 Supplemental information 
 
Supplemental Figure 2.1 Purification and biophysical characterisation of mTORC1. 
A Size exclusion chromatography (SEC) elution profile of mTORC1 from a tandem-
Superose 6 Increase 10/300 GL column at 0.1 mL/min. The lower panel shows an 
SDS-polyacrylamide gel of the purification process: T, total fraction; S, soluble fraction; 
W, wash fraction; IN, SEC input. Elution fractions E1 and E2 contained mTORC1 and 
were used for subsequent experiments. B Molecular weight determination by multi-
angle laser light scattering (MALLS, Superose 6 10/300 GL, 0.2 mL/min). The elution 
profile shows the molecular weight (left axis) and the scattering intensity (Rayleigh ratio) 
at the 90° detector (right axis). mTORC1 elution peaks are visible corresponding to 
both dimeric (1047 kDa ± 5%) and monomeric (483 kDa ± 5%) species. C Kinase 
activity assay of purified mTORC1 (expressed in the absence of rapamycin) using 
4EBP1 as a substrate. Western blots (top panel: anti-phospho-4EBP, bottom panel: 
anti-total-4EBP) show the phosphorylation state of 4EBP1 after incubation with 
mTORC1 in presence of the indicated mTORC1 inhibitors.  
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S.p.|1-1313                    F F    L T A F    L          P P  Q L P  V L Q V L L S Q  H R  R A L  L L   F L D L G  W A V  L  L S  G I F P Y V L K L L Q S  A  E LY S   E Q     V W  S G R   D    L         V   L      K          A   I                . . . . . . . . . G I A Y E K H T S E Q L I . S K I S V D P I
M.m.|1-1335                    F F    L T A F    L          P P  Q L P  V L Q V L L S Q  H R  R A L  L L   F L D L G  W A V  L  L S  G I F P Y V L K L L Q S  A  E LF S   E Q     V W  T G R   E    I         V   L      R      P     A   V                . . . . . . . . . . . . T A R H P A Q M V E . N S D G S S R
H.s.|1-1335                    F F    L T A F    L          P P  Q L P  V L Q V L L S Q  H R  R A L  L L   F L D L G  W A V  L  L S  G I F P Y V L K L L Q S  A  E LF S   E Q     V W  T G R   E    I         V   L      R      P     A   V                . . . . . . . . . . . . T A R H P A Q M V E . N N D G S S R
  6 9 0        7 0 0         7 1 0        7 2 0                                                           7 3 0    
C.t.|1-1504  P   V F I W   I    D     Q   L  K   G   Y F                                                                     K  V M     R  L A V  S C  D  I  D N    S I MT I . Q Y T S R P N E T I P V V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G L S V
S.c.|1-1557  P   V F I W   I    D     Q   L  K   G   Y F                                                                     K  I L     A R  M I   E  I  E    V T V LS Y K N T S K Y M V P D W G V N G M S A T N G S A M I N S G N P L T M T A S Q N I N G P S S R Y Y E R Q Q G N R T S N L G H N N L P F Y H S N D T
S.p.|1-1313  P   V F I W   I    D     Q   L  K   G   Y F                                                                     K  V L     A R  L A V  S C  D  L  D N    V Q I LD . A Y G N P N S S I . . F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P S S N
M.m.|1-1335  P   V F I W   I    D     Q   L  K   G   Y F                                                                     R  L L     A K  L A V  S C  D  V  D N    L S V LS . A H K A D P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Y M
H.s.|1-1335  P   V F I W   I    D     Q   L  K   G   Y F                                                                     R  L L     A K  L A V  S C  D  V  D N    L S V LS . A H K A D P . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Y M
    7 4 0        7 5 0        7 6 0        7 7 0        7 8 0        7 9 0        8 0 0        8 1 0        8 2 0        8 3 0    
C.t.|1-1504   E    M   F  L          G Q   C                    L L R Q W                        A    L      D   P E V R      A    F H K  A  I  M F T   V  S I M C L P P      L C I L W F A K W G I R E N  K  L A      A M I  M T  I D A C S L C K G K V N T E T S Y H T E H D N S C S Q K D N E R L Q A A R S C A H T
S.c.|1-1557   E    M   F  L          G Q   C                    L L R Q W                        A    L      D   P E V R      A    F K  V  V  F    S L V I P      I L L F R F M   L  V     A I  L  T D Q A A A S F V R N P L K N F L E N K L C F Y D N S E I C V L G L A D N P L N V C N T G V E I L K S K P T S F K H
S.p.|1-1313   E    M   F  L          G Q   C                    L L R Q W                        A    L      D   P E V R      A    F H R  A  I  V F Q   A  N V L C L L P      L C I L W Y A K W G R D N  K  I I  V     V L  T  I S A C S F C R G P L L P Q S H S H N S D . S A C S Q E N S E S T H V A E V S A S T F T
M.m.|1-1335   E    M   F  L          G Q   C                    L L R Q W                        A    L      D   P E V R      A    F H R  A  I  V Y T   A  Q L I C L L P P      I C L I W F A R W G V R D S  K  L L  I     A A V  L T  P A T T A I V N S T E L G N A I E Q S D H . V A G R Q N D S C H E Y S S P C F G
H.s.|1-1335   E    M   F  L          G Q   C                    L L R Q W                        A    L      D   P E V R      A    F H R  A  I  V Y T   A  Q L I C L L P P      I C L I W F A R W G V R D S  K  L L  I     A A V  L T  P A T T A I V N S H E L G N A I E Q N D H . V A G R Q N D S C H E Y S S P C F G
     8 4 0                                                                           8 5 0        8 6 0      
C.t.|1-1504                                                                                               D  S   VL G E T D L E I A A L L M A T  G  P I  I P . V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E V A R E G W E
S.c.|1-1557                                                                                               D  S   VI D E L I I L L I N  G  L  S G F Q A E V I L R L Q Q E F E E Q Y Q Q L H S Q L Q H L Q N Q S H L Q Q Q Q S Q Q Q Q Q H L E Q Q Q M K I E K Q I R H C Q V M Q N Q L E V I D L R K L K R Q I G N S P S
S.p.|1-1313                                                                                               D  S   VL G E T E V E I A I A A L A L S   P L  F P . K . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E V V A T Y A A
M.m.|1-1335                                                                                               D  S   VV G E T D I D V A M M L A L I N  G  P M  N S A R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . H S T T H N Q
H.s.|1-1335                                                                                               D  S   VV G E T D I D V A M M L A L V S  G  P M  N S A R . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . H S T T H N Q
  8 7 0        8 8 0        8 9 0        9 0 0        9 1 0                                                        
C.t.|1-1504 R  E L     S   V   Y                                                                                       K   L V   L  N F A A L E EF W V F R E K L V Y E Q L K E Y M L Y P P P E D G L E H K M . . . . . . . . . . . . . . . . . G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
S.c.|1-1557 R  E L     S   V   Y                                                                                       K   V V  H   N F V V L E EY F I S R S F I V F N D L I K L L E K S D I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
S.p.|1-1313 R  E L     S   V   Y                                                                                       H   V I  H  V  V A DF L F N K K Q L M V Y E S S L A I L . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M.m.|1-1335 R  E L     S   V   Y                                                                                       K   V V  H  V  S F V A M E EA L L Q E N C T L Q F E K N Y P L P S P A A T E G G S L T P V R D S P C T P R L R S V S S Y G N I R A V T T A R N L N K S L Q N L S L T E E S G S S V A F S P G N L
H.s.|1-1335 R  E L     S   V   Y                                                                                       K   V V  H  V  S F V A I E EA L L Q E N C T L Q F E K N Y A L P S P A T T E G G S L T P V R D S P C T P R L R S V S S Y G N I R A V A T A R S L N K S L Q N L S L T E E S G G A V A F S P G N L
RNC
RNC
RNC
ARM
ARM
ARM
ARM
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Supplemental Figure 2.5 Sequence conservation of Raptor. 
Multiple sequence alignment of Raptor from selected species. Invariant residues are shown in 
red boxes and highly conserved residues (> 70%) in red font. Residues conserved between 
the Raptor family and the active site of CASPases are highlighted in blue boxes. Sequences 
were retrieved from the UniProt database: C.t., Chaetomium thermophilum (G0S1S2); S.c., 
Saccharomyces cerevisiae (P38873); S.p., Schizosaccharomyces pombe (P87141); M.m. Mus 
musculus (Q8K4Q0); H.s., Homo sapiens (Q8N122). Alignments were generated using Clustal-
Omega and are represented with ESPript 3.0.   
           9 2 0                      9 3 0        9 4 0        9 5 0        9 6 0        9 7 0         9 8 0        9 9 0  
C.t.|1-1504                                                     W         D P                                      S V S L Y I  K L M V   E V Q A I V I L L M. . . . . . . L H Y A R P E N R E . . . . . . . . . . . . . . K D G T I K P A Y G A H D A A H C I S H P R D T T D Y H H A . L H S P V G T Q A Q T D E I L
S.c.|1-1557                                                     W         D P                                      V S S I F T V  K L L L A   E L V I I A M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N T R N T S D K Y S Q G Y S I E F L N K E S K Q D Y L L E L S H K E L G G P F A V E K F L L
S.p.|1-1313                                                     W         D P                                      N I S T I Y T V  V L L A A   E I S A A I I V L L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E K K H N S A S E Q A V S I L E A N Y Y Q S . M N S E L R E S F L A F L Q H L
M.m.|1-1335                                                     W         D P                                      S V S S V Y Q I  R L L L A A   D V S L A V L I V I LS T S S S A S S T L G S P E N E E Y I L S F E T I D K M R R V S S Y S A L N L I G F N T V H Y P D M K N S A Y K A T N A . . . . R P Q R D T . .
H.s.|1-1335                                                     W         D P                                      S V S S V Y Q I  R L L L A A   E V S V A V L I V V LS T S S S A S S T L G S P E N E E H I L S F E T I D K M R R A S S Y S S L N L I G F N T V H Y P D M K N S A Y K A T N A . . . . R P Q R D T . .
     1 0 0 0        1 0 1 0                          1 0 2 0        1 0 3 0       1 0 4 0       1 0 5 0             1 0 6 0     
C.t.|1-1504                               P                                                                      S T P Q  L S S S T S GR R A S K V R G D N S Q R . S S A A G . . . R A A A M . . . . . . . . . . . . . . . . P S A . G L K R T A Y L F G P L L G V T D G S S T S V S S T . . . . . . P A P M N R S S S
S.c.|1-1557                               P                                                                      S S  N H S T S S NK R S S K A H Q T G K F G F N S S Q V Q F V K S L R S F E R V D N N A F K K E Q Q Q H D P K I S P M R T S L A K L F Q S L G F S E N S D S D . . . . . . . . . . . Q . . . T S M K S
S.p.|1-1313                               P                                                                      S P  S K I S S G SP A L H K A L S K D T D T N S V T S D . . . P K P H F V . . . . . . . . . . . . . . . . V S E N L N R S F . L T R S L K G L . . . . . . . . . . . . . . . . . . . A L L A D R A S E
M.m.|1-1335                               P                                                                      S T P S  T H M S S N S S G T. . . . . S L . . . . . . . . . . . . . . . Q S A A . . . . . . . . . . . . . . . . N K G M H Q V G G . . . . P P A S S T S C S L T D V A K Q T V S R D L P R P A . . . .
H.s.|1-1335                               P                                                                      S T P S  T H I S S N S G T. . . . . S L . . . . . . . . . . . . . . . Q S A A . . . . . . . . . . . . . . . . N K G V H Q A G G . . . . P P A S S T S S S L T D V A K Q P V S R D L P G R P T . . . .
  1 0 7 0       1 0 8 0       1 0 9 0        1 1 0 0       1 1 1 0       1 1 2 0       1 1 3 0       1 1 4 0       1 1 5 0       1 1 6 0    
C.t.|1-1504      G                                                     S   Y F     M    E      S      R  W R   R N           N A A Y L L S F E W    P  K  E       V QQ R S R K L A N V L P E K P D Q V A P P A H V A P E P L . S P G Y Q E R K P K E M P T P V T L T E R E Q P P A E P G H E Y N Q L R S E A L R E T P
S.c.|1-1557      G                                                     S   Y F     M    E      S      R  W R   R N           S L N I Y L L L N S F D Y    P  K  E       I QH T S K K P G Y L L N G . . . . . . N N P T A E . . . . . . T P R F R K H T E P Q P S L R E Q E Q K Q A D P G V E Y N A L R N E T I Q E T G
S.p.|1-1313      G                                                     S   Y F     M    E      S      R  W R   R N           N N L M L T S D W    P  R  E       LL L S L N E K . . . . . . . P A E . S L N H L T S A K V P G . P P A F N E L E Y Q S E D P Y L F R K T E Q P N D D P G I C Y N Q L R N E K I Y R T R P
M.m.|1-1335      G                                                     S   Y F     M    E      S      R  W R   R N           T A T M F I A M Q T F D W     K  D       V Q. . . . . P G Q Y T P H S H Q F P R R K D K G P D Q T T D D A D D A A G H K S F C S G C A R A Q A V I P E H L E Q I R K E E F L T R R K Q A Q
H.s.|1-1335      G                                                     S   Y F     M    E      S      R  W R   R N           A T M F I A V Q T F D W    P  K  D       V Q. . . . . P A G Q Y T P H S H Q F P R R K D K G P E Q T A D D A D D A A G H K S F S T G C A R A Q V I P E H L E Q I R K E E F L S R R R Q A Q
   1 1 7 0       1 1 8 0       1 1 9 0       1 2 0 0       1 2 1 0       1 2 2 0       1 2 3 0       1 2 4 0       1 2 5 0       1 2 6 0    
C.t.|1-1504                   N    P     F   F         D    I    D W      L   F        T         N   D   L L  T    D G  I          R Q I   M  H  V A A  T  W     N G N P  K I S L I     M  S   V  R I Y YQ K L Y A R T H W N N G L I N G T Q S K T Q E N C V D G N T V K T N A R S R S E G D C F E D Q A G S N N D S D
S.c.|1-1557                   N    P     F   F         D    I    D W      L   F        T         N   D   L L  T    D G  I          L   M   L I A  R T  F   K   N G T P  K V T L I     L  S   V  K I Y R YE K K L S I Y G N W S K K I S L N K S Q K L K A Q E D Q T D S T V E G K T S K S F G D K L E D S A G S D Q D V
S.p.|1-1313                   N    P     F   F         D    I    D W      L   F        T         N   D   L L  T    D G  I          R Q L   L  H  L I L  K  W   R   T  V T M L     M  S    K L Y R YL A E Y S T N G W N Q M T F N T I A R K M Q E D Q T G D I Q V R N R C N S K S A S A T N D Q L E D V A G S T D E N .
M.m.|1-1335                   N    P     F   F         D    I    D W      L   F        T         N   D   L L  T    D G  I          R Q I   V  H  I A A  K S  W   K   N G N P  R V T M L     L  T   A  R V W K FV . I Q K G I T L D D F L N R P G V S V K P T P C V . D C F E G E K D Y H R Y A E Y G Q C S A D N A D L
H.s.|1-1335                   N    P     F   F         D    I    D W      L   F        T         N   D   L L  T    D G  I          R Q I   V  H  I A A  K S  W   K   N G N P  R V T M L     L  T   A  R V W K FV . I Q K G I T L D D F L N R P G V S V K P T P C V . D C F E G E K D Y H R Y A E Y G Q C S A D N A D L
    1 2 7 0       1 2 8 0       1 2 9 0       1 3 0 0       1 3 1 0       1 3 2 0       1 3 3 0       1 3 4 0       1 3 5 0       1 3 6 0   
C.t.|1-1504          W   L                W  Q   G      G D     R  W     E       P        T S L   D        V A G   D G   R V  D  R      E E L A S A   T M V S G M V E    V L   R V I  I   E I  S V    T  Q N I      I   F   L E. R V R A H P N V N S F L V N R V A E S A G Q I C T H A R S G C S M T G F F G A S R P H
S.c.|1-1557          W   L                W  Q   G      G D     R  W     E       P        T S L   D        V A G   D G   R V  D  R      D I V S A   T D M L T R G L L E    L L   V K V I  V  D  D I  S I    T  Q N I      L   Y  R  L D. T F K R G L P S T T L I R S T T A H T T V E V A K T S L A L A G F F A S D P R
S.p.|1-1313          W   L                W  Q   G      G D     R  W     E       P        T S L   D        V A G   D G   R V  D  R      E E L V T   S D L V R L L    L L   V R V I  I  D  L  N I    T  N I      L   Y  K  L D. K V S N S F G D N A S M S Q N C H V A A S K I C Y A N V R S S S S L V G C I F S V P A R
M.m.|1-1335          W   L                W  Q   G      G D     R  W     E       P        T S L   D        V A G   D G   R V  D  R      E E M V T A   S D M L T R G M V D    L M   V R I V  I  D  D I  S V    S  S S L      I   Y  R  M EK N P Q G P T G A V E E T L S S T D R T K V Q T G A D C C H . R I L G S A L S
H.s.|1-1335          W   L                W  Q   G      G D     R  W     E       P        T S L   D        V A G   D G   R V  D  R      E E M V T A   S D M L T R G M V D    L M   V R I V  I  D  D I  S V    S  S S L      I   Y  R  M EK N P Q G P T G A V E E T L S S T D R M K V Q T G A D C C H . R I L G S A L S
    1 3 7 0          1 3 8 0       1 3 9 0       1 4 0 0       1 4 1 0                  1 4 2 0       1 4 3 0       1 4 4 0         
C.t.|1-1504                       Q         S     G      D  R                                H       A  G             G  V W K D W V V M  R G L L  A S N  I L W   M L Q L A  L V   T V F  A M R K D . . . A R Q R S H G Q R E R K S I D Q P K T F S T . . . . . . . . . . . K E I R T S T E H P F V S A H M V K D F D N
S.c.|1-1557                       Q         S     G      D  R                                H       A  G             G  I W R Q W I V L  R G L V  N  V L W   V M T M V  A I   T I W  S M R R A G N D K G V N N H G Y R E G A T V E I S E D P E S F V D Q N V T S Q Y G S Q Q K P T T C Q E H P I T K . . Q I K T T S D
S.p.|1-1313                       Q         S     G      D  R                                H       A  G             G  W K E S V M  G L I  A S  V L W   M L S L T L V  A V   S I W  S L T D V H . . . S E I . V N E S S M R E S D E K I N H S Q T F T D . . . . . . . . . . . N S G S T S H P Y T S N Q S I K D T L Q
M.m.|1-1335                       Q         S     G      D  R                                H       A  G             G  V Y R E T W V A L  K P I V  V S N  V F   M V Q L T L I  A L   S I Y  C R M T H . . . . A V K Y H E G H V D R F P P E S N V M I V . . . . . . . . . . . . K G A D P Q N I C M N Q F T A N G N E
H.s.|1-1335                       Q         S     G      D  R                                H       A  G             G  V Y R E T W V A L  K P I V  V S N  V I F   M V Q L T L I  A L   S I Y  C R M T H . . . . A V K S R D G H V D R P P E S N V L I V . . . . . . . . . . . . K G A D P Q D I C V N Q F T A N S S E
1 4 5 0       1 4 6 0                       1 4 7 0       1 4 8 0       1 4 9 0       1 5 0 0                                 
C.t.|1-1504                                         F H P H           D      Y                                        L T F L S K I A     L S  I S L  SE R L E P Y S N . . . . . . . . . . . . . . . . Q G A S P A T T R M I G C A R G N Y C S N E R V P N L V . . . .
S.c.|1-1557                                         F H P H           D      Y                                        L N S K T L M A     I A N S  V N I  L F N S H N N G V T S T L A A T G I P K S L S Y S S S D A F S S R M M A T H S I K C E D E R I D Y F . . . . .
S.p.|1-1313                                         F H P H           D      Y                                        I N T R F L K L L     L A N  V N L  SN F E N P R . . . . . . . . . . . . . . . . N Q P P S S M C K H L L C G D T S R C T K N E I H T D S P N E F
M.m.|1-1335                                         F H P H           D      Y                                        I N N K F M Q R I L A     L A S N  I S V  SL I Y Y D G . . . . . . . . . . . . . . . . G . V G A S C W P H V G . Y Y V E K R V R . . . . . . . .
H.s.|1-1335                                         F H P H           D      Y                                        I N N K F M Q R I L A     L A S N  I S V  SL I Y Y D G . . . . . . . . . . . . . . . . G . V G A S C W P H V G . Y Y V E K R V R . . . . . . . .
WD40
WD40
WD40
WD40
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Supplemental Table 2.1 Crystallographic statistics for CtRaptor structure 
determination. 
   
 Hg-derivative Native 
Data Collection 
Space group P41212 P41212 
Unit cell axes a, c (Å) 194.6, 291.1 183.8, 272.1 
Wavelength (Å) 1.00003 0.99188 
Resolution range (Å) 48.4-5.8 (5.90-5.80) 50.0-4.3 (4.37-4.30) 
Unique reflections 29272 (1423)* † 32407 (1601) 
Completeness (%) 99.2 (97.3) 99.6 (99.7) 
Redundancy 3.9 (3.8)* † 5.7 (5.8) 
Mosaicity (º) 0.123 0.366 
Rmerge (%) 6.5 (146.7)* † 15.1 (127.1) 
Rpim (%) 3.7 (84.7)* † 6.8 (57.3) 
I/σI 14.8 (1.0)* 9.1 (1.5) 
CC1/2 (%) 100 (31.3)* 99.7 (61.2) 
 
Phasing 
Anomalous Correlation (%) 42%  
Number of Hg-sites 19  
Figure-of-merit (MR-SAD phasing) 0.59  
 
Refinement (poly-alanine model) 
Number of alanine residues  2033 
Resolution range (Å)  49.0-4.3 
Rwork/Rfree  0.37/0.39# 
Average atomic B-Factor  78.7 
Rms deviations:   
    bonds (Å)  1.07 
    angles (°)  0.005 
Ramachandran plot:   
    favored (%)  94.9§ 
    allowed (%)  4.9§ 
    disallowed (%)  0.2§ 
   
*The values recorded in parentheses are those for the highest resolution shell 
†Friedel mates treated separately 
#The values are in the expected range for a correct model lacking side chain atoms beyond 
the β-carbon position 
§After refinement with PHENIX.refine using Ramachandran restraints. The number of 
Ramachandran outliers increases from 0.2% to 2.8% when no Ramachandran restraints are 
applied. 
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3.1 Abstract 
Polo-like kinases (PLK) are eukaryotic regulators of cell cycle progression, mitosis and 
cytokinesis; PLK4 is a master regulator of centriole duplication. Here, we demonstrate 
that the SCL/TAL1 interrupting locus (STIL) protein interacts via its coiled-coil region 
(STIL-CC) with PLK4 in vivo. STIL-CC is the first identified interaction partner of Polo-
box 3 (PB3) of PLK4 and also uses a secondary interaction site in the PLK4 L1 region. 
Structure determination of free PLK4-PB3 and its STIL-CC complex via NMR and 
crystallography reveals a novel mode of Polo-box-peptide interaction mimicking 
coiled-coil formation. In vivo analysis of structure-guided STIL mutants reveals distinct 
binding modes to PLK4-PB3 and L1, as well as interplay of STIL oligomerization with 
PLK4 binding. We suggest that the STIL-CC/PLK4 interaction mediates PLK4 
activation as well as stabilization of centriolar PLK4 and plays a key role in centriole 
duplication. 
 
3.2 Introduction 
Centrosomes are the major organizing centers for the microtubule network in animal 
cells and facilitate many microtubule-dependent cellular processes throughout the cell 
cycle168-170. During interphase, centrosomes contribute to cell shape, motility and 
polarity; in mitosis, they form the poles of the mitotic spindle and direct chromosome 
segregation. The core components of centrosomes, the centrioles, also function as 
basal bodies for the assembly of cilia and flagella. Mutations of centrosomal proteins 
have been associated with a variety of human diseases, notably ciliopathies, 
microcephalies and dwarfisms171,172. Furthermore, numerical and/or structural 
centrosome abnormalities have been implicated in carcinogenesis172-175. 
Centrosomes duplicate during S-phase by formation of a procentriole, the daughter 
centriole, orthogonally arranged to each pre-existing mother centriole176,177. The 
duplication process relies on a set of proteins conserved from Caenorhabditis elegans 
and Drosophila melanogaster to humans. The human core components are: the 
serine/threonine Polo-like kinase PLK4 (ZYG-1 in C. elegans), the centrosomal protein 
Cep192 (SPD-2 in C. elegans), the spindle assembly 6 homolog (C. elegans) protein 
SAS-6, the SCL/TAL1 interrupting locus protein STIL (SAS-5 in C. elegans) and the 
centrosome protein CPAP (SAS-4 in C. elegans) 170,178-182. Overexpression of either, 
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PLK4, SAS-6 or STIL, causes formation of multiple daughter centrioles around a single 
mother centriole99,183-187, while depletion of any one of these proteins blocks centriole 
formation99,100,183,186-188. Thus, PLK4, SAS-6 and STIL constitute key centriole 
duplication factors, the activity and levels of which need to be tightly controlled to 
maintain the correct centriole number107,185,189,190. In addition to these core 
components, other proteins are also essential for centriole duplication in human cells, 
this includes notably Cep152191-193, which cooperates with Cep192 in PLK4 
recruitment111,113,194. 
The early phase of centriole biogenesis is marked by the assembly of the cartwheel 
structure that serves as a scaffold for deposition of centriolar microtubules and confers 
the characteristic nine-fold symmetry to the centriole170,195-197. SAS-6 has been shown 
to self-assemble into cartwheel-like structures in vitro, indicating that it is a central 
component of the cartwheel115,116,198,199. In human cells, SAS-6, STIL and PLK4 localize 
to the cartwheel region, suggesting a functional interaction of these proteins in 
cartwheel assembly183,185,200,201. Such an interaction is supported by recent evidence 
demonstrating that PLK4 regulates complex formation between STIL and SAS-6 via 
phosphorylation of STIL202-204. This process depends on two highly conserved regions 
of STIL: a short coiled-coil motif (STIL-CC, residues 720-751) and the STAN 
(STIL/Ana2) domain (residues 1061-1147)202,205. This recent progress focuses 
attention on a detailed mechanistic understanding of the interaction between STIL and 
PLK4, and this in turn requires definitive structural information. 
PLK4 belongs to the PLK family, which in vertebrates comprises four functional 
paralogues, PLK1-4. PLKs are characterized by an N-terminal Ser/Thr- kinase domain 
followed by a C-terminal region containing two or three Polo-box folds (PB), which 
regulate substrate binding, kinase activity, and localization83,84,206. Among the PLKs, 
PLK1 is the best studied; it comprises two Polo-boxes, PB1 and PB2, that form a 
Polo-box domain (PBD), through intramolecular heterodimerization. The PLK1-PBD 
generally binds to target proteins after their phosphorylation on Ser/Thr- sites within a 
PBD-docking motif80,94,95,97,207; however, in the context of the Drosophila microtubule-
associated protein Map205 phospho-independent binding has also been described96. 
PLK4 is unique among the PLKs as it contains three -rather than two- Polo-boxes 
(PB1-3)109. The first two Polo-boxes of PLK4, PB1 and PB2 (formerly referred to as 
cryptic Polo-box, CPB), are sufficient for centriole localization of PLK499,109. Isolated 
PLK4-PB3 can also localize to centrioles, but with less efficiency109,112. In contrast to 
PLK1-PBD, PLK4-PB1/2 as well as PB3 have been described to form intermolecular 
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homodimers and to bind their targets in a different, phospho-independent manner109-
113. Recent work has established a crucial role for the binding of acidic regions in 
Cep192 and Cep152 to basic residues in PLK4-PB1/2111,113,194. However, no 
interactions of PLK4-PB3 with binding partners have been resolved so far. Moreover, 
the relevance of the reported domain-swapped structure of murine PB3112 for in vivo 
interactions remains unclear. 
Here, we identify STIL as a direct interaction partner and substrate of PLK4 and 
confirm that the STIL-CC region is essential for STIL function in centriole duplication. 
Most importantly, we determined the solution structure of the human PLK4-PB3 and 
a crystal structure of the PLK4-PB3/STIL-CC complex and use structure-based 
mutagenesis of STIL to demonstrate an essential role of STIL-CC for PLK4 binding 
and the regulation of centriole biogenesis in vivo. Specifically, we show that STIL-CC 
interacts with two regions within PLK4: it targets not only the L1 region but also is the 
first identified binding partner of the unique PLK4-PB3. We further show that STIL-CC 
binding is implicated in the stabilization of centriolar PLK4 and its concomitant 
activation. Collectively, our results contribute to a detailed structural and mechanistic 
understanding of a crucial initial step of centriole biogenesis. 
 
3.3 Results 
3.3.1 PLK4 and STIL interact in vivo to regulate centriole duplication 
To identify centrosomal binding partners of the PLK4 Polo-box motifs, we performed 
an S-peptide pulldown experiment coupled to mass spectrometry analysis. We 
generated a U2OS Flp-In T-REx cell line that allowed for inducible expression of an S-
peptide-EGFP-tagged PLK4 fragment (residues 570-970) comprising the three Polo-
boxes PB1-3. We identified a set of centrosomal proteins including the two well-
known PLK4-PB1/2 binding partners Cep152 and Cep192 (sixteen and four identified 
peptides, respectively)113,191-194. In addition, the key centriole duplication factor STIL 
co-purified with the PLK4 fragment (one identified peptide)208. This prompted us to 
further analyze the functional and structural interaction between PLK4 and STIL. 
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Figure 3.1 STIL is an interaction partner of PLK4. 
A U2OS cells were fixed and stained with the indicated antibodies for 3D-SIM imaging. A 
representative 3D-SIM image is shown, demonstrating the co-localization of PLK4 and STIL at 
the daughter centriole. Top panel: Centrin (purple), PLK4 (red), STIL (green). Scale bar: 0.5 µm. 
Bottom panel: Magnified view of the centrosome (overlay image). The rectangles illustrate the 
orientation of the mother (M) and daughter (D) centrioles. B Immunostaining of STIL localization 
in U2OS cells depleted of endogenous PLK4. Cells were transfected for 72 hours with control 
or PLK4 siRNA oligonucleotides and stained with the indicated antibodies. DAPI is shown in 
blue. Scale bars: 1 µm. C Immunostaining of PLK4 localization in U2OS cells depleted of 
endogenous STIL (control and siSTIL). Experimental procedures as in (B). In (B) and (C), only 
prophase cells harboring 1-2 centrioles were analyzed (indicative of successful PLK4 or STIL 
depletion, respectively). D Western blots showing the interaction of myc-tagged PLK4 and 
FLAG-tagged STIL in HEK293T cells. Cells were transfected with the indicated plasmids for 
36 hours, followed by lysis and immunoprecipitation using anti-myc or anti-FLAG antibodies. 
Antibodies used for Western blot detection are indicated. E Western blot showing the 
interaction of myc-PLK4 with endogenous STIL. Myc-PLK4 expression was induced by 
addition of tetracycline to U2OS T-REx cells stably harboring the myc-PLK4 transgene (-/+ 
Tet, 24 hours). Cells were processed for anti-myc co-immunoprecipitations and Western blot 
analysis using the indicated antibodies. 
As 3D-SIM imaging of U2OS cells revealed extensive co-localization of STIL and PLK4 
at the proximal end of daughter centrioles (Figure 3.1A), we asked whether the two 
proteins depend on each other for recruitment to this site. Upon depletion of PLK4, 
localization of STIL to centrioles was drastically reduced (1.7 ± 2.3% residual intensity 
compared to untreated cells, Figure 3.1B), suggesting that PLK4 is essential for STIL 
centriolar targeting and/or maintenance. On the other hand, PLK4 localization to 
centrioles was not abrogated in STIL depleted cells. On the contrary, centriolar PLK4 
levels were strongly elevated and PLK4 localized in a ring-, rather than a spot-like 
pattern to the outer wall of centrioles203 (Figure 3.1C). Western blot analysis confirmed 
significant elevation of PLK4 levels in STIL depleted cells (A-D). This increase in PLK4 
levels was comparable to that observed after depletion of bTrCP, which is known to 
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interfere with PLK4 degradation104,105,107,190 (Supplemental Figure 3.1). These data 
suggest that PLK4 degradation is strongly reduced in the absence of STIL, which then 
results in its accumulation around centrioles. In further support of a functional 
interaction between PLK4 and STIL, we also observed that STIL was phosphorylated 
by a recombinant GST-PLK41-430 fusion protein in vitro and in vivo202-204 (Supplemental 
Figure 3.2A). 
To confirm the interaction of STIL with PLK4, we transfected HEK293T cells with myc- 
and FLAG-tagged versions of both proteins and performed co-immunoprecipitation 
experiments. As expected, we found STIL and PLK4 to be present in the 
immunoprecipitates of the respective interaction partner (Figure 3.1D). Moreover, we 
detected endogenous STIL along with Cep152 in an immunoprecipitate of myc-PLK4, 
which had been isolated from a U2OS T-REx cell line (Figure 3.1E). Thus, STIL and 
PLK4 form a stable complex in vivo. 
 
3.3.2 The STIL-CC motif is necessary for PLK4 binding and centriole 
duplication 
To map the region of STIL required for binding to PLK4, we cloned truncated versions 
of the STIL protein: an N-terminal (STIL N-ter., residues 1-440), middle (STIL-MD, 
residues 441-880) and C-terminal (STIL C-ter., residues 881-1287) part, and 
subjected these fragments to co-immunoprecipitation experiments with myc-tagged 
PLK4-ND (Figure 3.2A-B). The PLK4-ND point mutant exhibits enhanced 
stabilization107 and thus facilitates the visualization of STIL binding (Supplemental 
Figure 3.2B). We found that the N- and C-terminus of STIL did not bind PLK4-ND, 
whereas the middle part displayed efficient PLK4 binding. Accordingly, two STIL 
truncations containing the middle part but lacking either the N- or C-terminus (STIL-
ΔN, residues 441-1287; STIL-ΔC, residues 1-880), strongly bound to PLK4-ND 
(Figure 3.2A-B). 
The middle region of STIL contains a predicted coiled-coil (CC) motif (residues 720-
751)205. To test the involvement of STIL-CC in PLK4 binding, we further truncated the 
STIL-MD and analyzed the interaction with PLK4-ND (Figure 3.2A,C). As long as the 
CC motif was intact, immunoprecipitation of PLK4-ND was not affected. However, 
truncating or removing the CC motif severely disrupted PLK4 binding, indicating that 
PLK4 interacts with the STIL-CC region. This finding was further confirmed by the 
observation that an EGFP-tagged version of STIL-CC efficiently pulled down PLK4 
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(Figure 3.2D), suggesting that STIL-CC alone is sufficient to bind PLK4. Accordingly, 
a mutant of STIL lacking the CC motif (STIL-ΔCC) did not interact with PLK4, whereas 
removal of another conserved region in STIL, the STAN domain (STIL-ΔSTAN), had 
no impact on the interaction with the kinase (Figure 3.2A, E). Therefore, the CC domain 
is both necessary and sufficient for STIL binding to PLK4. 
 
Figure 3.2 The STIL-CC motif binds to PLK4. 
A Schematic illustration of STIL constructs used to map the PLK4-binding region in STIL. On 
the right, the relative strengths of the interactions as determined by co-immunoprecipitation 
experiments are indicated (+, strong; +/-, weak; -, not detected). B - E Western blot analysis 
of co-immunoprecipitation experiments from HEK293T cells co-expressing STIL fragments or 
STIL-DCC/DSTAN mutants and myc-PLK4-ND. Cells were transfected for 36 hours with the 
indicated plasmids and whole cell lysates were used for co-immunoprecipitation experiments 
with anti-myc, anti-FLAG or anti-EGFP antibodies. Antibodies for Western blot detection are 
indicated. 
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Having established the importance of the CC motif for the PLK4/STIL interaction, we 
next tested the requirement of this motif for STIL functionality in centriole reduplication. 
Therefore, we transiently overexpressed STIL-ΔCC in U2OS cells and monitored 
centriole numbers using immunofluorescence microscopy (Figure 3.3A-B). 
Overexpression of wild-type STIL (STIL-WT) caused centriole amplification in 45% of 
transfected cells, and roughly 20% of cells displayed ‘flower-like’ staining, the near-
simultaneous formation of several daughter centrioles around one mother centriole 
(Figure 3.3A-B). In cells overexpressing STIL-ΔCC only background levels of centriole 
amplification could be detected (Figure 3.3B). Moreover, we observed a similar 
reduction in centriole amplification with the STIL-∆STAN mutant, in line with the 
requirement for the STAN domain in centriole duplication 187. Importantly, deletion of 
the STAN domain had only little impact on centriolar association of STIL, whereas 
removal of the CC motif strongly impaired the localization of STIL to centrioles 203 
(Figure 3.3C). Thus, together with the observation that PLK4 depletion leads to loss 
of STIL from centrioles (Figure 3.1B), these results indicate that PLK4 directly recruits 
STIL to the site of centriole formation. We next asked whether STIL overexpression 
has an impact on the localization of PLK4 to centrioles (Figure 3.1C). To this end, we 
overexpressed EGFP tagged STIL in U2OS cells and stained for endogenous PLK4 
(Figure 3.3D-G). Under these conditions, STIL-WT triggered the near-simultaneous 
formation of several daughter centrioles and PLK4 formed a ring around preexisting 
centrioles, suggesting that STIL stabilizes centriolar PLK4 (Figure 3.3D). 
Overexpression of STIL-DCC had no effect on either centriole amplification or PLK4 
localization (Figure 3.3E) and, most importantly, overexpression of STIL-DSTAN 
stabilized PLK4 at centrioles, even though this mutant did not cause formation of extra 
centrioles (Figure 3.3F). Therefore, we conclude that STIL can stabilize PLK4 at 
centrioles in a manner that is independent of centriole formation. 
As STIL has been shown to self-associate186, we also tested a possible involvement 
of the STIL CC motif in self-interaction. We found that STIL-MD, and, more precisely, 
the CC motif, is indeed strictly required for STIL self-association, whereas the STAN 
domain is not (Supplemental Figure 3.3). We conclude that the CC motif is critical for 
the function of STIL in centriole duplication through its role in PLK4 binding, STIL self-
interaction, and STIL centriolar recruitment. 
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Figure 3.3 The STIL-CC motif is essential for centriole duplication.  
A Immunofluorescence microscopy of U2OS cells transfected with STIL-WT, STIL-DCC or 
STIL-DSTAN for 48 hours. Cells were fixed and stained with the indicated antibodies. Scale 
bar denotes 1 µm. B Quantification of centriole numbers in U2OS cells after overexpression of 
the indicated STIL plasmids (3 experiments, a total of 300 cells were analyzed for each 
condition). Error bars denote SD. C Scatter plot to illustrate STIL signal intensity at 
centrosomes, after overexpression of STIL-WT, STIL-DCC or STIL-DSTAN (20 centrosomes 
were analyzed for each condition). D - F 3D-SIM images of U2OS cells that have been 
transfected with EGFP-tagged STIL-WT, STIL-DCC and STIL-DSTAN and stained with the 
indicated antibodies. G Scatter plot to illustrate measured PLK4 signal intensities at 
centrosomes, after overexpression of STIL-WT/DCC or DSTAN (60 centrosomes were 
analyzed for each condition). Scale bar denotes 1 µm. 
3.3.3 STIL-CC directly binds PLK4-PB3 with nanomolar affinity 
To determine which regions of PLK4 are involved in STIL binding, we generated a 
series of EGFP- and FLAG-tagged PLK4 fragments comprising either the N-terminal 
PLK4 part (residues 1-570), including the kinase domain (1-271) and the linker region 
L1 (265-570), or the C-terminal region containing the Polo-boxes (PB1/2 and PB3, 
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residues 570-970; PB1/2, residues 570-820; L2-PB3, residues 814-970; PB3, 
residues 880-970) (Figure 3.4A). Co-expression of the EGFP-tagged PLK4 fragments 
with FLAG-tagged full-length STIL, followed by anti-EGFP co-immunoprecipitation, 
revealed that both, the N-terminal PLK4 fragment spanning 1-570 or all C-terminal 
fragments harboring PB3 were sufficient for the interaction with full-length STIL (Figure 
3.4B). Moreover, the STIL-CC motif alone was sufficient to bind both the N-terminus 
(residues 1-570) and PB3 (residues 880-970) of PLK4 (Figure 3.4C). Within the N-
terminal PLK4 part, the linker region (265-570) participated in the interaction, whereas 
the kinase domain itself (1-271) did not (Figure 3.4D). Attempts to further narrow down 
the interaction region in L1 were unsuccessful, indicating a non-linear folded binding 
region. To quantify the PLK4-PB3/STIL-CC interaction we determined the binding 
affinity of PLK4-PB3 and STIL-CC using isothermal titration calorimetry. For this 
purpose, PB3 (residues 884-970) was recombinantly expressed in E.coli and purified, 
and a synthetic peptide corresponding to STIL-CC was subsequently titrated into a 
solution of PLK4-PB3. The integrated raw data are well fitted by a one-site binding 
model demonstrating a direct interaction between PB3 and STIL-CC with a 
dissociation constant Kd of 280 ± 60 nM and an equimolar stoichiometry (Figure 3.4E). 
In summary, we find that the STIL-CC motif directly interacts with PLK4-PB3 and that 
binding occurs with nanomolar affinity. Moreover, we show that STIL-CC additionally 
interacts with the N-terminus of PLK4, but not the PB1/2 domain. Importantly, our 
findings thus identify a novel binding mode for PLK4, since the previously known PLK4 
binding partners Cep152 and Cep192 interact exclusively with the PB1/2 
domain113,191-194. As STIL is the first protein known to bind PLK4-PB3, we next 
characterized the structural basis of the PLK4-PB3/STIL-CC interaction. 
 
3.3.4 Structure determination and dynamics of PLK4-PB3 and its 
STIL-CC complex 
NMR diffusion experiments confirmed that both free and STIL-bound PLK4-PB3 are 
monomeric in solution (Supplemental Table 3.1). The structure of human PLK4-PB3 
(residues 884–970) was determined by solution NMR spectroscopy (  
Figure 3.5A, Table 3.1). No crystals diffracting to high resolution were obtained for this 
construct, despite extensive screening of conditions. In contrast, plate-like crystals of 
the PLK4-PB3/STIL-CC complex diffracting to 2.6 Å resolution were obtained using 
seeding. The structure was solved by molecular replacement, and refined to Rwork/free 
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of 0.22/0.25, respectively (Table 3.1) with one monomeric PLK4-PB3/STIL-CC per 
asymmetric unit (Figure 3.5B). The NMR structure of PLK4-PB3 in solution and the 
crystal structure of its STIL-CC complex display a conserved overall fold (Figure 3.5C) 
comprising a six-stranded antiparallel β-sheet (β1–β6) and a C-terminal α-helix (α1), 
which packs against the β-sheet and contacts residues from all six strands. The α-
helical STIL-CC is bound in a hydrophobic cleft formed by both the β-sheet and the 
α1 helix of PLK4-PB3. 
 
Figure 3.4 PB3 of PLK4 directly interacts with STIL-CC. 
A Schematic illustration of PLK4 fragments used to map the STIL-CC binding site. Kinase 
domain (KD), grey; PB1, yellow; PB2, orange; PB3, blue. The relative strengths of the 
interactions are indicated (+, strong; -, not detected). B - D Western blots of co-
immunoprecipitation experiments using HEK293T cells co-transfected with plasmids 
expressing PLK4 fragments and FLAG-STIL (B) or EGFP-STIL-CC (C and D). Antibodies used 
for Western blot detection are indicated. E Isothermal titration calorimetry of STIL-CC into a 
solution of PLK4-PB3. Left panel: Direct measurement of the Gibbs energy associated with 
STIL-CC binding to PLK4-PB3. Right panel: Integrated and fitted raw data using a one-site 
binding model. 
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Table 3.1 NMR and X-ray data collection and refinement statistics. 
     
 PLK4-PB3   PLK4-PB3/STIL-CC 
NMR constraints   X-ray data collection  
Distance constraints   Space group C2221 
   Total NOE 399  Cell dimensions    
   Intra-residue 49      a, b, c (Å) 86.6, 136.3, 33.4 
   Inter-residue 350      ɑ, β, ɣ (°)  90.0, 90.0, 90.0 
     Sequential (|i – j| = 1) 109  Resolution (Å) 68.1 – 2.60 (2.60 – 2.76) 
     Medium-range (|i – j| < 4) 100  Rmerge 0.15 (2.37) 
     Long-range (|i – j| > 5) 141  CC1/2 outer shell 0.63 
   Hydrogen bonds 16  I / sI 10.3 (0.9) 
Total dihedral angle restraints 122  Completeness (%) 99.7 (99) 
   f 61  Redundancy 6.4 (6.6) 
   y 61    
     
Structure statistics   Refinement  
Violations (mean and s.d.)   Resolution (Å) 20.80 – 2.60 
   Distance constraints (Å)     0.0158±0.0028  No. reflections 6409 
   Dihedral angle constraints (º) 1.686±0.147  Rwork / Rfree 0.22 / 0.25 
   Max. dihedral angle violation (º)     8.40  No. atoms  
   Max. distance constraint violation (Å) 0.278      Protein 1829 
Deviations from idealized geometry       Water 15 
   Bond lengths (Å)     0.004±0.000  B-factors  
   Bond angles (º) 0.483±0.017      Protein 89.7 
   Impropers (º) 1.391±0.102      Water 78.6 
Average pairwise r.m.s.d.a (Å)    R.m.s. deviations  
    Heavyb    1.60±0.21      Bond lengths (Å) 0.01 
    Backboneb 1.09±0.25      Bond angles (°) 1.15 
aPairwise r.m.s. deviation was calculated among 20 refined structures. 
bStatistics applied for ordered regions (residues 890-961). 
 
To further characterize differences in structure and dynamics of PLK4-PB3 seen upon 
STIL-CC binding in aqueous solution, free and STIL-CC-bound PLK4-PB3 were 
subjected to 2D [15N,1H]-TROSY experiments to reveal chemical shift perturbations 
and to 15N-{1H}NOE measurements to characterize backbone dynamics on the ps- 
to ns-timescale (Supplemental Figure 3.4 and Supplemental Figure 3.5). Chemical 
shift perturbations are observed throughout most of the PB3 backbone and comprise 
direct STIL-CC interactions and perpetuated structural changes throughout PLK4-
PB3. The most significant changes locate however around residues C954 and L955 
on helix α1, where a slight kink is formed in apo PLK4-PB3. Notably, the secondary 
chemical shifts of these residues are substantially increased upon binding STIL-CC, 
suggesting a stabilization of helical conformation (Supplemental Figure 3.6). STIL-CC 
binding leads to an increase in averaged heteronuclear NOEs for β-strands and the 
α1 helix, suggesting a general reduction of fast backbone motions of PLK4-PB3 upon 
STIL-CC binding. Overall, the structural data reveal two core differences in PLK4-PB3 
induced by STIL-CC binding: First, strand b1 is N-terminally extended by three 
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In SAK-PB3, the β-sheet is formed by strands β2, β3 and β4 from one monomer and 
strands β5 and β6 from the second (numbering according to human PLK4-PB3) and 
the α1 helix is shortened compared to human PLK4-PB3. The sequence region 
corresponding to the C-terminal half of this helix is swapped between monomers in 
SAK-PB3 and transformed into a β-strand, which occupies the position of strand β1 
in human PLK4-PB3. The best explanation for this divergence might be the existence 
of an equilibrium between a monomeric and a domain-swapped form of SAK-PB3, 
the latter of which may be a lowly populated species that is not occurring in the full-
length protein in vivo. Either the chemical conditions of crystallization shifted this 
equilibrium towards the non-native domain-swapped form or crystallization occurred 
selectively for the domain-swapped state. Nevertheless, our consistent results from 
solution and crystal structure determination strongly indicate that the canonical Polo-
box fold is a relevant physiological state of the PLK4 PB3 domain.183 
 
3.3.6 STIL-CC binding to PLK4-PB3 mimics coiled-coil interactions  
PLK4-PB3 and STIL-CC interact along the entire STIL-helix and form a substantial 
interface of 934 Å2 buried surface area210. Two regions on PLK4-PB3 contribute to the 
predominantly hydrophobic binding interface: First, the surface of the PLK4-PB3 β-
sheet around residues V907, L917, V919, I926 and Y928 (Supplemental Figure 3.8), 
and second the α1 helix (I948, L952, L955 and L959) and the linker (L944) leading 
into it (Figure 3.6A). Key interacting residues on STIL-CC are leucine and isoleucine 
residues (L733, L736, I740, L743, L744) pointing towards the hydrophobic surface of 
PLK4-PB3. Additional interactions are provided by backbone-backbone hydrogen 
bonds between PB3G922-STILQ739 and PB3K943-STILM750 (Supplemental Figure 3.8), 
respectively. The orientation of the two helices and their hydrophobic interactions is 
mainly mediated by leucine residues and resembles a leucine zipper interaction, 
consistent with the predicted coiled-coil propensity of STIL-CC205. 
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values (according to Kyte-Doolittle) for each amino are depicted in red. CC probability values 
(according to MARCOIL prediction) for each amino acid are depicted in black below the 
alignment. The position of each amino acid in the predicted heptad repeat (labelled a-g, 
whereas a and d are hydrophobic positions) is shown in green on top of the alignment. C - D 
Control, WT or mutant versions (M1-7) of HA-S-EGFP-tagged STIL-CC were co-transfected 
with either PLK4-L2-PB3 (814-970) (C) or N-terminal PLK4 (1-570) (D) in HEK293T cells. 
EGFP-immunoprecipitations were performed and analysed by Western blotting with the 
indicated antibodies. E - F To assess centriole amplification, EGFP-tagged WT and mutants 
of full-length STIL (M1-7) were overexpressed in U2OS cells (48 hours). EGFP was used as 
control. E) Quantification of transfected cells with more than 4 centrioles (n=3, 50 cells each). 
F) Immunofluorescence images of U2OS cells after overexpression of EGFP-tagged STIL-WT 
or mutants M1-7 (48 hours). Centrioles were visualized by staining with antibodies against 
CP110 and g-Tubulin (gTub) was used as marker for centrosomes. Scale bar: 1 µm. 
Polo-box domains are crucial mediators of the interaction of Polo-like kinases with 
their targets and have been demonstrated to interact with irregular substrate peptides 
and phosphopeptides. PLK1, for example, binds phosphopeptides containing a 
consensus Ser-[pSer/pThr]-[Pro/X] motif95 through a cleft within its PBD (comprising 
PB1 and PB2)80,94,211 and a neighboring binding site on PB1 is used for phospho-
independent recognition of a Map205 peptide97 (Supplemental Figure 3.9A). The 
PLK4-PB1/2 domain has recently been shown to bind either two Cep192- or one 
Cep152-derived peptide in a mutually exclusive manner using large interaction 
interfaces extending along PB1 and PB2111. PLK4-PB3 reveals a novel binding mode 
by interacting with the helical STIL-CC region in a leucine-zipper-style via the α1 helix 
with further hydrophobic contacts to the central β-sheet. Remarkably, this external 
target interaction of PLK4-PB3 closely resembles an intramolecular interaction 
observed in PLK1: there, the internal Polo-cap (Pc), an N-terminal extension of PLK1-
PB1 which comprises an α-helix and a linker to PB1, directly binds to PLK1-PB2 and 
thereby determines the relative orientation of PB1 and PB280. The 17-residue α-helix 
of the Pc is shorter compared to the 31-residue STIL-CC, but forms a leucine-zipper 
with the α1-helix of PLK1-PB2, very much like STIL-CC with the α1-helix of PB3 in 
PLK4 (Supplemental Figure 3.9B).  
 
3.3.7 Mutations demonstrate the relevance of PLK4/STIL-CC 
interactions in vivo 
Guided by the structure of the PLK4-PB3/STIL-CC complex, we designed seven 
mutants of STIL to functionally evaluate the role of the PLK4-PB3 interaction with STIL 
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(mutants M1 to M7): In the first mutant (M1) L733 and L743 were replaced by two 
large residues (L733Y, L743Y). In the second mutant (M2) as well as in the mutants 
M4-7 we replaced hydrophobic residues (at positions a and d of the coiled-coil 
heptads) with charged amino acids. In mutant M3 we exchanged Q737E and Q739K 
in order to interfere with hydrogen bond formation (STILQ739-PB3K943) (Figure 3.6B). To 
test the impact of these mutations on the binding affinity to PLK4, we co-transfected 
HA-S-EGFP-tagged mutants of STIL-CC with either FLAG-tagged PLK4-L2-PB3 
(residues 814-970) or N-terminal PLK4 (residues 1-570). The corresponding EGFP-
immunoprecipitation experiments revealed that all mutants except for M3 completely 
lost binding to PB3 (Figure 3.6C). Thus, the hydrophobic residues L733 and L743 as 
well as L736 and I740 are indeed essential for the interaction. Disruption of a hydrogen 
bond at position Q739 in M3 severely diminished the interaction with PB3 but still 
allowed for residual binding. Interestingly, all mutants maintained binding to the N-
terminal PLK4 fragment spanning residues 1-570 (Figure 3.6D). This indicates that 
STIL-CC binds to the two PLK4 regions in different ways and hence may associate 
with the two regions simultaneously. 
In parallel to the above binding studies, we also analysed the ability of the STIL mutants 
to cause centriole amplification. We overexpressed EGFP-tagged full-length WT or 
mutant STIL proteins in U2OS cells and scored for cells with more than four centrioles. 
STIL-WT produced centriole amplification in 54% of cells, half of them displaying a 
flower-like centriole arrangement. In contrast, the mutants M1-2 and M4-7 caused 
centriole amplification in only 11-14% of cells, comparable to centriole amplification in 
EGFP-transfected control cells (Figure 3.6E-F). Interestingly, in the case of M3, 30% 
of cells produced amplified centrioles (7% with a flower-like centriole arrangement) 
(Figure 3.6E-F), in line with the observed residual binding capacity to PB3 (Figure 
3.6C).  
 
3.4 Discussion 
Polo-like kinases are a family of kinases with key regulatory roles in cell cycle 
progression, mitosis, cytokinesis and centriole duplication, with all human genes 
thought to have arisen by gene duplication from an ancestral PLK1-like gene84. PLK4, 
the master regulator of centriole duplication, is the most distant member of the family. 
It is distinguished from all other PLKs by the presence of a third C-terminally located 
Polo-box, PB3, in addition to the two central and closely linked Polo-boxes PB1 and 
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PB284. PB1 and PB2 provide a dimerization platform to regulate PLK4 trans-
autophosphorylation212 and mediate recognition of crucial interaction partners84,109,111. 
However, no interaction partner of PLK4-PB3 had previously been identified. 
Here, we demonstrate that monomeric PB3 of human PLK4 adopts a canonical Polo-
box-fold and directly interacts with nanomolar affinity with the central STIL coiled-coil 
region, STIL-CC. The binding mode of the PLK4-PB3/STIL-CC interaction is 
completely different from all previously described target interactions of Polo-boxes, 
but resembles an intramolecular interaction of PB2 with the Pc-helix in PLK1. 
We show that the interaction of STIL with PLK4 in vivo regulates centriole biogenesis, 
confirming and extending recent reports that PLK4-mediated STIL phosphorylation is 
crucial for SAS-6 recruitment and for triggering centriole duplication202-204. We further 
demonstrate that the STIL-CC region is necessary and sufficient to mediate the STIL-
PLK4 interaction and map the binding of STIL-CC on PLK4 to two distinct domains, 
first to PB3, and second, to the L1 linker between the kinase and PB1/2 domain. 
Previous studies indicated that either the N-terminal kinase and L1204 or, alternatively, 
the PB1/2 domain203 of PLK4 are required for STIL interaction, but had failed to reveal 
an involvement of PB3. However, our in vivo, quantitative biophysical and structural 
data firmly establish a PLK4-PB3/STIL-CC interaction. 
The binding of STIL-CC to PB3 resembles a zipper-type coiled-coil interaction based 
on an amphiphilic helix in PB3. However, the L1 linker region is predicted to not 
contain any Polo-box folds or other regions favouring coiled-coil interactions. This 
suggests different interaction modes between STIL-CC and PB3 or L1, respectively, 
and raises the exciting prospect that STIL-CC could regulate internal interactions 
between PB3 and the L1 linker region. As further discussed below, this may constitute 
an important mechanism for regulating PLK4 activity. Furthermore, our data clearly 
demonstrate a dual role for the STIL-CC region: first, it is an interaction partner for 
PLK4-PB3 in its monomeric form, and, second, it is involved in STIL-self interactions, 
presumably via tetramerization213. Mutations in the CC motif clearly abolish the 
interaction with PLK4-PB3. However, the same hydrophobic residues of STIL-CC are 
also predicted to be essential for STIL self-interaction and it is thus likely that these 
two processes are coupled. Therefore, the inability of STIL-CC mutations to support 
centriole amplification can be due to either compromised PLK4-PB3 binding, lack of 
STIL self association or due to failure in both processes. Furthermore, PB3-binding to 
STIL-CC is expected to affect the self-association of STIL with potential consequence 
for protein-protein interactions downstream of STIL. 
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Recent studies have revealed a regulatory role for PB3 in the activation of SAK/PLK4 
in Drosophila212. Specifically, it was suggested that PB3, autophosphorylation of L1, 
and potentially further yet unidentified protein partners are important for relief of kinase 
auto-inhibition after SAK/PLK4 homodimerization. Our data on human PLK4 suggest 
to attribute a key role in such regulatory mechanism to STIL: first, STIL is the only 
identified interaction partner of PB3 with a direct influence on PB3 structure and 
dynamics; second, through its CC domain STIL is also able to interact with purported 
regulatory regions within L1 of human PLK4. These features make STIL a prime 
candidate for the role of an external factor regulating relief of PLK4 auto-inhibition in 
time and space (Figure 3.7, upper panel).  
 
Figure 3.7 STIL binding to PLK4 regulates centriole duplication. 
Hypothetical mechanism for STIL-mediated PLK4 activation: (1) PLK4 is bound to the mother 
centriole. It is intrinsically inactive, likely due to an autoinhibition by linker L1. (2a) STIL binds to 
PLK4 that has been recruited to centrioles through interactions with CEP192 and/or Cep152. 
(2b) STIL binding relieves the autoinhibition of PLK4, thus activating PLK4. (3) Activated PLK4 
phosphorylates STIL in the STAN motif, which induces SAS-6 recruitment and daughter 
centriole biogenesis (4). Activated PLK4 also phosphorylates neighboring PLK4s in the 
degradation motif, triggering their degradation. At the site of cartwheel formation, the STIL-
bound PLK4 is protected against degradation. 
Although some mechanistic aspects of centriole biogenesis are likely to differ between 
species214 it is interesting to consider our structural data on the interaction between 
PLK4 and STIL-CC in light of recent insights into the first steps of centriole formation. 
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Specifically, our data supports a model where STIL binds to PLK4 that has been 
recruited to centrioles through interactions with CEP192 and/or Cep152 (Figure 3.7, 
lower panel), either around the centriolar ring or in a localized dot-like pattern. 
Additional contributions to stable localization of STIL to centrioles may arise from its 
STAN-motif or C-terminal region, as a STIL C-terminal truncation (amino acids 1-1060) 
that contains the CC domain, interfered with correct localization to the centrioles187,189. 
Similarly, the isolated CC domain of Ana2 is not sufficient for centriolar targeting in 
Drosophila embryos213. Therefore, further interactions, presumably between the 
STAN-motif or the C-terminal region of STIL and SAS6, are likely required to stably 
integrate STIL into the centriolar cartwheel structure.  
Once in a complex with PLK4, STIL is phosphorylated, triggering the recruitment of 
SAS-6 in preparation for cartwheel formation202,203,215. In parallel, phosphorylation may 
affect STIL oligomerization and association with the walls of centrioles. In view of most 
recent studies on PLK4 activation, our data additionally indicate that STIL-CC relieves 
the auto-inhibition of PLK4212,215. The resulting PLK4 trans-autophosphorylation is 
predicted to cause recruitment of bTrCP-SCF, followed by ubiquitin-dependent 
proteasomal degradation of activated PLK4107,190. In line with this idea, depletion of 
STIL leads to remarkable increase of PLK4 levels (Figure 3.1C and Supplemental 
Figure 3.1), suggesting that PLK4 is accumulating in an inactive and hence stabilized 
conformation in the absence of STIL. Our data also indicate that STIL protects 
activated PLK4 from degradation (Figure 3.3D-G and Ohta et al.203), possibly through 
binding to the PLK4-L1 linker region, which might shield the phosphorylated 
degradation motif (DSGHAT, residues 284-289) from recognition by bTrCP-SCF. 
Overall, these mechanisms provide a possible explanation for the concentration of 
PLK4 at the site of centriole formation (Figure 3.7, lower panel). 
In summary, we have identified and structurally characterized an interaction between 
STIL and PLK4, two key centriole duplication factors. We show that the interaction is 
mediated via the STIL-CC domain and is crucial for centriole biogenesis. Importantly, 
STIL-CC is the first bona fide interaction partner of PLK4-PB3. The interaction of STIL-
CC with PLK4-PB3 and a second region within the PLK4 L1 linker likely results in 
PLK4 activation and STIL phosphorylation by PLK4. These novel insights into the 
interaction and crosstalk of two key factors in centriole biogenesis provide a new 
perspective for further work on the critical step of condensing a PLK4 ring to a spot 
in localizing the initial position of daughter centriole growth. 
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3.5 Experimental Procedures 
3.5.1 Antibodies 
Antibodies against Cep152 (rabbit)201, Centrin-3 (rabbit)216 CP110 (rabbit)217, CP110 
(mouse)189, myc (9E10, mouse)218, PLK4 (mouse)107, SAS-6 (mouse)184, and STIL 
(rabbit)183 were described previously. Monoclonal anti-FLAG M2 (Sigma-Aldrich), 
rabbit polyclonal anti-GFP (Abcam), monoclonal anti-g-Tubulin TU-30 (Abcam), 
polyclonal anti-STIL (Abcam) and monoclonal anti-PLK4 MABC544, clone 6H5 (Merck 
Millipore) were purchased from the respective manufacturers. Alexa-555-, Alexa-488-
, Alexa-647-labeled secondary anti-mouse and anti-rabbit antibodies were purchased 
from Invitrogen (Carlsbad, CA, USA). Whenever appropriate, antibodies were directly 
labeled with Alexa-555, Alexa-488 and Alexa-647 fluorophores, using the 
corresponding Antibody Labeling Kits (Invitrogen). 
 
3.5.2 Plasmids 
Cloning of myc-PLK4 full-length WT99, myc-PLK4 full-length ND (S285A/T289A)107 and 
FLAG-STIL183 was described previously. pgLAP1 was a gift from Peter Jackson 
(Addgene plasmid #19702). All other plasmids were generated via the Gateway 
technology (Invitrogen) using the pENTR/D-TOPO entry vector (Invitrogen) and 
pcDNA3.1-based destination vectors containing the appropriate N-terminal tags. 
Mutations in STIL were generated with the QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent) according to the manufacturer’s instructions. 
 
3.5.3 Kinase assays 
In vitro kinase assays using recombinant GST-PLK4 1-430 WT/D154A (cloned into 
pGEX-5X-2 (Thesis J. Westendorf)) were carried out at 30°C in kinase buffer (50 mM 
HEPES pH 7.0, 100 mM NaCl, 10 mM MgCl2, 5% glycerol, 1 mM DTT). Reactions 
were stopped after 30 minutes by addition of Laemmli sample buffer. Samples were 
then analyzed by autoradiography and Western blotting. 
 
3.5.4 Cell culture and transfections 
U2OS and HEK293T cells were grown at 37 °C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM), supplemented with 10% heat-inactivated fetal calf serum 
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(FCS, PAN Biotech, Aidenbach, Germany) and penicillin-streptomycin (100 µg/ml, 
Gibco-BRL, Karlsruhe, Germany). The U2OS cell line harboring the tetracycline-
inducible myc-PLK4 transgene has been described184. The T-REx U2OS Flp-IN cell 
line harboring the tetracycline-inducible S-peptide-EGFP-tagged PLK4 fragment 
(residues 570-970) has been generated as described previously189. Transgene 
expression was induced by the addition of 1 µg/ml tetracycline. PLK4, STIL and bTrCP 
were depleted using siRNA oligonucleotides described previously99,183,219. 
Transfections of siRNA oligonucleotides or plasmids were performed using the 
transfection reagents Oligofectamin (Invitrogen) or TransIT-LT1 (Mirus Bio), 
respectively, according to the manufacturer’s instructions. 
 
3.5.5 Cell extracts, immunoprecipitation, Western blots and mass 
spectrometry 
Cell lysis was performed as described previously107 using Tris lysis buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.5% IgePal) supplemented with protease and 
phosphatase inhibitors. For immunoprecipitation experiments, cell extracts (2-5 mg 
total protein) were incubated for 2 hours at 4 °C with appropriate beads [Anti-FLAG 
M2 Affinity Gel (Sigma-Aldrich), GFP-Trap agarose (ChromoTek), Affi-Prep protein A 
matrix (Bio-Rad Laboratories) crosslinked with 9E10 anti-myc antibodies or S-protein 
Agarose beads (Novagen)]. Immunocomplexes were washed 4-6 times with wash 
buffer (50 mM Tris-HCl pH 7.4, 150-500 mM NaCl, 0.5-1% IgePal), eluted with 
Laemmli buffer and analyzed by Western blotting. For mass spectrometry analysis of 
proteins copurifying with the S-peptide-EGFP-PLK4 fragment (residues 570-970), 
transgene expression was induced for 24 hours with Tetracycline (1 µg/ml). Cell 
extracts were subjected to S-protein immunoprecipitations and the samples were 
processed for mass spectrometry as described previously220. 
 
3.5.6 Immunofluorescence microscopy 
Cells were fixed in methanol (5 minutes at -20 °C) and processed for 
immunofluorescence microscopy as described previously221. Stainings were analyzed 
using a DeltaVision microscope on a Nikon TE200 base (Applied Precision), equipped 
with a Plan Apochromat 60x 1.42 and an APOPLAN 100x 1.4 N.A. oil-immersion 
objective (Olympus), and a CoolSNAP HQ2 camera (Photometrics). Serial optical 
sections acquired 0.2 µm apart along the z-axis were processed and projected into 
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one image using Softworx (Applied Precision). For quantifications of STIL and PLK4 
levels, intensities were measured with ImageJ and background signal intensity was 
subtracted. Identical image acquisition and image processing settings were used 
whenever measurements were compared. 3D-SIM was performed on a DeltaVision 
OMX-Blaze microscope system as described previously194. 
 
3.5.7 Expression and purification of PLK4-PB3 for structural studies  
The human PLK4-PB3 (884-970) was cloned into pETG-30A (EMBL) with a N-terminal 
thioredoxin and hexashistidine tag, followed by tobacco etch virus (TEV) protease 
cleavage site (Gateway Cloning, life technologies). The vector was transformed into 
BL21 DE3 cells. The expression culture was induced with 0.5 mM IPTG at an OD600nm 
of 0.5 and then grown for 18 hours at 20 °C. The protein was purified using High 
Affinity Nickel Charged Resin (Genscript). The N-terminal tag was removed by 
incubation with tobacco etch virus protease and rebinding to High Affinity Nickel 
Charged Resin. The PLK4-PB3 was further purified by size exclusion chromatography 
using a Hiload 16/60 Superdex75 column (GE). Based on this procedure, the following 
isotope-labeled samples were prepared for NMR experiments: [U-99%-2H, 15N]-
PLK4-PB3, [U-99%-2H, 15N, 13C]-PLK4-PB3, [U-99%-2H, 15N; 99%-1Hδ,13Cδ-IL;99%-
1Hγ,13Cγ-V]-PLK4-PB3, and [U-99%-2H, 15N,13C; 99%-1Hδ-IL;99%-1Hγ,13Cγ-V]-PLK4-
PB3. All isotope-labeled reagents were purchased from Sigma-Aldrich.  
 
3.5.8 Isothermal titration calorimetry 
Isothermal titration calorimetry measurement employed a VP-ITC Instrument 
(Microcal). Recombinant PB3 (35.5 µM) and synthetic STIL-CC Peptide (414 µM) were 
dialyzed against 50 mM Hepes pH 8.0, 150 mM NaCl and 1 mM TCEP. The 
experiment was conducted at 25 °C. Titrations employed 30 STIL-CC injections (10 
µl) each followed by a 300 s delay. The experimental data was fit with a one-site 
binding model. 
 
3.5.9 NMR spectroscopy and structure determination of PLK4-PB3 
All protein samples were prepared in 20 mM MOPS pH 7, 30 mM NaCl and 2 mM 
TCEP in 5%/95% D2O/H2O with a protein concentration between 0.6 and 1.2 mM. All 
NMR spectra were recorded at 20°C on Bruker Avance spectrometers equipped with 
cryogenic triple-resonance probes (field strengths 700, 800 and 900 MHz). For the 
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sequence-specific backbone resonance assignment of [U-2H, 15N, 13C]-labeled PLK4-
PB3 with and without bound STIL, the following NMR experiments were recorded: 2D 
[15N-1H]-TROSY-HSQC222, 3D TROSY-HNCA, 3D TROSY-HNCACB, 3D TROSY-
HNCO and 3D TROSY-HNCACO223. Chemical shift perturbations (Dd(HN)) of amide 
moieties were calculated as: Dd(HN) = [((dHref-dH)2+((dNref-dN)/5)2)/2]0.5. For the 
sequence-specific side chain resonance assignment of [U-2H, 15N, 13C-methyl-ILV]-
labeled PB3, the following experiments were recorded: 3D (H)C(CC)-TOCSY-(CO)-
15N-HSQC and 3D H(C)(CC)-TOCSY-(CO)-15N-HSQC with a TOCSY mixing time of 
26.6 ns224. The NOE distance restraints for structural calculation were derived from 3D 
[1H,1H]-NOESY-15N-TROSY225,226 and 3D [1H,1H]-NOESY-13C-HMQC226 with a NOE 
mixing time of 100 ms. For determination of the dynamic properties of [U-2H, 15N]-
PLK4-PB3 with and without bound STIL, 15N{1H}-NOE experiments were measured227. 
15N-filtered BPP-LED-diffusion experiments were recorded to measure the lateral 
diffusion of [U-2H, 15N]-PLK4-PB3, [U-2H, 15N]-PLK4-PB3/STIL-CC and [U-2H, 15N]-
GB1 as a control228. 
Data were processed using Prosa229 and analyzed with CARA230. The backbone 
assignment was done manually using CARA. Structure calculations were performed 
using CYANA 3.96231, based on NOE restraints and dihedral angle restraints 
calculated by Talos+232. Hydrogen bonding restraints were added for residues in 
secondary structural elements that were unambiguously predicted by Talos+, and that 
showed the characteristic backbone NOE pattern for these secondary structural 
elements. A total of 100 structures were calculated by CYANA and the 20 conformers 
with the lowest target function were selected. A final water-refinement step of 15 ns 
was performed with CNS233 Ramachandran statistics were 90.7 % in most favored 
regions, 7.2 % in additionally allowed regions, 1.7 % in generously allowed regions 
and 0.4 % in disallowed regions. Structures were analyzed using Molmol234. 
 
3.5.10 Crystallization and structure determination of PB3/STIL-CC 
Synthetic STIL-CC peptide was incubated with recombinant PLK4-PB3 on ice for 1 
hour in 20 mM HEPES-KOH pH 8.0, 150 mM NaCl and 2 mM TCEP in a 1.2-fold 
molar excess. The complex was concentrated to 16 mg ml-1 and set up for 
crystallization using the sitting-drop vapour diffusion method with a 1:1 (v/v) ratio of 
the complex and precipitant solutions. Thin needles grew in precipitant solution 
containing 100 mM Hepes, pH 7.0, 20 mM MgCl2 and 22% Poly(acrylic acid sodium 
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salt) 5100. After extensive optimization and seeding plate-like crystals were grown in 
a drop consisting of 50% PLK4-PB3/STIL-CC complex solution, 33.3% precipitant 
solution (100 mM phosphate/citrate pH 4.2, 40% (v/v) Ethanol, 5% (w/v) PEG 1000) 
and 16.7% of seed stock solution. Crystals were flash frozen in liquid nitrogen using 
Perfluoropolyether (Hampton Research) as cryoprotectant. 
X-ray diffraction data was collected at the beamline X06DA (PXIII) at the Swiss Light 
Source (Paul Scherrer Institute, Switzerland) using a PILATUS 2M detector. Crystals 
in the space group C2221 diffracted to 2.6 Å resolution. The X-ray diffraction data was 
processed using XDS159. The structure was solved by molecular replacement with 
Phaser162 using PLK1-PB1 (3P34, residues 147-331) as an initial search model. The 
asymmetric unit comprises one monomeric PLK4-PB3/STIL-CC complex. Model 
building and refinement was performed with Coot235 and PHENIX236 to Rwork/free of 
0.22/0.25, respectively 
 
3.6 Accession numbers 
Atomic coordinates for PLK4-PB3 have been deposited in the Protein Data Bank with 
accession code 2n19. Sequence-specific resonance assignments have been 
submitted to the Biological Magnetic Resonance Data Bank under the following 
codes: PLK4-PB3, 25552 and holo PLK4-PB3 with bound STIL-CC, 26547. Atomic 
coordinates and structure factors for PLK4-PB3/STIL-CC have been deposited in the 
Protein Data Bank with accession code 4YYP. 
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Supplemental Figure 3.1 Plk4 levels are elevated in STIL depleted cells. 
A U2OS cells were transfected with control (siGL2), three different STIL (siSTIL1-3), bTrCP and 
Plk4 siRNA oligonucleotides for 72 hours, lysed and subjected to Western blot analysis using 
the indicated antibodies. B Graph representing Plk4 band intensities measured in Western 
blots from two independent experiments as described in (a). Error bars represent SEM. C HeLa 
S3 cells were transfected with control (siGL2), three different STIL (siSTIL1-3), bTrCP and Plk4 
siRNA oligonucleotides for 72 hours, lysed and subjected to Western blot analysis using the 
indicated antibodies. D Graph representing Plk4 band intensities measured in Western blots 
from two independent experiments as described in (C). Error bars represent SEM. E U2OS 
cells were transfected with control (siGL2), three different STIL (siSTIL1-3), bTrCP and Plk4 
siRNA oligonucleotides for 72 hours, fixed, stained with indicated antibodies and analysed in 
immunofluorescence microscopy. Representative images are shown. Scale bar: 1 µm. F Graph 
representing Plk4 levels measured in the centrosomal region of images as described in (E). 15 
cells were measured for each condition in three independent experiments, error bars denote 
SEM.   
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Supplemental Figure 3.2 STIL is a phosphorylation target of PLK4 and PLK4-ND. 
A FLAG-STIL is phosphorylated by GST-PLK41-430 in vitro. HEK293T cells were transfected 
with FLAG-STIL for 48 hours. After cell lysis, FLAG-STIL was purified using anti-FLAG 
antibodies and subjected to an in vitro kinase assay with recombinant GST-PLK41-430 or, as a 
control, with a kinase-inactive version of GST-PLK41-430 (D154A). On the left, the Western blot 
probed with anti-FLAG antibody shows the amounts of FLAG-STIL used for the reactions. The 
autoradiograph (right side) shows the phosphorylation of FLAG-STIL by GST-PLK41-430 (upper 
band) as well as the autophosphorylation of GST-PLK41-430 (lower band). B HEK293T cells were 
transfected with the indicated plasmids and cell extracts were subjected to anti-myc co-
immunoprecipitations followed by Western blot analysis. PLK4-ND – the non-degradable PLK4 
mutant used throughout this study (S285A and T289A107) – exhibits enhanced stabilization and 
thus facilitates visualization of STIL binding (higher amounts of FLAG-STIL were detected in 
the precipitate of myc-PLK4-ND compared to wild-type myc-PLK4). Note the upshift of the 
STIL band upon co-expression with PLK4-ND, indicating that FLAG-STIL is phosphorylated 
by myc-PLK4-ND.54 
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Supplemental Figure 3.3 The STIL-CC domain is essential for STIL oligomerization. 
A Schematic illustration of STIL constructs used for the co-immunoprecipitation experiments 
shown in (B-D). On the right, the relative strengths of the interactions are indicated (+, strong; 
+/-, weak; -, not detected). B-D Western blot analysis of co-immunoprecipitation experiments 
to map the region required for STIL self-association. HEK293T cells were transfected with the 
indicated plasmids to co-express the corresponding STIL constructs for 24-36 hours. 
Subsequently, cells were lysed and co-immunoprecipitations were performed with anti-myc or 
anti-FLAG antibodies.   
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4.1 Abstract 
Acetyl-CoA carboxylases (ACCs) catalyze the committed step in fatty acid 
biosynthesis, the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. They 
are important regulatory hubs for metabolic control and relevant drug targets for the 
treatment of the metabolic syndrome and cancer. Eukaryotic ACCs are single-chain 
multienzymes characterized by a large, non-catalytic central domain (CD), whose role 
in ACC regulation remains poorly characterized. Here we report the crystal structure 
of the yeast ACC CD, revealing a unique four-domain organization. A regulatory loop, 
which is phosphorylated at the key functional phosphorylation site of fungal ACC, 
wedges into a crevice between two domains of CD. Combining the yeast CD structure 
with intermediate and low-resolution data of larger fragments up to intact ACCs 
provides a comprehensive characterization of the dynamic fungal ACC architecture. 
In contrast to related carboxylases, large-scale conformational changes are required 
for substrate turnover, and are mediated by the CD under phosphorylation control. 
 
4.2 Introduction 
Biotin-dependent acetyl-CoA carboxylases (ACCs) are essential enzymes that 
catalyze the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA. This 
reaction provides the committed activated substrate for the biosynthesis of fatty acids 
via fatty acid synthase239,240. By catalyzing this rate-limiting step in fatty acid 
biosynthesis, ACC plays a key role in anabolic metabolism. ACC inhibition and knock-
out studies show the potential of targeting ACC for treatment of the metabolic 
syndrome241-243. Furthermore, elevated ACC activity is observed in malignant 
tumors244,245. A direct link between ACC and cancer is provided by cancer-associated 
mutations in the breast cancer susceptibility gene 1 (BRCA1), which relieve inhibitory 
interactions of BRCA1 with ACC125,126. Thus, ACC is a relevant drug target for type 2 
diabetes and cancer117,246,247. Microbial ACCs are also the principal target of antifungal 
and antibiotic compounds, such as Soraphen A134,248.  
The principal functional protein components of ACCs have been described already in 
the late 1960’s for Escherichia coli (E. coli) ACC249,250: Biotin carboxylase (BC) 
catalyzes the ATP-dependent carboxylation of a biotin moiety, which is covalently 
linked to the biotin carboxyl carrier protein (BCCP). Carboxyltransferase (CT) transfers 
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the activated carboxyl group from carboxy-biotin to acetyl-CoA to yield malonyl-CoA. 
Prokaryotic ACCs are transient assemblies of individual BC, CT and BCCP subunits133. 
Eukaryotic ACCs, instead, are multienzymes, which integrate all functional 
components into a single polypeptide chain of Here we report the crystal structure of 
the yeast ACC CD, revealing a unique four-domain organization ~2300 amino acids240. 
Human ACC occurs in two closely related isoforms, ACC1 and 2, located in the 
cytosol and at the outer mitochondrial membrane, respectively251,252. In addition to the 
canonical ACC components, eukaryotic ACCs contain two non-catalytic regions, the 
large central domain (CD) and the BC-CT interaction domain (BT). The CD comprises 
one third of the protein and is a unique feature of eukaryotic ACCs without homologs 
in other proteins. The function of this domain remains poorly characterized, although 
phosphorylation of several serine residues in the CD regulates ACC activity253-255. The 
BT domain has been visualized in bacterial carboxylases, where it mediates contacts 
between α- and β-subunits256,257. 
Structural studies on the functional architecture of intact ACCs have been hindered 
by their huge size and pronounced dynamics, as well as the transient assembly mode 
of bacterial ACCs. However, crystal structures of individual components or domains 
from prokaryotic and eukaryotic ACCs, respectively, have been solved118,135,136,258,259. 
The structure determination of the holoenzymes of bacterial biotin-dependent 
carboxylases, which lack the characteristic CD, such as the pyruvate carboxylase 
(PC)260, propionyl-CoA carboxylase (PCC)256, 3-methyl-crotonyl-CoA carboxylase 
(MCC)257 and a long-chain acyl-CoA carboxylase (LCC)261 revealed strikingly divergent 
architectures despite a general conservation of all functional components. In these 
structures, the BC and CT active sites are at distances between 40 and 80 Å, such 
that substrate transfer could be mediated solely by the mobility of the flexibly tethered 
BCCP. 
Human ACC1 is regulated allosterically, via specific protein-protein interactions and 
by reversible phosphorylation. Dynamic polymerization of human ACC1 is linked to 
increased activity and is regulated allosterically by the activator citrate and the inhibitor 
palmitate123,253 or by binding of the small protein MIG12124. Human ACC1 is further 
regulated by specific phosphorylation-dependent binding of BRCA1 to Ser1263 in the 
CD. BRCA1 binds only to the phosphorylated form of ACC1 and prevents ACC 
activation by phosphatase-mediated dephosphorylation125,127. Furthermore, 
phosphorylation by AMP-activated protein kinase (AMPK) and cAMP-dependent 
protein kinase (PKA) leads to a decrease in ACC1 activity. AMPK phosphorylates 
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ACC1 in vitro at Ser80, Ser1201 and Ser1216 and PKA at Ser78 and Ser1201. 
However, regulatory effects on ACC1 activity are mainly mediated by phosphorylation 
of Ser80 and Ser1201128,129. Phosphorylated Ser80, which is highly conserved only in 
higher eukaryotes, presumably binds into the Soraphen A-binding pocket262. The 
regulatory Ser1201 shows only moderate conservation across higher eukaryotes, 
while the phosphorylated Ser1216 is highly conserved across all eukaryotes. 
However, no effect of Ser1216 phosphorylation on ACC activity has been reported in 
higher eukaryotes. 
For fungal ACC, neither spontaneous nor inducible polymerization has been detected 
despite considerable sequence conservation to human ACC1. The BRCA1-interacting 
phosphoserine position is not conserved in fungal ACC, and no other phospho-
dependent protein-protein interactions of fungal ACC have been described. In yeast 
ACC, phosphorylation sites have been identified at Ser2, Ser735, Ser1148, Ser1157 
and Ser1162. Of these, only Ser1157 is highly conserved in fungal ACC and aligns to 
Ser1216 in human ACC1. Its phosphorylation by the AMPK homologue SNF1 results 
in strongly reduced ACC activity130,132,255. 
Despite the outstanding relevance of ACC in primary metabolism and disease, the 
dynamic organization and regulation of the giant eukaryotic, and in particular fungal 
ACC, remain poorly characterized. Here we provide the structure of Saccharomyces 
cerevisiae (Sce) ACC CD, intermediate- and low-resolution structures of human (Hsa) 
ACC CD and larger fragments of fungal ACC from Chaetomium thermophilum (Cth; 
Figure 4.1A). Integrating these data with small-angle X-ray scattering (SAXS) and 
electron microscopy (EM) observations yield a comprehensive representation of the 
dynamic structure and regulation of fungal ACC. 
 
4.3 Results 
4.3.1 The organization of the yeast ACC CD 
First, we focused on structure determination of the 82 kDa CD. The crystal structure 
of the CD of SceACC (SceCD) was determined at 3.0 Å resolution by experimental 
phasing and refined to Rwork/Rfree= 0.20/0.25 (Table 4.1). The overall extent of the 
SceCD is 70 by 75 Å (Figure 4.1B, Supplemental Figure 4.1A,B) and the attachment 
points of the N-terminal 26-residue linker to the BCCP and the C-terminal CT are 
separated by 46 Å (termini are indicated with spheres in Figure 4.1B). SceCD 
comprises four distinct domains, an N-terminal α-helical domain (CDN), and a central 
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four-helix bundle linker domain (CDL) followed by two α-β-fold C-terminal domains 
(CDC1/CDC2). CDN adopts a letter C shape, where one of the ends is a regular four-
helix bundle (Nα3-6), the other end is a helical hairpin (Nα8,9) and the bridging region 
comprises six helices (Nα1,2,7,10-12). CDL is composed of a small, irregular four-helix 
bundle (Lα1-4) and tightly interacts with the open face of CDC1 via an interface of 1300 
Å2 involving helices Lα3 and Lα4. CDL does not interact with CDN apart from the 
covalent linkage and forms only a small contact to CDC2 via a loop between Lα2/α3 
and the N-terminal end of Lα1 with an interface area of 400 Å2. CDC1/CDC2 share a 
common fold; they are composed of six-stranded β-sheets flanked on one side by 
two long, bent helices inserted between strands β3/β4 and β4/β5. CDC2 is extended 
at its C-terminus by an additional β-strand and an irregular β-hairpin. On the basis of 
root mean square deviation of main chain atom positions of 2.2 Å, CDC1/CDC2 are 
structurally more closely related to each other than to any other protein (Figure 4.1C); 
they may thus have evolved by duplication. Close structural homologs could not be 
found for the CDN or the CDC domains.  
 
4.3.2 A regulatory loop mediates interdomain interactions 
To define the functional state of insect-cell expressed ACC variants, we employed 
mass spectrometry (MS) for phosphorylation site detection. In insect-cell expressed 
full-length SceACC, the highly conserved Ser1157 is the only fully occupied 
phosphorylation site with functional relevance in S. cerevisiae. Additional 
phosphorylation was detected for Ser2101 and Tyr2179, however these sites are 
neither conserved across fungal ACC nor natively phosphorylated in yeast. MS 
analysis of dissolved crystals confirmed the phosphorylated state of Ser1157 also in 
SceCD crystals. The SceCD structure thus authentically represents the state of 
SceACC, where the enzyme is inhibited by SNF1-dependent phosphorylation.  
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Table 4.1 Crystallographic data collection and refinement statistics.  
*Resolution cutoffs determined based on internal correlation significant at the 0.1% level as 
calculated by XDS. 
wHighest-resolution shell is shown in parentheses.	
zModelled only as poly-alanine. 
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In the SceCD crystal structure, the phosphorylated Ser1157 resides in a regulatory 
36-amino acid loop between strands β2 and β3 of CDC1 (Figure 4.1B,D), which 
contains two additional less conserved phosphorylation sites (Ser1148, Ser1162) 
confirmed in yeast263, but not occupied here. This regulatory loop wedges between 
the CDC1 and CDC2 domains and provides the largest contribution to the interdomain 
interface. The N-terminal region of the regulatory loop also directly contacts the C-
terminal region of CDC2 leading into CT. Phosphoserine 1157 is tightly bound by two 
highly conserved arginines (Arg1173, Arg1260) of CDC1 (Figure 4.1D). Already the 
binding of phosphorylated Ser1157 apparently stabilizes the regulatory loop 
conformation, the accessory phosphorylation sites Ser1148 and Ser1162 in the same 
loop may further modulate the strength of interaction between the regulatory loop and 
the CDC1 and CDC2 domains. Phosphorylation of the regulatory loop thus determines 
interdomain interactions of CDC1 and CDC2 suggesting that it may exert its regulatory 
function by modifying the overall structure and dynamics of the CD. 
The functional role of Ser1157 was confirmed by an activity assay based on the 
incorporation of radioactive carbonate into acid non-volatile material264. 
Phosphorylated SceACC shows only residual activity (kcat = 0.4 ± 0.2 s-1), which 
increases 16-fold (kcat = 6.5 ± 0.3 s-1) after dephosphorylation with λ protein 
phosphatase. The values obtained for dephosphorylated SceACC are comparable to 
earlier measurements of non-phosphorylated yeast ACC expressed in E. coli265. 
 
4.3.3 The variable CD is conserved between yeast and human 
To compare the organization of fungal and human ACC CD, we determined the 
structure of a human ACC1 fragment that comprises the BT and CD domains (HsaBT-
CD), but lacks the mobile BCCP in between (Figure 4.1A). An experimentally-phased 
map was obtained at 3.7 Å resolution for a cadmium-derivatized crystal and was 
interpreted by a poly-alanine model (Figure 4.1E, Table 4.1). Each of the four CD 
domains in HsaBT-CD individually resembles the corresponding SceCD domain; 
however, human and yeast CDs exhibit distinct overall structures. In agreement with 
their tight interaction in SceCD, the relative spatial arrangement of CDC1 and CDL is 
preserved in HsaBT-CD, but the human CDL/CDC1 didomain is tilted by 30° based on 
a superposition of human and yeast CDC2 (Supplemental Figure 4.1C). As a result, the 
N-terminus of CDL at helix Lα1, which connects to CDN, is shifted by 12 Å. 
Remarkably, CDN of HsaBT-CD adopts a completely different orientation compared 
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to SceCD. With CDL/CDC1 superposed, CDN in HsaBT-CD is rotated by 160° around 
a hinge at the connection of CDN/CDL (Supplemental Figure 4.1D). This rotation 
displaces the N-terminus of CDN in HsaBT-CD by 51 Å compared to SceCD resulting 
in a separation of the attachment points of the N-terminal linker to the BCCP domain 
and the C-terminal CT domain by 67 Å (the attachment points are indicated with 
spheres in Figure 4.1E). The BT domain of HsaBT-CD consists of a helix that is 
surrounded at its N-terminus by an anti-parallel eight-stranded β-barrel. It resembles 
the BT of PCC256, only the four C-terminal strands of the β-barrel are slightly tilted. 
On the basis of MS analysis of insect-cell expressed human full-length ACC Ser80 
shows the highest degree of phosphorylation (90%). Ser29 and Ser1263, implicated 
in insulin-dependent phosphorylation and BRCA1 binding, respectively, are 
phosphorylated at intermediate levels (40%). The highly conserved Ser1216 
(corresponding to S. cerevisiae Ser1157), as well as Ser1201, both in the regulatory 
loop discussed above, are not phosphorylated. However, residual phosphorylation 
levels were detected for Ser1204 (7%) and Ser1218 (7%) in the same loop. MS 
analysis of the HsaBT-CD crystallization sample reveals partial proteolytic digestion of 
the regulatory loop. Accordingly, most of this loop is not represented in the HsaBT-
CD crystal structure. The absence of the regulatory loop might be linked to the less 
restrained interface of CDC2 and CDL/CDC1 and altered relative orientations of these 
domains. Besides the regulatory loop, also the phosphopeptide target region for 
BRCA1 interaction is not resolved presumably because of pronounced flexibility. 
At the level of isolated yeast and human CD, the structural analysis indicates the 
presence of at least two hinges, one with large-scale flexibility at the CDN/CDL 
connection, and one with tunable plasticity between CDC2 and CDL/CDC1, plausibly 
affected by phosphorylation in the regulatory loop region. 
 
4.3.4 The integration of CD into the fungal ACC multienzyme 
To further obtain insights into the functional architecture of fungal ACC, we 
characterized larger multidomain fragments up to the intact enzymes. Using molecular 
replacement based on fungal ACC BC, CD and CT models, we obtained structures 
of a variant comprising CthCT and CDC1/CDC2 in two crystal forms at resolutions of 
3.6 Å and 4.5 Å (CthCD-CTCter1/2), respectively, as well as of a CthCT linked to the 
entire CD at 7.2 Å resolution (CthCD-CT) (Figure 4.1A, Figure 4.2, Table 4.1). No 
crystals diffracting to sufficient resolution were obtained for larger BC-containing 
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fragments, or for full-length Cth or SceACC. To improve crystallizibility, we generated 
ΔBCCP variants of full-length ACC, which based on SAXS analysis preserve 
properties of intact ACC (Supplemental Figure 4.2A-C). For CthΔBCCP, crystals 
diffracting to 8.4 Å resolution were obtained. However, molecular replacement did not 
reveal a unique positioning of the BC domain. Owing to the limited resolution the 
discussion of structures of CthCD-CT and CthΔBCCP is restricted to the analysis of 
domain localization. Still, these structures contribute considerably to the visualization 
of an intrinsically dynamic fungal ACC.  
In all these crystal structures, the CT domains build a canonical head-to-tail dimer118, 
with active sites formed by contributions from both protomers (Figure 4.2, 
Supplemental Figure 4.3A). The connection of CD and CT is provided by a 10-residue 
peptide stretch, which links the N-terminus of CT to the irregular β-hairpin/β-strand 
extension of CDC2 (Supplemental Figure 4.3B). The connecting region is remarkably 
similar in isolated CD and CthCD-CTCter structures, indicating inherent conformational 
stability. CD/CT contacts are only formed in direct vicinity of the covalent linkage and 
involve the β-hairpin extension of CDC2 as well as the loop between strands β2/β3 of 
the CT N-lobe, which contains a conserved RxxGxN motif. The neighboring loop on 
the CT side (between CT β1/β2) is displaced by 2.5 Å compared to isolated CT 
structures (Supplemental Figure 4.3C). On the basis of an interface area of ~600 Å2 
and its edge-to-edge connection characteristics, the interface between CT and CD 
might be classified as conformationally variable. Indeed, the comparison of the 
positioning of eight instances of the C-terminal part of CD relative to CT in crystal 
structures determined here reveals flexible interdomain linking (Figure 4.3A): The 
CDC2/CT interface acts as a true hinge with observed rotation up to 16°, which results 
in a translocation of the distal end of CDC2 by 8 Å.  
The interface between CDC2 and CDL/CDC1, which is mediated by the phosphorylated  
regulatory loop in the SceCD structure, is less variable than the CD-CT junction, and 
permits only limited rotation and tilting (Figure 4.3B). Analysis of the impact of 
phosphorylation on the interface between CDC2 and CDL/CDC1 in CthACC variant 
structures is precluded by the limited crystallographic resolution. However, MS 
analysis of CthCD-CT and CthΔBCCP constructs revealed between 60 and 70% 
phosphorylation of Ser1170 (corresponding to SceACC Ser1157). 
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4.3.5 Large-scale conformational variability of fungal ACC  
To obtain a comprehensive view of fungal ACC dynamics in solution, we employed 
SAXS and EM. SAXS analysis of CthACC agrees with a dimeric state and an elongated 
shape with a maximum extent of 350 Å (Supplemental Table 4.1). The smooth 
appearance of scattering curves and derived distance distributions might indicate 
substantial interdomain flexibility 266 (Supplemental Figure 4.2A-C). Direct observation 
of individual full- length CthACC particles, according to MS results predominantly in a 
phosphorylated low-activity state, in negative stain EM reveals a large set of 
conformations from rod-like extended to U-shaped particles. Class averages, 
obtained by maximum-likelihood-based 2D classification, are focused on the dimeric 
CT domain and the full BC-BCCP-CD domain of only one protomer, due to the non-
coordinated motions of the lateral BC/CD regions relative to the CT dimer. They 
identify the connections between CDN/CDL and between CDC2/CT as major 
contributors to conformational heterogeneity (Supplemental Figure 4.4A,B). The 
flexibility in the CDC2/CT hinge appears substantially larger than the variations observed 
in the set of crystal structures. The BC domain is not completely disordered, but 
laterally attached to BT/CDN in a generally conserved position, albeit with increased 
flexibility. Surprisingly, in both the linear and U-shaped conformations, the 
approximate distances between the BC and CT active sites would remain larger than 
110 Å. These observed distances are considerably larger than in static structures of 
any other related biotin-dependent carboxylase. Furthermore, based on an average 
length of the BCCP-CD linker in fungal ACC of 26 amino acids, mobility of the BCCP 
alone would not be sufficient to bridge the active sites of BC and CT. Consequently, 
increased flexibility or additional modes of conformational changes may be required 
for productive catalysis. The most relevant candidate site for mediating such additional 
flexibility and permitting an extended set of conformations is the CDC1/CDC2 interface, 
which is rigidified by the Ser1157-phosphorylated regulatory loop as depicted in the 
SceCD crystal structure.  
 
4.4 Discussion 
Altogether, the architecture of fungal ACC is based on the central dimeric CT domain 
(Figure 4.4D). The CD consists of four distinct subdomains and acts as a tether from 
the CT to the mobile BCCP and an oriented BC domain. The CD has no direct role in 
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substrate recognition or catalysis but contributes to the regulation of all eukaryotic 
ACCs. In higher eukaryotic ACCs, regulation via phosphorylation is achieved by 
combining the effects of phosphorylation at Ser80, Ser1201 and Ser1263. In fungal 
ACC however, Ser1157 in the regulatory loop of the CD is the only phosphorylation 
site that has been demonstrated to be both phosphorylated in vivo and involved in the 
regulation of ACC activity. In its phosphorylated state, the regulatory loop containing 
Ser1157 wedges between CDC1/CDC2 and presumably limits the conformational 
freedom at this interdomain interface. However, flexibility at this hinge may be required 
for full ACC activity, as the distances between the BCCP anchor points and the active 
sites of BC and CT observed here are such large, that mobility of the BCCP alone is 
not sufficient for substrate transfer. The current data thus suggest that regulation of 
fungal ACC is mediated by controlling the dynamics of the unique CD, rather than 
directly affecting catalytic turnover at the active sites of BC and CT. A comparison 
between fungal and human ACC will help to further discriminate mechanistic 
differences that contribute to the extended control and polymerization of human ACC. 
Most recently, a crystal structure of near full-length non-phosphorylated ACC from S. 
cerevisae (lacking only 21 N-terminal amino acids, here denoted as flACC) was 
published by Wei and Tong265. In flACC, the ACC dimer obeys two-fold symmetry and 
assembles in a triangular architecture with dimeric BC domains (Supplemental Figure 
4.5). In their study, mutational data indicate a requirement for BC dimerization for 
catalytic activity. The transition from the elongated open shape, observed in our 
experiments, towards a compact triangular shape is based on an intricate interplay of 
several hinge-bending motions in the CD (Figure 4.4D). Comparison of flACC with our 
CthΔBCCP structure reveals the CDC2/CT hinge as a major contributor to 
conformational flexibility (Supplemental Figure 4.5B,C). In flACC, CDC2 rotates ~120° 
with respect to the CT domain. A second hinge can be identified between CDC1/CDC2. 
On the basis of a superposition of CDC2, CDC1 of the phosphorylated SceCD is rotated 
by 30° relative to CDC1 of the non-phosphorylated flACC (Supplemental Figure 4.5D), 
similar to what we have observed for the non-phosphorylated HsaBT-CD 
(Supplemental Figure 4.1D). When inspecting all individual protomer and fragment 
structures in their study, Wei & Tong also identify the CDN/CDC1 connection as a highly 
flexible hinge, in agreement with our observations. 
The only bona-fide regulatory phophorylation site of fungal ACC in the regulatory loop 
is directly participating in CDC1/CDC2 domain interactions and thus stabilizes the hinge 
conformation. In flACC, the regulatory loop is mostly disordered, illustrating the 
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increased flexibility due to the absence of the phosphoryl-group. Only in three out of 
eight observed protomers a short peptide stretch (including Ser1157) was modeled. 
In those instances the Ser1157 residue is located at a distance of 14 – 20 Å away 
from the location of the phosphorylated serine observed here, based on superposition 
of either CDC1 or CDC2. Applying the conformation of the CDC1/CDC2 hinge observed in 
SceCD on flACC leads to CDN sterically clashing with CDC2 and BT/CDN clashing with 
CT (Supplemental Figure 4.6A,B). Thus, in accordance with the results presented 
here, phosphorylation of Ser1157 in SceACC most likely limits flexibility in the 
CDC1/CDC2 hinge such that activation through BC dimerization is not possible (Figure 
4.4D), which however does not exclude intermolecular dimerization. In addition, EM 
micrographs of phosphorylated and dephosphorylated SceACC display for both 
samples mainly elongated and U-shaped conformations and reveal no apparent 
differences in particle shape distributions, (Supplemental Figure 4.7). This implicates 
that the triangular shape with dimeric BC domains has a low population also in the 
active form, even though a biasing influence of grid preparation cannot be excluded 
completely.  
Large-scale conformational variability has also been observed in most other carrier-
protein based multienzymes, including polyketide267 and fatty acid synthases (with the 
exception of fungal-type fatty acid synthases)268,269, non-ribosomal peptide 
synthetases270 and the pyruvate dehydrogenase complexes271, although based on 
completely different architectures. Together, this structural information suggests that 
variable carrier protein tethering is not sufficient for efficient substrate transfer and 
catalysis in any of these systems. The determination of a set of crystal structures of 
SceACC in two states, unphosphorylated265 and phosphorylated at the major 
regulatory site Ser1157, provides a unique depiction of multienzyme regulation by 
post-translational modification (Figure 4.4D). The phosphorylated regulatory loop 
binds to an allosteric site at the interface of two non-catalytic domains and restricts 
conformational freedom at several hinges in the dynamic ACC. It disfavors the 
adoption of a rare, compact conformation, in which intramolecular dimerization of the 
BC domains265 results in catalytic turnover. The regulation of activity thus results from 
restrained large-scale conformational dynamics rather than a direct or indirect 
influence on active site structure. To our best knowledge, ACC is the first multienzyme 
for which such phosphorylation-dependent mechanical control mechanism has been 
visualized. However, the example of ACC now demonstrates the possibility of 
regulating activity by controlled dynamics of non-enzymatic linker regions also in other 
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families of carrier-dependent multienzymes. Understanding such structural and 
dynamic constraints imposed by scaffolding and linking in carrier-protein based 
multienzyme systems is a critical prerequisite for engineering of efficient biosynthetic 
assembly lines.  
 
4.5 Experimental Procedures 
4.5.1 Protein expression & purification 
All proteins were expressed in the Baculovirus Expression Vector System. The 
MultiBac™ insect cell expression plasmid pACEBACI (Geneva Biotech) was modified 
to host a GATEWAY® (LifeTechnologies) cassette with an N-terminal 10xHis-tag, 
named pAB1GW-NH10 hereafter. Full-length HsaACC (Genebank accession 
#U19822), SceACC (#NC_001146), CthACC (#XM_006692575) were cloned into 
pAB1GW-NH10 using GATEWAY® according to manufacturers manual. Truncated 
variants were constructed by PCR amplification, digestion of the template DNA with 
DpnI, phosphorylation of the PCR-product and religation of the linear fragment to a 
circular plasmid. The following constructs were used for this study: SceACC (1-2233), 
CthACC (1-2297), CthΔBCCP (1-2297, Δ700-765), CthCD-CT (788-2297), CthCD-
CTCter (1114-2297), SceCD (768-1494), HsaBT-CD (622-1584, Δ753-818). Bacmid 
and virus production was carried out according to MultiBac™ instructions154. 
Baculovirus generation and amplification as well as protein expression were performed 
in Sf21 cells (Expression Systems) in Insect-Xpress medium (Lonza). The cells were 
harvested between 68-96h post infection by centrifugation and stored at -80 °C until 
being processed. 
Cells were lysed by sonication and the lysate was cleared by ultracentrifugation. 
Soluble protein was purified using Ni-NTA (Genscript) and size exclusion 
chromatography (Superose 6, GE Healthcare). The affinity tag was removed by TEV-
cleavage overnight at 4°C. TEV-protease and uncleaved protein were removed by 
orthogonal Ni-NTA purification prior to size exclusion chromatography. SceACC, 
CthACC and CthΔBCCP were further purified by high-resolution anion exchange 
chromatography prior to size exclusion chromatography. Purified SceCD, CthCD-
CTCter, CthCD-CT, CthΔBCCP, SceACC were concentrated to 10 mg ml-1 in 30 mM 
MOPS pH 7, 200 mM ammonium sulfate, 5% glycerol and 10 mM dithiothreitol and 
purified HsaBT-CD was concentrated to 20 mg ml-1 in 20 mM bicine pH 8.0, 200 mM 
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NaCl, 5% glycerol, and 5 mM TCEP. Proteins were used directly or were stored at -
80°C after flash-freezing in liquid nitrogen. 
 
4.5.2 Protein crystallization 
All crystallization experiments were conducted using sitting drop vapour diffusion. 
SceCD crystals were grown at 19 °C by mixing protein and reservoir solution (0.1 M 
BisTrisPropane pH 6.5, 0.05 – 0.2 M di-sodium malonate, 20 – 30% polyethylene 
glycol (PEG) 3350, 10 mM trimethylamine or 2% benzamidine) in a 1:1 or 2:1 ratio. 
Crystals appeared after several days and continued to grow for 20 to 200 days. 
Crystals were cryo-protected by short incubation in mother liquor supplemented with 
22% ethylene glycol and flash-cooled in liquid nitrogen. For heavy metal derivatization 
the crystals were incubated in stabilization solution supplemented with 1 mM 
Thimerosal or 10 mM EuCl2, respectively, and then backsoaked for 15 seconds in 
stabilization solution without heavy metal. 
Initial crystals of HsaBT-CD grew in 0.1 M Tris pH 8.5, 0.35 M tri-potassium citrate 
and 2 – 3.5% PEG10000 at 19 °C. After several rounds of optimization good quality 
diffraction crystals were obtained at 20°C in 0.1M MES pH 6, 0.25 – 0.35 M tri-
potassium citrate, 2 – 5% PEG10000, 0.01 – 0.04 M cadmium chloride. The protein 
drop contained a 1:1 ratio of protein and reservoir solution. Crystals grew immediately 
and stopped growing after 3 days. They were dehydrated and cryoprotected in several 
steps in artificial mother liquor containing incrementally increasing concentrations of 
tri-potassium citrate, PEG10000 and ethylene glycol and then flash-cooled in liquid 
nitrogen. The final solution was composed of 0.1 M MES pH6, 0.5 M tri-potassium 
citrate, 6.75% PEG10000, 0.01 M cadmium chloride.  
CthCD-CTCter crystals were grown at 19°C by mixing protein and reservoir solution (0.1 
M Hepes pH 7.5, 2 – 7% Tacsimate pH 7, 7.5 – 15% PEGMME5000) in a 1:1 ratio. 
Crystals appeared after several days and continued to grow for up to two weeks. 
Crystals were cryo-protected by short incubation in mother liquor supplemented with 
22% ethylene glycol. 
CthCD-CT ACC crystals were grown at 19 °C by mixing protein and reservoir solution 
(0.1 M Bicine pH 8.5 – 9.5, 4 – 8% PEG8000) in a 1:1 or 1:2 ratio. Crystals grew 8 to 
10 days and were cryo-protected by short incubation in mother liquor supplemented 
with 22% ethylene glycol before flash-cooling in liquid nitrogen. 
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CthΔBCCP ACC crystals were grown at 19 °C by mixing protein and reservoir solution 
(0.1 M morpheus buffer 3, 7 – 12% Morpheus ethylene glycols mix, 8 – 12% 
PEG4000, 17 – 23% glycerol) in a 1:1 or 1:2 ratio. Crystals grew up to three weeks 
and were cryo-protected in reservoir solution before flash cooling in liquid nitrogen. 
 
4.5.3 Structure determination and analysis of phosphorylation 
All X-ray diffraction data were collected at beamlines X06SA (PXI) and X06DA (PXIII) at 
the Swiss Light Source (SLS, Paul Scherrer Institute, Villigen, Switzerland) equipped 
with PILATUS detectors, respectively. The wavelength of data collection was 1.000 Å 
for native crystals, and 1.527 Å and 1.907 Å for crystals derivatized with europium and 
cadmium, respectively. Raw data were processed using XDS159. Molecular 
replacement was carried out using Phaser 2.5.7 and 2.6.0, density modification was 
done using Parrot272,273 and resolve, multi crystal averaging165 was carried out using 
phenix. All model building was conducted using Coot163 and figures were prepared 
using PyMOL (Schrödinger LLC).  
Diffraction of initial SceCD crystals in space group P43212 with unit cell dimensions of 
a = b = 110.3 Å and c = 131.7 Å was limited to 3.5 Å. The resolution was improved 
to 3 Å by addition of trimethylamine or benzamidine to the reservoir solution without 
significant changes in unit cell dimensions. Crystals derivatized with thimerosal and 
europium were used for initial SAD phase determination using the SHELXC/D 
package160. Two mercury and four europium sites were located and an initial model 
was placed in the resulting maps. Since crystals derivatized with europium were 
slightly non-isomorphous with a c-axis length of 127 Å, multi crystal averaging was 
used for density modification and provided directly interpretable maps. Iterative cycles 
of model building and refinement in Buster (version 2.10.2; Global Phasing Ltd.) 
converged at Rwork/Rfree of 0.20/0.25. The final model lacks the disordered N-terminus 
(amino acids 768 – 789), an extended loop in the CDC1 domain (1204 – 1215) and a 
short stretch (1147 – 1152) preceding the regulatory loop. Based on temperature 
factor analysis, the start and end of the regulatory loop show higher disorder than the 
region around the interacting phosphoserine 1157. MS analysis of dissolved crystals 
detected quantitative phosphorylation of the regulatory Ser1157, as also found for full 
length SceACC, and additionally albeit with much lower occurrence, phosphorylation 
of Ser790, Ser1137, Ser1148 and Ser1159. A modeled phosphoryl-position for 
Ser1159 could overlap with the one of Ser1157, and might be represented in the 
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crystal. For all other phosphorylation sites no difference density could be observed, 
probably due to very low occupancy. PDBeFold 237 was used to search for structural 
homologues. The thresholds for lowest acceptable percentage of matched secondary 
structure elements were 70% for the search query and 20% for the result. 
Initial HsaBT-CD crystals were obtained in space group I4122 with a = b = 240.1 Å 
and c = 768.9 Å and diffracted to only 7.5 Å. Optimized and dehydrated crystals also 
belonged to space group I4122 but with unit cell parameters a = b = 267.3 Å and c = 
210.6 Å and diffracted up to a resolution of 3.7 Å. Phase information was obtained 
from SAD based on bound cadmium ions from the crystallization condition. Six 
cadmium positions were located in a 4.0 Å resolution dataset at 1.9 Å wavelength 
using SHELXC/D 274 via the HKL2MAP interface 161. Density modification and phasing 
based on this anomalous dataset, a 3.7 Å resolution data set at 1.0 Å wavelength, 
and additional non-isomorphous lower resolution datasets led to a high-quality 
electron density map. At the intermediate resolution obtained, the map was 
interpreted by a poly-alanine model, which was guided by predicted secondary 
structure as well as sequence and structural alignment with SceCD. The final model 
refines against experimental data with with Rwork/Rfree of 0.38/0.41, as expected for a 
poly-alanine model165. Two HsaBT-CD monomers are packed in the asymmetric unit 
via the CDN and BT domains. Density on top of the β-barrel of one BT most likely 
representing parts of the BT-CD linker guided the assignment of this BT to its linked 
CD partner domain. This BT-to-CD assignment was further supported by the analysis 
of an additional lower resolution crystal form. Cadmium ions were found to participate 
in crystal packing.  
In HsaACC phosphorylation at regulatory sites was detected as provided in the main 
text. No phosphorylation was detected for other phosphosites previously identified in 
large-scale phosphoproteomics studies, namely serines 5, 23, 25, 48, 53, 78, 488, 
786, 1273275-277. 
Two different crystal forms were obtained for CthCD-CTCter, diffracting to 3.6 Å and 
4.5 Å, respectively. Both forms packed in space group P212121 with unit cell constants 
of a = 97.7 Å, b = 165.3 Å and c = 219.2 Å or a = 100.2 Å, b = 153.5 Å and c = 249.2 
Å, respectively. Phases were determined by molecular replacement using a homology 
model based on SceCT (pdb 1od2) as search model in Phaser162,273,278, multi crystal 
averaging was applied in density modification. The CT domain was rebuilt and an initial 
homology model based on the SceCD structure was fitted into difference density for 
CthCD-CTCter1. Iterative cycles of rebuilding and refinement in Buster converged at 
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Rwork/Rfree of 0.20/0.25. The refined CD fragment served as a starting model for 
rebuilding CthCD-CTCter2 at lower resolution. Coordinate refinement in Buster was 
additionally guided by reference model restraints and converged at Rwork/Rfree of 
0.26/0.30. Residues 1114 – 1188, 1213 – 1252, 1380 – 1385 and 2188 – 2195 were 
disordered in both crystal forms and are not included in the models. Conservation was 
mapped onto the CthCD-CTCter1 crystal structure using al2co279 based on a sequence 
alignment of 367 fungal ACC sequences calculated by Clustal Omega209. MS analysis 
of purified protein detected 7% phosphorylation at Ser1170 (corresponding to 
Ser1157 in SceCD). 
CthCD-CT crystallized in P31212 with unit cell constants of a = b = 195.0 Å and c = 
189.5 Å and crystals diffracted to a resolution of 7.2 Å. The structure was solved by 
molecular replacement using a model composed of CthCT and CDC2 as search model 
in Phaser. CDC1 and CDN were placed manually into the resulting maps and the model 
was refined using rigid-body, domain-wise TLS and B-factor refinement and NCS- 
and reference model restrained coordinate refinement in Buster to Rwork/Rfree of 
0.26/0.28. Residues 1033 – 1035, 1134 – 1152, 1214 – 1252, 2188 – 2195 and 2260 
– 2297 were not included in the models. Conservation was mapped onto the CthCD-
CT crystal structure as for CthCD-CTCter. MS analysis of purified protein detected 60% 
phosphorylation at Ser1170 (corresponding to Ser1157 in SceCD). 
CthΔBCCP ACC crystallized in P6422 with unit cell constants of a = b = 462.2 Å and 
c = 204.6 Å, resolution was limited to 8.4 Å. Structure determination and refinement 
was performed as for CthCD-CT. Final Rwork/Rfree were 0.31/0.34. Although substantial 
difference density is observed, in accordance with the lack of the BT and BC domains 
in the model, no defined positioning of these domains could be derived. In Addition, 
residues 1033 – 1035, 1134 – 1152, 1214 – 1252, 2188 – 2195 and 2260 – 2297 
were not included in the models. MS analysis of purified protein detected 70% 
phosphorylation at Ser1170 (corresponding to Ser1157 in SceCD). 
 
4.5.4 Small-angle x-ray scattering 
Proteins were thawed on ice and dialyzed overnight against 30 mM MOPS pH 7, 200 
mM ammonium sulfate, 5% glycerol and 10 mM dithiothreitol. Raw scattering data 
were measured at SAXS beamline B21 at Diamond Light Source. The samples were 
measured at concentrations of 2.5, 5 and 10 mg ml-1. Data were processed using the 
ATSAS package 280 according to standard procedures281,282. A slight increase in 
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scattering in the very low-resolution range was observed with increasing protein 
concentrations, which may be due to interparticle attraction or minor aggregation. 
Scattering intensities were thus extrapolated to zero concentration using point-wise 
extrapolation implemented in Primus283. Direct comparison of raw scattering curves 
demonstrates the similarity of CthACC and CthΔBCCP, and the derived values such 
as Rg and Porod Volume match within expected error margins. Molecular mass 
estimations based on the SAXS-MOW method284 derive values of 534.7 kDa and 
534.0 kDa for CthACC and CthΔBCCP, respectively. The relative discrepancies to the 
theoretical weights of 516.8 kDa (CthACC) and 503.0 kDa (CthΔBCCP) are 3.5% and 
6.2%, which is in a typical range for this method284. 
 
4.5.5 Electron microscopy 
Full-length CthACC was diluted to 0.01 mg ml-1 in 30 mM MOPS pH 7.0, 200 mM 
ammonium sulphate, 5% glycerol, and 10 mM dithiothreitol. Protein sample was 
adsorbed to a 200 µm copper grid and stained with 2% uranyl acetate. Grids of 
CthACC were imaged on a CM-200 microscope (Philips) equipped with a TVIPS F416 
4k CMOS camera (Tietz Video and Image Processing Systems). The voltage used was 
200 kV; and a magnification of 50000 x results in a pixel size of 2.14 Å. Initial image 
processing and particle picking was carried out using Xmipp285,286. 22309 particles 
were picked semi-automatically from 236 micrographs with a box size of 300x300 
pixels. After extraction, particles with a z-score of >3 were discarded and 22257 
particles were aligned and classified into 48 2D class averages using maximum-
likelihood target function in Fourier space (MLF2D). After 72 iterations, 4226 additional 
particles were discarded and the remaining 18031 particles were re-aligned and 
classified into 36 classes using MLF2D with a high-resolution cutoff of 30 Å. After 44 
iterations the alignment converged and class averages were extracted. 
 
4.5.6 In vitro biotinylation and activity assay 
To ensure full functionality, SceACC was biotinylated in vitro using the E. coli biotin 
ligase BirA. The reaction mixture contained 10 µM ACC, 3.7 µM BirA, 50 mM Tris-HCl, 
pH 8, 5.5 mM MgCl2, 0.5 mM biotin, 60 mM NaCl, 3 mM ATP, 10% glycerol and the 
reaction was allowed to proceed for 7 h at 30 °C. 
The catalytic activity of phosphorylated and dephosphorylated SceACC was 
measured following the incorporation of radioactive 14C into acid-stable non-volatile 
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material264. Dephosphorylated ACC was prepared by over-night treatment with λ 
protein phosphatase (New England Biolabs) of partially purified ACC before the final 
gel filtration step. The removal of the phosphoryl group from Ser1157 was confirmed 
by MS. The reaction mixture contained 0.5 µg recombinant ACC in 100 mM potassium 
phosphate, pH 8, 3 mM ATP, 5 mM MgCl2, 50 mM NaH14CO3 (specific activity 7.4 
MBq mmol-1) and 1 mM acetyl-CoA in a total reation volume of 100 µl. The reaction 
mixture was incubated for 15 min at 30 °C, stopped by addition of 200 µl 6 M HCl 
and subsequently evaporated to dryness at 85 °C. The non-volatile residue was 
redissolved in 100 µl of water, 1 ml Ultima Gold™ XR scintillation medium (Perkin 
Elmer) was added and the 14C radioactivity was measured in a Packard Tricarb 
2000CA liquid scintillation analyzer. Measurements were carried out in five replicates 
and catalytic activities were calculated using a standard curve derived from 
measurements of varying concentrations of NaH14CO3 in reaction buffer. 
 
4.6 Accession numbers 
Atomic coordinates and structure factors have been deposited in the Protein Data 
Bank with accession codes 5I6E (SceCD), 5I87 (HsaBT-CD), 5I6F/5I6G (CthCD-
CTCter1/2), 5I6H CthCD-CT), and 5I6I (CthΔBCCP). 
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Supplemental Figure 4.2 SAXS analysis of fungal ACC.  
Scattering curves A, distance distribution B and Kratky plots C of full-length CthACC (orange) 
and CthΔBCCP (black) demonstrating that BCCP-deletion has no impact on the overall 
solution structure. For clarity, scattering curves are shown with a y-axis offset. 
  
0 0.1 0.2 0.3 0.5
s [Å-1]
full length
ΔBCCP
A
400
r [Å]
full length
ΔBCCP
p(
r) 
[1
0-
5 ]
1.2
1
0.8
0.6
0.4
0.2
0 50 100 150 200 250 300 350
full length
ΔBCCP
4
3.5
3
2.5
2
1.5
1
0.5
I(s
) x
 s2
 [1
0-
6 ]
s [Å-1]
SAXS scattering curves distance distribution Kratky
0 0.1 0.2 0.3 0.4
lo
g(
I)
B C

4  The dynamic organization of fungal acetyl-CoA carboxylase 
 
 132
 
 
Supplemental Figure 4.4 Negative stain electron microscopy class averages of 
CthACC illustrating its flexibility. 
A 18031 particles were 2D-classified into 36 classes using the MLF2D method. Classes are 
sorted by number of particles per class, with the highest number at the top left and the lowest 
number at the bottom right. Scale bar 200 Å. B 2D-class averages from negative stain EM 
analysis depict the ensemble of solution conformations of the intrinsic flexibility of CthACC. 
Scale bar 200 Å.  
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Supplemental Figure 4.5 Conformational variability in fungal ACC. 
A Cartoon representation of triangular flACC (PDB accession code: 5csl). In (a) and (b) domains 
are colored according to the linear sequence scheme in (b). B Cartoon representation of 
Cth∆BCCP. The orientations of (a) and (b) are based on a superposition of the CT domains. 
Fields of view for panels (c) and (d) are indicated with boxes and eyes. C Left: Detailed view of 
the CDC2/CT 120° hinge motion viewed along the rotation axis. Cth∆BCCP is colored and 
flACC is shown in gray for clarity. Corresponding ends of CDC2-helices are colored in yellow 
and magenta. The rotation axis is indicated and the view for the right subpanel is indicated 
with an eye. Right: View onto the rotation axis. D Conformational states of the CDC1-CDC2 
hinge in the non-phosphorylated flACC and in the phosphorylated SceCD crystal structures 
when superimposed on CDC2 domains. Lα1, the first N-terminal helix of the CDL domain, is 
labeled to illustrate the conformational differences. The left panel shows the view along the 
rotation axis, the right panel corresponds to a view onto the axis. The position of the 
phosphorylated Ser1157 in the regulatory loop is indicated by a magenta triangle.  
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Supplemental Figure 4.7 Negative stain electron microscopy of phosphorylated and 
dephosphorylated SceACC shows similar degree of conformational flexibility. 
Micrographs of phosphorylated (left) and dephosphorylated SceACC (right) are shown side by 
side. Selected particles representing elongated and U-shaped molecules are indicated with 
black and orange arrows, respectively. The scale bar is 200 nm.  
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Supplemental Table 4.1 Small angle x-ray scattering data collection and processing. 
 
 
   
  full length CthACC CthΔBCCP 
Instrument B21 at  Diamond Light Source B21 at  Diamond Light Source 
Beam size (mm) 1 x 5  1 x 5  
Wavelength (Å) 1 1 
q range (Å-1) 0.005 - 0.4 0.005 - 0.4 
Detector distance (m) 3.92 3.92 
Temperature (K) 293 293 
Protein concentration (mg/ml) 3, 6, 10 3, 6, 10 
Scan repeats 30 30 
Total exposure time (s) 300 300 
Capillary diameter (mm) 1.6 1.6 
I(0) (Å-1) [from P(r)]  0.023 0.024 
Rg (Å) [from P(r)] 94 97 
Rg (Å) (from Guinier) 89 ± 2 92 ± 3 
Porod volume estimate (Å3) 1176290 1174390 
Dmax (Å) 350 350 
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5 Discussion and Outlook 
5.1 The organization of mTOR complex 1 
The structure determination of the human mTORC1 by cryo-electron microscopy 
revealed a truly unique architecture. Both, the previously solved crystal structure of 
the mTOR∆N-mLST8 fragment reported by Yang et al.19, as well as the structure of 
isolated Raptor from Chaetomium thermophilum are unambiguously placed in the EM-
map. Furthermore, the high quality of the EM map allowed de novo interpretation of 
the mTOR HEAT domain region by placement of α-helical repeats without assigned 
register or directionality, providing a first complete model of the entire mTOR complex 
1 at pseudo-residue resolution. mTORC1 adopts a dimeric, lozenge shaped structure 
with the two catalytic clefts facing outwards. Access to the active site is not only 
recessed by mLST8 and the FRB domain as reported earlier19, but also by the highly 
conserved Raptor RNC domain. The structure of isolated CtRaptor reveals a Z-shaped 
domain arrangement with central ARM repeats flanked by the amino-terminal RNC 
and a carboxy-terminal WD40 propeller on opposite sides. 
Very recently, Baretic et al. reported the structure of a Tor-Lst8 complex from the 
thermotolerant yeast Kluyveromyces marxianus.287 In this study, Lst8 and a ZZ-tagged 
Tor were stably integrated into the K. marxianus genome under a galactose inducible 
promoter. Galactose induced expression followed by antibody purification yielded a 
monodisperse Tor-Lst8 sample, which was subjected to single particle analysis by 
cryo-electron microscopy. Despite the absence of the Kluyveromyces marxianus 
ortholog of Raptor, the organization of Tor-Lst8 closely resembles those of the 
corresponding regions in the human mTORC1 reconstruction (Figure 5.1A,B). The 
structural core comprising the bridge, FAT and kinase domain is significantly better 
resolved than the horn region and Lst8, again similar to human mTORC1 
(Supplemental Figure 2.2).  
Baretic et al. observed weak density of the negative regulatory domain (NRD), whose 
deletion increases mTORC1 activity75,76. The NRD is an integral part of the kinase 
domain, but could not be modeled in the crystal structure due to high flexibility19. It 
blocks the catalytic cleft from the opposite side as Raptor does in our reconstruction 
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The experimentally well supported topology proposed by Baretic et al. now provides 
an unambiguous assignment of the dimeric topology of mTOR, superseding the initial 
hypothesis formulated in chapter 2 (2.3.6): Raptor contacts both mTOR protomers 
(Figure 5.2C) such that the two dimerization interfaces are equivalent to those 
described as interfaces between Raptor and the horn and bridge of one mTOR 
protomer in 2.3.6. 
 
5.2 Implications for mTORC2 
The preservation of the basic core structure in the absence of a Raptor ortholog of K. 
marxianus Tor-Lst8 shows that mTOR provides the basic scaffold for mTORC1, which 
remains mostly unaffected by Raptor binding, although Raptor interaction may further 
stabilize the overall complex 287. This hints to a preserved central mTOR scaffold also 
in mTORC2 with the mTORC2-specific Rictor subunit occupying the position of 
Raptor or other accessible sites. A recent bioinformatics search analyzed the Rictor 
domain arrangement and found a resemblance to Raptor288. The prediction algorithm 
identified amino-terminal and central HEAT repeats and a carboxy-terminal WD40 
domain. The study further predicts a pleckstrin homology (PH) domain which mediates 
cellular localization and a ribosome binding domain that could mediate the reported 
ribosome association50. 
 
Figure 5.3 S. cerevisiae TORC2 negative stain EM reconstruction at 26 Å resolution. 
Top view (left) and side view (right) of the single particle EM reconstruction of yeast TORC2 at 
26 Å150. Incomplete information causes blurring along the top view axis. 
Recent work from Gaubitz et al. aimed to determine the architecture of TORC2 from 
budding yeast150. Purification via TAP-tagged AVO3, the yeast Rictor ortholog, from 
90º
yeast
TORC2
26 Å
top view side view
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Saccharomyces cerevisiae cell extracts yielded a sample that was subjected to single 
particle negative stain EM analysis. The low resolution reconstructions at 26 Å reveals 
a dimeric, rhomboid shape with a central cavity, similar to mTORC1 (Figure 5.3). 
However, the overall quality of the EM-map is impaired due to a preferred orientation 
of the particles on the EM-grid. The information for the reconstruction is hence 
incomplete, which causes blurring of the EM density along the top view axis (Figure 
5.3, right panel). Localization of individual proteins was approached using deletion or 
truncation of specific subunits or insertion of bulky maltose binding protein (MBP)-
fusions followed by EM-analysis. The carboxy-terminal region of AVO3 likely shields 
the FRB domain, as its deletion renders mTORC2 sensitive to rapamycin mediated 
inhibition. 
The low resolution as well as the overall quality of the reconstruction hinder a 
meaningful interpretation of the TORC2 architecture presented by Gaubitz et al. 
However, it confirms an expected dimeric mTORC2 assembly. It is of great relevance 
to further elucidate the architecture of mTORC2. A similar approach as used for the 
mTORC1 reconstruction could be employed, by combining a single particle cryo-EM 
reconstruction of intact mTORC2, complemented with structure determination of the 
core components Rictor and Sin1. The determination of the mTORC2 structure would 
permit the design of targeted structural but also biochemical studies in order to dissect 
the divergent regulatory mechanism between mTORC1 and mTORC2. The structure 
could reveal domains in proximity to the catalytic site which might be involved in 
substrate recognition. It would further allow to elucidate the structural basis for 
membrane targeting of mTORC2 which could be mediated by the PH domains of 
Sin1, Rictor or both289. 
 
5.3 Implications for the regulation of the mTOR complexes 
The novel insights to mTOR complex 1 organization provide a framework for an 
analysis of mTOR regulation. The Raptor RNC domain is positioned in close proximity 
to the kinase active site in mTORC1. In addition to the FRB19 and the NRD287, it further 
limits the accessibility of the mTOR active site. The RNC adopts a caspase fold, but 
has not been reported to have proteolytic activity. Despite the presence of a 
conserved Cys-His dyad79, this is not unexpected, as caspases are activated by 
specific proteolytic cleavage and the functional assembly is dimeric 290. Both the high 
conservation and its location within mTORC1 suggest a key role in substrate 
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recognition and delivery via the TOS-motif, which has been shown to directly interact 
with Raptor66,67. The resemblance between the TOS-motif and caspase target 
sequence with an aspartate at position four might hint to a related binding mode. 
Further biochemical and structural work is required to characterize the interaction 
between Raptor and its substrate via the TOS-motif. Structure determination of a 
synthetic TOS-peptide bound to Raptor would reveal its TOS-binding site. Moreover, 
a Raptor crystal structure at atomic resolution would allow identification of the residues 
involved in substrate binding. Additional biophysical techniques such as fluorescence 
polarization or isothermal calorimetry can be applied to determine the kinetics and 
thermodynamics of the binding. An established binding experiment would allow 
verification of identified interacting residues by comparing the binding affinities of 
Raptor mutants to wild-type Raptor. Moreover, it would permit to compare the binding 
affinities for the S6K, 4EBP1 and the negative regulator PRAS40 TOS-motifs in order 
to determine the relative specificity. 
Importantly, substrate binding needs to be examined on the level of the entire complex 
using cryo-EM reconstruction of mTORC1 substrate complexes. 4EBP1 belongs to a 
family of intrinsically disordered proteins291, which might hinder its visualization in such 
a complex. S6K is larger than 4EBP1 (S6K1, 59 kDa; 4EBP1, 12 kDa) and possesses 
a folded kinase domain, which facilitates its visualization by cryo-EM. The 
reconstruction of a S6K bound to mTORC1 would allow to dissect how Raptor and 
the FRB domain orchestrate its positioning during catalysis. 
The mTOR complex 1 adopts a surprisingly open structure and exposes a large 
surface area. One side is exclusively formed by α-helical HEAT repeats (Figure 2.1). 
HEAT repeats are versatile mediators of protein-protein interactions292, exemplified by 
the two HEAT repeat comprising proteins Importin β and Cullin-associated NEDD8-
dissociated protein 1 (Cand1, Figure 5.4A,B). Importin β binds Ran-GTP and conducts 
its transport through the nuclear pore complex293 and Cand1 binds and inhibits Cullin-
1 (Cul1) and Roc1, which form the catalytic core of the SCF ubiquitin ligation 
complex294. In both instances HEAT repeats adopt a characteristic curved structure 
and bind the interaction partner in the concave surface. The mTOR HEAT domain 
comprising the bridge and the highly curved horn provides a large platform for mTOR 
interacting proteins. Tel2 stabilizes all members of the PIKK family295 by binding to their 
HEAT repeat domain. The binding interface on mTOR was mapped to the residues 
residues 400-806 located in the horn. The crystal structure of Saccharomyces 
cerevisiae reveales two HEAT-like repeat domains (Figure 5.4), which are artificially 
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Recently Klebba et al.212 dissected the mode of PLK4 activation in Drosophila 
melanogaster. They found that the PLK4 is regulated via an autoinhibitory mechanism, 
related to PLK197 regulation. In the proposed mechanism, the L1 linker between the 
kinase and the first two Polo-boxes shields the activation loop from an activating 
phosphorylation. This model is in agreement with elevated kinase activity by mutations 
in the linker region, that likely impair the inhibitory interaction between L1 and the 
activation loop. Moreover, PLK4 was dramatically stabilized upon PB3 truncation. This 
suggests a role of the PB3 domain in stimulation of PLK4 kinase activity by relieving 
the autoinhibition, which evidently leads to autophosphorylation and subsequent 
proteasomal degradation107. The relief of the autoinhibition requires an unidentified 
factor, as recombinantly produced PB3 fails to stimulate kinase activity in vitro. 
The conservation of an autoinhibitory regulation between human PLK1 and Drosophila 
melanogaster PLK4 argues that a mechanism similar to Polo regulation described 
above also holds true for human PLK4. The results presented in chapter 3 are in 
agreement with such a model. STIL-CC interacts with PLK4 both with PB3 and L1, 
presumably via distinct interfaces. This makes STIL a prime candidate for the unknown 
mediator of PB3-dependent relief of the L1-autoinhibition proposed by Klebba et al. 
Taken together with the results from chapter 3, this suggests the following mechanism 
(Figure 3.7): STIL is recruited to the centriole by PLK4. STIL binding relieves PLK4 
autoinhibition and activates the kinase. PLK4 phosphorylates STIL, which triggers 
SAS-6 recruitment and cartwheel formation, the structural framework for formation of 
a daughter centriole. Activated PLK4 autophosphorylates and causes its proteasomal 
degradation. 
Further studies are needed to confirm this model. Analogous experiments to the study 
by Klebba et al. should be transferred to a human system to elucidate the 
autoinhibitory mechanism for PLK4. In Addition, the role of STIL as a PLK4 activator 
can be assessed both in vitro and in vivo. Moreover, structural characterization of the 
STIL interaction with PLK4-L1 using linker comprising fragments for co-crystallization 
with STIL-CC is of great interest. However, this might be very challenging due to the 
linker presumably being highly flexible and unstructured. It is also of great relevance 
to temporally resolve the individual events in PLK4 regulation: the recruitment to the 
centriole, activation, phosphorylation of targets and degradation. In Addition, studies 
aiming to identify new players are key to further dissect the detailed mechanisms in 
centriole duplication in the future. 
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5.5 Regulation of ACC activity 
Our structure determination of isolated yeast and human central domain of ACC 
reveals its unique domain composition. Together with studies on larger up to almost 
full-length variants of Chaetomium thermophilum ACC the work demonstrates the 
highly flexible nature of ACCs. Furthermore, it provides the structural basis for the 
inhibition of SNF1-mediated phosphorylation. The phospho-Ser1157 drastically 
reduces the flexibility by locking the hinge between CDC1 and CDC2 , which evidently 
obstructs an activated conformation with dimerizing BC domains reported by Wei and 
Tong265. 
Taken together, the results presented in chapter 4 deliver an experimentally well 
founded model of yeast ACC regulation. But the work also raises new questions 
regarding the mechanisms of human ACC regulation. Although the domain 
architecture is conserved across species, several observations suggest a divergent 
mode of regulation. First, AMPK mediated phosphorylation of Ser1216, the equivalent 
of yeast Ser1157, has not been shown to reduce the activity of human ACC. Secondly, 
the most active form of human ACC is polymeric. And lastly, activity depends on the 
two modulating proteins BRCA1 and MIG12. BRCA1 binds and inhibits 
phosphorylated Ser1263, a site which is not conserved in yeast, and MIG12 as well 
as citrate promote ACC polymerization.  
Regulatory phosphorylation by AMPK occurs at Ser80 and Ser1201129. Ser1201 is 
located in the loop between CDC1 and CDC2 as Ser1157 in yeast, however not in the 
same position. It still might conduct an analogous function, as the two phosphoryl-
coordinating arginines from yeast are conserved in humans. Mass spectrometric 
analysis revealed that Ser1201 was not phosphorylated to high levels in insect cell 
expressed human CD, which was used for crystallization and structure determination. 
The regulatory loop between CDC1 and CDC2 was thus flexible and could not be built 
at position Ser1201 in the electron density map. Structure determination of AMPK 
treated or a phosphomimetic S1201D mutated CD could reveal an analogous 
mechanism to yeast Ser1157. Ser80, however, is conserved in all higher eukaryotes, 
but not in yeast. Ser80 precedes the BC domain and prevents BC dimerization upon 
phosphorylation and might have an imprortant regulatory role. 
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Figure 5.5 human ACC forms filamentous polymers 
Negative-stain electron micrographs of human ACC1 filaments taken by Moritz Hunkeler. 
ACC1 is most active in the polymeric form. 
A highly interesting question is the regulation of the polymeric form of the human ACC 
(Figure 5.5). First, the role of the promoting factors MIG12 and citrate needs to be 
elucidated. And secondly, the consequences of ACC polymerization on its activity 
have to be characterized. The work on yeast ACC has demonstrated that flexibility is 
crucial for activity. It is thus puzzling how ACC in a fixed, polymeric conformation can 
be more active. The catalytic sites of the BC and CT domains might be positioned in 
close proximity in the filamentous form and thus lock ACC in a highly active 
conformation. Structural characterization of the polymeric ACC is fundamental to 
address this question. Cryo-electron microscopy of filaments to at least intermediate 
resolution would allow docking of individual ACC dimers and provide the structural 
basis of ACC activation upon polymerization. 
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5.6 General Outlook  
 
Proteins are the functional units of life and conduct the majority of essential regulatory 
and enzymatic processes. The work presented in this thesis, highlights the complex 
architecture of multidomain proteins and the importance of interdomain crosstalk and 
conformational changes for the regulation of protein function. Comparative proteomic 
and bioinformatic studies have revealed a particular enrichment of multidomain 
proteins in higher eukaryotic organisms: Only 40 % of all prokaryotic proteins but 65 
% of all eukaryotic proteins comprise multiple domains; and more than 8 % of all 
proteins in multicellular organisms consists of domain repeats compared to only 3-4 
% in archaea, bacteria and yeast300. Many multidomain proteins occurred late in 
evolution, and their development is presumably linked to processes specific for 
multicellular organisms, such as cell adhesion and signaling301. Linking of multiple 
domains and the duplication of domains has permitted diversification of basal 
evolutionary capabilities and the adoption of a new cellular tasks. PLK4, for example, 
originates from a gene duplication event of an earlier precursor PLK 84, which allowed 
uncoupling from of ancestral PLKs and diversification of the regulation of centriole 
duplication. The PB3 domain of PLK4 originated from either PB1 or PB284 and 
provided an additional site for interaction and regulation by STIL.  
Domain duplication is commonly accompanied by recombination with additional 
domains302. In yeast ACC, the duplicated CD1 and CD2 are recombined with two helical 
subdomains, which join to form the regulatory central domain. Domain duplication has 
created a hinge region, which can be locked in a specific orientation by 
phosphorylation to restrict the conformational flexibility of the BC and CT domains and 
to efficiently control overall multienzyme activity. mTOR is composed of α-helical HEAT 
repeat units fused to a catalytic kinase domain. The mTORC1 core component Raptor 
is a repeat containing multi-domain protein as well. Seven WD40 repeats at the 
carboxy-terminal end form a β-propeller, that is connected to the proposed substrate 
recognition domain via α-helical armadillo repeats.  
At a general perspective, the examples presented in this thesis demonstrate the 
necessity to study intact eukaryotic multidomain proteins because their emergent 
regulatory properties can’t simply be extrapolated from structures of prokaryotic 
homologues or isolated fragments. Due to the difficulties in studying very large and 
dynamic systems, multidomain proteins are dramatically underrepresented in the 
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current set of known protein structures. The examples provided here clearly 
demonstrate that for comprehensive studies a multimethod approach is required to 
obtain both, atomic models, as well as representations of natural conformational 
variability.  
Cryo-EM analysis of intact multidomain proteins combined with crystallographic 
experiments of isolated subunits permits identification and structural characterization 
of interdomain interactions and regulatory mechanisms. Complementary 
characterization by small-angle X-ray scattering and NMR resolves dynamic 
interdomain and interprotein properties and allows dissection of regulatory 
consequences upon association or dissociation. A particular challenge for structure 
determination of highly dynamic systems is the establishment of conformationally 
homogenous samples. This requires careful monitoring of the functional state of the 
respective proteins and may involve interventions such as alterations of 
posttranslational modifications by mutations or trapping of specific conformation by 
chemical cross-linking. Studies of even more elaborate eukaryotic protein multidomain 
and multisubunit complex may eventually require the development of completely novel 
techniques for in vitro or in silico sample purification: The human proteasome is a 
central cellular proteolytic machine required for protein homeostasis that is composed 
of 33 distinct subunits303. The kinetochore complex, that connects centromeric DNA 
to the spindle microtubules during cell division comprises over 80 subunits 304. End 
the spliceosome complexes feature over 300 distinct subunits305. 
Structural and mechanistic studies of intact multidomain proteins are critically required 
to understand patient-specific mutations. While direct variation of conserved catalytic 
residues are lethal for essential proteins, disease-related variations can accumulate in 
accessory and regulatory regions. For example, genetic alterations e.g. SNPs of 
mTOR are distributed throughout the mTOR sequence and involve numerous regions 
outside the catalytic core306. Due to their relevance for regulation of protein activity, 
interdomain interactions in complex eukaryotic proteins should also be regarded as 
relevant targets for therapeutically interfering with protein function, in addition to direct 
targeting of active sites or of protein-protein interactions. mTOR, for example, is a 
relevant drug target for metabolic diseases and cancer. However, current drugs either 
specifically target only either the active site or or the nearby FKBP12-dependent 
allosteric rapamycin binding site, while the largest part of the mTORC1 surface, in 
particular the defining and regulatory but non-catalytic Raptor protein has not been 
exploited for drug discovery. Targeted impairment of substrate recognition or 
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association with external stimulators may thus provide novel approaches for the 
development of mTOR inhibitors with unique specificity and pharmacological profiles.  
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